Senator Klein from the Committee on Commerce and Consumer Protection, to which was referred

S.F. No. 2744: A bill for an act relating to commerce; establishing a biennial budget for 1.3 Department of Commerce; modifying various provisions governing insurance; establishing 1.4 a strengthen Minnesota homes program; regulating money transmitters; establishing and 1.5 modifying provisions governing energy, renewable energy, and utility regulation; establishing 1.6 a state competitiveness fund; making technical changes; establishing penalties; authorizing 1.7 administrative rulemaking; requiring reports; appropriating money; amending Minnesota 1.8 Statutes 2022, sections 46.131, subdivision 11; 62D.02, by adding a subdivision; 62D.095, 1.9 subdivisions 2, 3, 4, 5; 62Q.46, subdivisions 1, 3; 62Q.81, subdivision 4, by adding a 1.10 subdivision; 216B.62, subdivision 3b; 216C.264, subdivision 5, by adding subdivisions; 1.11 1.12 216C.375, subdivisions 1, 3, 10, 11; proposing coding for new law in Minnesota Statutes, chapters 53B; 65A; 216C; repealing Minnesota Statutes 2022, sections 53B.01; 53B.02; 1.13 53B.03; 53B.04; 53B.05; 53B.06; 53B.07; 53B.08; 53B.09; 53B.10; 53B.11; 53B.12; 1.14 53B.13; 53B.14; 53B.15; 53B.16; 53B.17; 53B.18; 53B.19; 53B.20; 53B.21; 53B.22; 1.15 53B.23; 53B.24; 53B.25; 53B.26; 53B.27, subdivisions 1, 2, 5, 6, 7. 1.16 Reports the same back with the recommendation that the bill be amended as follows: 1.17 Delete everything after the enacting clause and insert: 1.18 **"ARTICLE 1** 1.19 **APPROPRIATIONS** 1.20 Section 1. APPROPRIATIONS. 1.21 The sums shown in the columns marked "Appropriations" are appropriated to the agencies 1.22 and for the purposes specified in this article. The appropriations are from the general fund, 1.23 or another named fund, and are available for the fiscal years indicated for each purpose. 1.24 The figures "2024" and "2025" used in this article mean that the appropriations listed under 1.25 them are available for the fiscal year ending June 30, 2024, or June 30, 2025, respectively. 1.26 "The first year" is fiscal year 2024. "The second year" is fiscal year 2025. "The biennium" 1.27 is fiscal years 2024 and 2025. If an appropriation in this act is enacted more than once in 1.28 the 2023 legislative session, the appropriation must be given effect only once. 1.29 APPROPRIATIONS 1.30 Available for the Year 1.31 Ending June 30 1.32 2024 2025 1.33 1.34 Sec. 2. DEPARTMENT OF COMMERCE Subdivision 1. Total Appropriation \$ 33,757,000 \$ 34,660,000 1.35 Appropriations by Fund 1.36 2024 2025 1.37 General 30,876,000 31,752,000 1.38

	04/04/23	SENATEE	ADB	SS2744R
2.1 2.2	<u>Special Revenue</u> 2,093,000 Workers'	2,093,000		
2.3	Compensation Fund 788,000	815,000		
2.4	The amounts that may be spent for each	ach		
2.5	purpose are specified in the followin	<u>g</u>		
2.6	subdivisions.			
2.7	Subd. 2. Financial Institutions		2,569,000	2,689,000
2.8	(a) \$400,000 each year is for a grant to	Prepare		
2.9	and Prosper to develop, market, evalu	late, and		
2.10	distribute a financial services inclusion	on		
2.11	program that (1) assists low-income	and		
2.12	financially underserved populations	to build		
2.13	savings and strengthen credit, and (2)	provides		
2.14	services to assist low-income and fin	ancially		
2.15	underserved populations to become r	nore		
2.16	financially stable and secure. Money			
2.17	remaining after the first year is available	able for		
2.18	the second year.			
2.19	(b) \$254,000 each year is to administ	ter the		
2.20	requirements of Minnesota Statutes,	chapter		
2.21	<u>58B.</u>			
2.22	(c) \$197,000 each year is to administ	ter the		
2.23	requirements of Minnesota Statutes,	section		
2.24	<u>58B.011.</u>			
2.25	Subd. 3. Administrative Services		10,088,000	10,114,000
2.26	(a) \$353,000 each year is for system			
2.27	modernization and cybersecurity upg	rades for		
2.28	the unclaimed property program.			
2.29	(b) \$586,000 in the first year and \$60	8,000 in		
2.30	the second year are for additional op	erations		
2.31	of the unclaimed property program.			
2.32	(c) \$249,000 each year is for the sent	ior safe		
2.33	fraud prevention program.			

3.1	(d) \$568,000 the first year and \$537,000 the
3.2	second year are for the duties under Minnesota
3.3	Statutes, sections 62J.841 to 64J.845. The base
3.4	for this appropriation beginning in fiscal year
3.5	<u>2026 is \$500,000.</u>
3.6	(e) \$150,000 each year are for a grant to
3.7	Exodus Lending to expand program and
3.8	operational capacity to help individuals reach
3.9	financial stability through small dollar
3.10	consumer loans, including through resolution
3.11	of consumer short-term loans carrying interest
3.12	rates grater than 36 percent. The
3.13	appropriations in this paragraph are available
3.14	<u>until June 30, 2027.</u>
3.15	(f) \$200,000 in fiscal year 2024 is appropriated
3.16	to the commissioner of commerce for a grant
3.17	to Exodus Lending to assist the development
3.18	of a character-based small dollar loan lending
3.19	program. Character-based lending is the
3.20	practice of issuing loans based on the
3.21	borrower's involvement in and ties to
3.22	community-based organizations that provide
3.23	client services, such as financial coaching.
3.24	This is a onetime appropriation and is
3.25	available until June 30, 2027.
3.26	Loans issued under the program must be (1)
3.27	interest- and fee-free, and (2) made to
3.28	Minnesotans facing significant barriers,
3.29	including banking history, credit history and
3.30	credit score requirements, scarcity of bank
3.31	branches in lower-income communities and
3.32	communities of color, and low or irregular
3.33	income flows, to mainstream financial
3.34	products. Mainstream financial products are
3.35	products provided most commonly by

4.1	regulated financial institutions, including
4.2	credit cards and installment loans. Program
4.3	participants must be recruited through a
4.4	statewide network of trusted community-based
4.5	partners. Loan payments by borrowers must
4.6	be reported to the credit bureaus.
4.7	(g) No later than July 15, 2024, and annually
4.8	thereafter until fiscal year 2027, Exodus
4.9	Lending must submit a report to the
4.10	commissioner of commerce on the activities
4.11	required of Exodus Lending under paragraphs
4.12	(e) and (f). The report must detail, at
4.13	minimum, each of the following for the prior
4.14	calendar year:
4.15	(1) the total number of loans granted;
4.16	(2) the total number of participants granted
4.17	loans;
4.18	(3) an analysis of the participants' race and
4.18 4.19	(3) an analysis of the participants' race and ethnicity, gender, and geographic locations;
4.19	ethnicity, gender, and geographic locations;
4.19 4.20	ethnicity, gender, and geographic locations; (4) the average loan amount;
4.194.204.21	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants;
4.194.204.214.22	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by
 4.19 4.20 4.21 4.22 4.23 4.24 	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f);
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 	ethnicity, gender, and geographic locations;(4) the average loan amount;(5) the total loan amounts paid back by participants;(6) a list of the trusted community-based partners described under paragraph (f);(7) the final criteria developed for
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 	ethnicity, gender, and geographic locations;(4) the average loan amount;(5) the total loan amounts paid back by participants;(6) a list of the trusted community-based partners described under paragraph (f);(7) the final criteria developed for
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program determinations under paragraph (f); and
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 	ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program determinations under paragraph (f); and (8) summary data on the significant barriers
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 	 ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program determinations under paragraph (f); and (8) summary data on the significant barriers to mainstream financial products faced by
 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 	 ethnicity, gender, and geographic locations; (4) the average loan amount; (5) the total loan amounts paid back by participants; (6) a list of the trusted community-based partners described under paragraph (f); (7) the final criteria developed for character-based small dollar loan program determinations under paragraph (f); and (8) summary data on the significant barriers to mainstream financial products faced by participants.

5.1	report to the chairs and ranking minority				
5.2	members of the legislative committees with				
5.3	primary jurisdiction over commerce and				
5.4	consumer protection. The report must detail				
5.5	the information collected by the commissioner				
5.6	of commerce under paragraph (f).				
5.7	(h) \$12,000 each year is for the intermediate				
5.8	blends of gasoline and biofuels report in				
5.9	Minnesota Statutes, chapter 239.791,				
5.10	subdivision 8.				
5.11	Subd. 4. Enforcement	7,185,000	7,473,000		
5.12	Appropriations by Fund				
5.13	<u>General</u> <u>6,977,000</u> <u>7,258,000</u>				
5.14 5.15	Workers' Compensation208,000215,000				
5.16	(a) \$811,000 each year is for five additional				
5.17	peace officers in the Commerce Fraud Bureau.				
5.18	Money under this paragraph is transferred				
5.19	from the general fund to the insurance fraud				
5.20	prevention account under Minnesota Statutes,				
5.21	section 45.0135, subdivision 6.				
5.22	(b) \$345,000 each year is for additional staff				
5.23	to focus on market conduct examinations.				
5.24	(c) \$283,000 each year is for the law				
5.25	enforcement salary increases authorized under				
5.26	Laws First Special Session 2021, chapter 4,				
5.27	article 9, section 1.				
5.28	(d) \$41,000 in fiscal year 2024 and \$21,000				
5.29	in fiscal year 2025 are for body cameras worn				
5.30	by Commerce Fraud Bureau agents.				
5.31	(e) \$208,000 in the first year and \$215,000 in				
5.32	the second year are from the workers'				
5.33	compensation fund.				

	04/04/23	SE	ENATEE	ADB	SS2744R
6.1	(f) \$100,000 in the second	vear is to create			
6.2	and operate the Mental Hea				
6.3	Substance Abuse Accountal		er		
6.4	Minnesota Statutes, section	5			
6.5	for fiscal year 2026 and bey	`			
6.6	Subd. 5. Telecommunicati		_	3,221,000	3,261,000
67		ng hy Eund			
6.7 6.8	<u>Appropriatio</u> General		,168,000		
6.9			2,093,000		
0.9			2,075,000		
6.10	\$2,093,000 each year is fro				
6.11	telecommunications access	Minnesota fund	-		
6.12	account in the special rever	ue fund for the			
6.13	following transfers:				
6.14	(1) \$1,620,000 each year is	to the			
6.15	commissioner of human ser	rvices to			
6.16	supplement the ongoing ope	erational expense	es		
6.17	of the Commission of Deaf	, DeafBlind, and	<u>l</u>		
6.18	Hard-of-Hearing Minnesota	ans. This transfer	<u>r</u>		
6.19	is subject to Minnesota Stat	tutes, section			
6.20	<u>16A.281;</u>				
6.21	(2) \$290,000 each year is to	the chief			
6.22	information officer to coord	linate technology	<u>y</u>		
6.23	accessibility and usability;				
6.24	(3) \$133,000 each year is to	the Legislative			
6.25	Coordinating Commission	for captioning			
6.26	legislative coverage. This tr	ransfer is subject	<u>t</u>		
6.27	to Minnesota Statutes, secti	on 16A.281; and	d		
6.28	(4) \$50,000 each year is to	the Office of			
6.29	MN.IT Services for a consol	idated access fun	nd		
6.30	to provide grants or service	s to other state			
6.31	agencies related to accessib	ility of web-base	ed		
6.32	services.				

	04/04/23		SENATEE	ADB	SS2744R
7.1	Subd. 6. Insurance			9,163,000	9,567,000
7.2	Appropriat	tions by Fund			
7.3	General	8,583,000	8,967,000		
7.4 7.5	Workers' Compensation	580,000	600,000		
7.6	(a) \$136,000 each year is		000,000		
7.7	standardized health plan				
7 0	(b) \$318,000 each year is	to conduct a			
7.8 7.9	feasibility study on a pro				
7.9	primary care to Minnesot	•			
7.10	onetime appropriations.				
/.11					
7.12	(c) \$105,000 each year is				
7.13	legislation for new mand				
7.14	under Minnesota Statutes	s, section 62J.26.	<u>.</u>		
7.15	(d) \$180,000 each year is	s for additional s	taff		
7.16	to focus on property- and	l casualty-related	1		
7.17	insurance products.				
7.18	(e) \$580,000 in the first y	vear and \$600,00	<u>0 in</u>		
7.19	the second year are from	the workers'			
7.20	compensation fund.				
7.21	(f) \$42,000 each year is f	for ensuring heal	th		
7.22	plan company complianc	e with Minnesot	a		
7.23	Statutes, section 62Q.47.				
7.24	(g) \$25,000 each year is	to pay the costs			
7.25	incurred to evaluate exist	ting statutory hea	alth		
7.26	benefit mandates under a	rticle 2, section	<u>39.</u>		
7.27	Subd. 7. Weights and M	easures Divisio	<u>n</u>	1,531,000	1,556,000
7.28	Sec. 3. ATTORNEY GE	ENERAL	<u>\$</u>	<u>549,000</u> <u>\$</u>	549,000
7.29	\$549,000 each year is for	r the duties under	<u>r</u>		
7.30	Minnesota Statutes, secti	ons 62J.841 to			
7.31	<u>64J.845.</u>				
7.32	Sec. 4. DEPARTMENT	OF HEALTH	<u>\$</u>	<u>74,000</u> <u>\$</u>	56,000

	04/04/23	SENATEE	ADB	SS2744R
8.1	\$69,000 the first year and \$51,000 the se	cond		
8.2	year are for the duties under Minnesota			
8.3	Statutes, sections 62J.841 to 64J.845.			
8.4	\$5,000 each year is for consultation with	n the		
8.5	commissioner of commerce to evaluate			
8.6	existing statutory health benefits under a	rticle		
8.7	2, section 39.			
8.8	Sec. 5. DEPARTMENT OF EDUCAT	<u>ION </u> \$	<u>100,000 §</u>	<u>-0-</u>
8.9	(a) \$100,000 in fiscal year 2024 is for a g	grant		
8.10	to the Minnesota Council on Economic			
8.11	Education. The money must be used by	the		
8.12	council to:			
8.13	(1) provide professional development to			
8.14	Minnesota teachers of courses or conten	<u>t</u>		
8.15	related to personal finance or consumer			
8.16	protection for students in grades 9 throug	<u>h 12;</u>		
8.17	(2) support the direct-to-student ancillar	<u>y</u>		
8.18	personal finance programs that Minneso	ta		
8.19	teachers supervise and coach or that the			
8.20	Minnesota Council on Economic Educat	tion		
8.21	delivers directly to students; and			
8.22	(3) provide support to geographically div	verse		
8.23	affiliated higher education-based centers	<u>s for</u>		
8.24	economic education engaged in financia	1		
8.25	literacy education as it pertains to finance	tial		
8.26	literacy education initiatives, including t	hose		
8.27	based at Minnesota State University Man	kato,		
8.28	St. Cloud State University, and St. Cathe	erine		
8.29	University, as their work relates to activity	ities		
8.30	in clauses (1) and (2).			
8.31	(b) The Minnesota Council on Economi	<u>e</u>		
8.32	Education must prepare and submit report	rts to		
8.33	the commissioner of education in the form	n and		
8.34	manner prescribed by the commissioner	that:		

9.1	(1) describe the number and type of in-person
9.2	and online teacher professional development
9.3	opportunities provided by the Minnesota
9.4	Council on Economic Education or its
9.5	affiliated state centers;
9.6	(2) list the content, length, and location of the
9.7	programs;
9.8	(3) identify the number of preservice and
9.9	licensed teachers receiving professional
9.10	development through each of these
9.11	opportunities;
9.12	(4) summarize evaluations of professional
9.13	opportunities for teachers; and
9.14	(5) list the number, types, and summary
9.15	evaluations of the direct-to-student ancillary
9.16	personal finance programs that are supported
9.17	with funds from the grant.
9.18	(c) By February 15 of each year following the
9.19	receipt of a grant, the Minnesota Council on
9.20	Economic Education must provide a mid-year
9.21	report to the commissioner of education and,
9.22	on August 15 of each year following receipt
9.23	of a grant, the Minnesota Council on
9.24	Economic Education must prepare a year-end
9.25	report according to the requirements of
9.26	paragraph (b). The reports must be prepared
9.27	and filed according to Minnesota Statutes,
9.28	section 3.195. The commissioner may request
9.29	additional information as necessary. This is a
9.30	onetime appropriation. Any balance in the first
9.31	year does not cancel and is available in the
9.32	second year.

	04/04/23	SENATEE	ADB	SS2744R
10.1	Sec. 6. <u>PREMIUM SEC</u>	URITY ACCOUNT TRANSF	'ER; OUT.	
10.2	\$275,775,000 in fiscal y	ear 2026 is transferred from the	premium security	y plan account
10.3	under Minnesota Statutes, s	ection 62E.25, subdivision 1, to	o the general fund	. This is a
10.4	onetime transfer.			
10.5	Sec. 7. TRANSFER FRO	OM CONSUMER EDUCATIO	<u>ON ACCOUNT.</u>	
10.6	\$100,000 in fiscal year 2	2024 is transferred from the con	sumer education	account in the
10.7	special revenue fund to the	general fund.		
10.8	Sec. 8. Laws 2022, chapte	er 93, article 1, section 2, subdiv	vision 5, is amend	ed to read:
10.9	Subd. 5. Enforcement and	Examinations	-0-	522,000
10.10	\$522,000 in fiscal year 202	3 is for the auto		
10.11	theft prevention library und	er Minnesota		
10.12	Statutes, section 65B.84, su	bdivision 1,		
10.13	paragraph (d). This is a onet	ime appropriation		
10.14	and is available until June 3	<u>30, 2024</u> .		
10.15		ARTICLE 2		
10.16		INSURANCE POLICY		
10.17	Section 1. Minnesota Stat	utes 2022, section 60A.14, subc	division 1, is ame	nded to read:
10.18	Subdivision 1. Fees oth	er than examination fees. In a	ddition to the fees	s and charges
10.19	provided for examinations,	the following fees must be paid	to the commission	ner for deposit
10.20	in the general fund:			
10.21	(a) by township mutual	fire insurance companies:		
10.22	(1) for filing certificate	of incorporation \$25 and amend	lments thereto, \$1	.0;
10.23	(2) for filing annual stat	ements, \$15;		
10.24	(3) for each annual certi	ficate of authority, \$15;		
10.25	(4) for filing bylaws \$25	5 and amendments thereto, \$10;		
10.26	(b) by other domestic an	nd foreign companies including	fraternals and rec	procal
10.27	exchanges:			
10.28	(1) for filing an applicat	ion for an initial certification of	f authority to be a	dmitted to
10.29	transact business in this stat	te, \$1,500;		

(2) for filing certified copy of certificate of articles of incorporation, \$100; 11.1 (3) for filing annual statement, \$225 \$300; 11.2 (4) for filing certified copy of amendment to certificate or articles of incorporation, \$100; 11.3 (5) for filing bylaws, \$75 or amendments thereto, \$75; 11.4 (6) for each company's certificate of authority, \$575 \$750, annually; 11.5 (c) the following general fees apply: 11.6 (1) for each certificate, including certified copy of certificate of authority, renewal, 11.7 valuation of life policies, corporate condition or qualification, \$25; 11.8 (2) for each copy of paper on file in the commissioner's office 50 cents per page, and 11.9 \$2.50 for certifying the same; 11.10 (3) for license to procure insurance in unadmitted foreign companies, \$575; 11.11 (4) for valuing the policies of life insurance companies, one cent two cents per \$1,000 11.12 of insurance so valued, provided that the fee shall not exceed \$13,000 \$26,000 per year for 11.13 any company. The commissioner may, in lieu of a valuation of the policies of any foreign 11.14 life insurance company admitted, or applying for admission, to do business in this state, 11.15 accept a certificate of valuation from the company's own actuary or from the commissioner 11.16 of insurance of the state or territory in which the company is domiciled; 11.17 (5) for receiving and filing certificates of policies by the company's actuary, or by the 11.18 commissioner of insurance of any other state or territory, \$50; 11.19 (6) for each appointment of an agent filed with the commissioner, \$30; 11.20 (7) for filing forms, rates, and compliance certifications under section 60A.315, \$140 11.21 per filing, or \$125 per filing when submitted via electronic filing system. Filing fees may 11.22 be paid on a quarterly basis in response to an invoice. Billing and payment may be made 11.23 electronically; 11.24 (8) for annual renewal of surplus lines insurer license, \$300 \$400. 11.25 The commissioner shall adopt rules to define filings that are subject to a fee. 11.26 11.27 Sec. 2. Minnesota Statutes 2022, section 62A.152, subdivision 3, is amended to read: Subd. 3. Provider discrimination prohibited. All group policies and group subscriber 11.28 11.29 contracts that provide benefits for mental or nervous disorder treatments in a hospital must provide direct reimbursement for those services at a hospital or psychiatric residential 11.30

<u>treatment facility</u> if performed by a mental health professional qualified according to section
 245I.04, subdivision 2, to the extent that the services and treatment are within the scope of
 mental health professional licensure.

12.4 This subdivision is intended to provide payment of benefits for mental or nervous disorder 12.5 treatments performed by a licensed mental health professional in a hospital <u>or psychiatric</u> 12.6 <u>residential treatment facility</u> and is not intended to change or add benefits for those services 12.7 provided in policies or contracts to which this subdivision applies.

Sec. 3. Minnesota Statutes 2022, section 62D.02, is amended by adding a subdivision toread:

12.10 Subd. 17. Preventive items and services. "Preventive items and services" has the 12.11 meaning given in section 62Q.46, subdivision 1, paragraph (a).

12.12 Sec. 4. Minnesota Statutes 2022, section 62D.095, subdivision 2, is amended to read:

Subd. 2. Co-payments. A health maintenance contract may impose a co-payment and
coinsurance consistent with the provisions of the Affordable Care Act as defined under
section 62A.011, subdivision 1a, and for items and services that are not preventive items
and services.

12.17 Sec. 5. Minnesota Statutes 2022, section 62D.095, subdivision 3, is amended to read:

Subd. 3. Deductibles. A health maintenance contract may must not impose a deductible
 consistent with the provisions of the Affordable Care Act as defined under section 62A.011,
 subdivision 1a for preventive items and services.

12.21 Sec. 6. Minnesota Statutes 2022, section 62D.095, subdivision 4, is amended to read:

Subd. 4. Annual out-of-pocket maximums. A health maintenance contract may must
not impose an annual out-of-pocket maximum consistent with the provisions of the

12.24 Affordable Care Act as defined under section 62A.011, subdivision 1a for services rendered

12.25 that are not listed under section 62D.02, subdivision 17, or for preventive items and services.

12.26 Sec. 7. Minnesota Statutes 2022, section 62D.095, subdivision 5, is amended to read:

12.27 Subd. 5. Exceptions. No Co-payments or deductibles may must not be imposed on

12.28 preventive health care items and services consistent with the provisions of the Affordable

12.29 Care Act as defined under section 62A.011, subdivision 1a.

	04/04/23	SENATEE	ADB	SS2744R
13.1	Sec. 8. [62J.841] DEFINITIONS.			
13.2	Subdivision 1. Scope. For purpos	ses of sections 62J.84	1 to 62J.845, the fo	ollowing
13.3	definitions apply.			
13.4	Subd. 2. Consumer Price Index	"Consumer Price In	dex" means the Cou	nsumer Price
13.4	Index, Annual Average, for All Urba			
13.6	reported by the United States Depart			
13.7	successor or, if the index is discontinu			
13.8	or, if no such index is reported, "Con		• • •	<u> </u>
13.9	by the Bureau of Labor Statistics.			
13.10	Subd. 3. Generic or off-patent dr	ug "Generic or off po	otent drug" means an	vorescription
13.10	drug for which any exclusive market			
13.12	Cosmetic Act, section 351 of the fed			
13.12	have expired, including any drug-dev			
13.14	drug.			<u>y or a generic</u>
				4
13.15	Subd. 4. Manufacturer. "Manufa			
13.16	subdivision 14a, but does not include or relabels drugs.	an entity required sol	ery because the entr	ty repackages
13.17	of relaters drugs.			
13.18	Subd. 5. Prescription drug. "Pre		<u>18 a drug for human</u>	use subject
13.19	to United States Code, title 21, section	on 353(b)(1).		
13.20	Subd. 6. Wholesale acquisition	cost. <u>"</u> Wholesale acq	uisition cost" has th	e meaning
13.21	provided in United States Code, title	42, section 1395w-3	<u>a.</u>	
13.22	Subd. 7. Wholesale distributor.	"Wholesale distribut	or" has the meaning	g provided in
13.23	section 151.441, subdivision 14.			
13.24	Sec. 9. [62J.842] EXCESSIVE PH	RICE INCREASES	PROHIBITED.	
13.25	Subdivision 1. Prohibition. No n	nanufacturer shall im	pose, or cause to be	e imposed, an
13.26	excessive price increase, whether dir	ectly or through a wh	nolesale distributor,	pharmacy, or
13.27	similar intermediary, on the sale of a	ny generic or off-pat	ent drug sold, dispe	nsed, or
13.28	delivered to any consumer in the stat	e.		
13.29	Subd. 2. Excessive price increas	e. A price increase is	s excessive for purp	oses of this
13.30	section when:			
13.31	(1) the price increase, adjusted for	inflation utilizing the	e Consumer Price In	dex, exceeds:

	04/04/23	SENATEE	ADB	SS2744R
14.1	(i) 15 percent of the wholesale acquis	sition cost over the imm	ediately preceding	calendar
14.2	year; or			
14.3	(ii) 40 percent of the wholesale acqu	isition cost over the im	mediately precedin	g three
14.4	calendar years; and			<u> </u>
14.5	(2) the price increase, adjusted for in	flation utilizing the Con	sumer Price Index.	exceeds
14.6	\$30 for:		<u> </u>	
14.7	(i) a 30-day supply of the drug; or			
14.8	(ii) a course of treatment lasting less	than 30 days.		
14.9	Subd. 3. Exemption. It is not a viola	tion of this section for	a wholesale distrib	utor or
14.10	pharmacy to increase the price of a gener	ric or off-patent drug if t	he price increase is	directly
14.11	attributable to additional costs for the dru	g imposed on the whole	sale distributor or p	harmacy
14.12	by the manufacturer of the drug.			
14.13	Sec. 10. [62J.843] REGISTERED A	GENT AND OFFICE	WITHIN THE ST	FATE.
14.14	Any manufacturer that sells, distributed	tes, delivers, or offers f	or sale any generic	or or
14.15	off-patent drug in the state must maintain	n a registered agent and	l office within the	state.
14.16	Sec. 11. [62J.844] ENFORCEMENT	· ·		
14.17	Subdivision 1. Notification. (a) The	commissioner of health s	hall notify the manu	ufacturer
14.18	of a generic or off-patent drug, the attorn	ey general, and the Boa	rd of Pharmacy of a	ny price
14.19	increase that the commissioner believes	may violate section 62.	J.842.	
14.20	(b) The commissioner of management	t and budget and any oth	er state agency that	provides
14.21	or purchases a pharmacy benefit except	the Department of Hum	an Services, and a	ny entity
14.22	under contract with a state agency to pro	ovide a pharmacy benefi	t other than an enti	ty under
14.23	contract with the Department of Human	Services, may notify the	e manufacturer of a	a generic
14.24	or off-patent drug, the attorney general,	and the Board of Pharn	nacy of any price in	ncrease
14.25	that the commissioner or entity believes	may violate section 62	J.842.	
14.26	Subd. 2. Submission of drug cost sta	tement and other info	rmation by manuf	acturer;
14.27	investigation by attorney general. (a) W	ithin 45 days of receivin	g a notice under sub	odivision
14.28	1, the manufacturer of the generic or of	-patent drug shall subm	nit a drug cost state	ment to
14.29	the attorney general. The statement mus	<u>t:</u>		
14.30	(1) itemize the cost components rela	ted to production of the	drug;	

	04/04/23	SENATEE	ADB	SS2744R
15.1	(2) identify the circumstances and t	iming of any increase in	n materials or man	ufacturing
15.2	costs that caused any increase during the			
15.3	years as applicable, in the price of the	drug; and		
15.4	(3) provide any other information the	hat the manufacturer be	lieves to be releva	nt to a
15.5	determination of whether a violation of	f section 62J.842 has oc	curred.	
15.6	(b) The attorney general may invest	tigate whether a violation	on of section 62J.8	42 has
15.7	occurred, in accordance with section 8	.31, subdivision 2.		
15.8	Subd. 3. Petition to court. (a) On p	petition of the attorney g	general, a court ma	y issue an
15.9	order:			
15.10	(1) compelling the manufacturer of	a generic or off-patent	drug to:	
15.11	(i) provide the drug cost statement	required under subdivis	ion 2, paragraph (a	a); and
15.12	(ii) answer interrogatories, produce	records or documents,	or be examined ur	nder oath,
15.13	as required by the attorney general und	ler subdivision 2, parag	raph (b);	
15.14	(2) restraining or enjoining a violati	on of sections 62J.841	to 62J.845, includi	ng issuing
15.15	an order requiring that drug prices be r	estored to levels that co	mply with section	62J.842;
15.16	(3) requiring the manufacturer to pr	rovide an accounting to	the attorney gener	al of all
15.17	revenues resulting from a violation of s	section 62J.842;		
15.18	(4) requiring the manufacturer to re	pay to all Minnesota co	onsumers, includin	g any
15.19	third-party payers, any money acquired	l as a result of a price in	ncrease that violate	es section
15.20	<u>62J.842;</u>			
15.21	(5) notwithstanding section 16A.15	1, requiring that all rev	enues generated fr	om a
15.22	violation of section 62J.842 be remitted	d to the state and deposi	ted into a special f	und, to be
15.23	used for initiatives to reduce the cost to	o consumers of acquirin	g prescription dru	gs, if a
15.24	manufacturer is unable to determine th	e individual transaction	s necessary to pro	vide the
15.25	repayments described in clause (4);			
15.26	(6) imposing a civil penalty of up to S	\$10,000 per day for each	violation of section	<u>n 62J.842;</u>
15.27	(7) providing for the attorney gener	al's recovery of costs ar	nd disbursements in	ncurred in
15.28	bringing an action against a manufactu	rer found in violation o	f section 62J.842,	including
15.29	the costs of investigation and reasonab	le attorney's fees; and		
15.30	(8) providing any other appropriate	relief, including any of	her equitable relie	fas
15.31	determined by the court.			

ADB

16.1	(b) For purposes of paragraph (a), clause (6), every individual transaction in violation
16.2	of section 62J.842 is considered a separate violation.
16.3	Subd. 4. Private right of action. Any action brought pursuant to section 8.31, subdivision
16.4	3a, by a person injured by a violation of section 62J.842 is for the benefit of the public.
16.5	Sec. 12. [62J.845] PROHIBITION ON WITHDRAWAL OF GENERIC OR
16.6	OFF-PATENT DRUGS FOR SALE.
16.7	Subdivision 1. Prohibition. A manufacturer of a generic or off-patent drug is prohibited
16.8	from withdrawing that drug from sale or distribution within this state for the purpose of
16.9	avoiding the prohibition on excessive price increases under section 62J.842.
16.10	Subd. 2. Notice to board and attorney general. Any manufacturer that intends to
16.11	withdraw a generic or off-patent drug from sale or distribution within the state shall provide
16.12	a written notice of withdrawal to the Board of Pharmacy and the attorney general at least
16.13	90 days prior to the withdrawal.
16.14	Subd. 3. Financial penalty. The attorney general shall assess a penalty of \$500,000 on
16.15	any manufacturer of a generic or off-patent drug that the attorney general determines has
16.16	failed to comply with the requirements of this section.
16.17	Sec. 13. [62J.846] SEVERABILITY.
16.18	If any provision of sections 62J.841 to 62J.845 or the application thereof to any person
16.19	or circumstance is held invalid for any reason in a court of competent jurisdiction, the
16.20	invalidity does not affect other provisions or any other application of sections 62J.841 to
16.21	62J.845 that can be given effect without the invalid provision or application.
16.22	Sec. 14. [62J.85] CITATION.
10.22	
16.23	Sections 62J.85 to 62J.95 may be cited as the "Prescription Drug Affordability Act."
16.24	Sec. 15. [62J.86] DEFINITIONS.
16.25	Subdivision 1. Definitions. For the purposes of sections 62J.85 to 62J.95, the following
16.26	terms have the meanings given.
16.27	Subd. 2. Advisory council. "Advisory council" means the Prescription Drug Affordability
16.28	Advisory Council established under section 62J.88.

17.1	Subd. 3. Biologic. "Biologic" means a drug that is produced or distributed in accordance
17.2	with a biologics license application approved under Code of Federal Regulations, title 42,
17.3	section 447.502.
17.4	Subd. 4. Biosimilar. "Biosimilar" has the meaning provided in section 62J.84, subdivision
17.5	2, paragraph (b).
17.6	Subd. 5. Board. "Board" means the Prescription Drug Affordability Board established
17.7	under section 62J.87.
17.8	Subd. 6. Brand name drug. "Brand name drug" means a drug that is produced or
17.9	distributed pursuant to:
17.10	(1) a new drug application approved under United States Code, title 21, section 355(c),
17.11	except for a generic drug as defined under Code of Federal Regulations, title 42, section
17.12	<u>447.502; or</u>
17.13	(2) a biologics license application approved under United States Code, title 45, section
17.14	<u>262(a)(c).</u>
17.15	Subd. 7. Generic drug. "Generic drug" has the meaning provided in section 62J.84,
17.16	subdivision 2, paragraph (e).
17.17	Subd. 8. Group purchaser. "Group purchaser" has the meaning given in section 62J.03,
17.18	subdivision 6, and includes pharmacy benefit managers, as defined in section 62W.02,
17.19	subdivision 15.
17.20	Subd. 9. Manufacturer. "Manufacturer" means an entity that:
17.21	(1) engages in the manufacture of a prescription drug product or enters into a lease with
17.22	another manufacturer to market and distribute a prescription drug product under the entity's
17.23	own name; and
17.24	(2) sets or changes the wholesale acquisition cost of the prescription drug product it
17.25	manufacturers or markets.
17.26	Subd. 10. Prescription drug product. "Prescription drug product" means a brand name
17.27	drug, a generic drug, a biologic, or a biosimilar.
17.28	Subd. 11. Wholesale acquisition cost or WAC. "Wholesale acquisition cost" or "WAC"
17.29	has the meaning given in United States Code, title 42, section 1395W-3a(c)(6)(B).

18.1	Sec. 16. [62J.87] PRESCRIPTION DRUG AFFORDABILITY BOARD.
18.2	Subdivision 1. Establishment. The commissioner of commerce shall establish the
18.3	Prescription Drug Affordability Board, which shall be governed as a board under section
18.4	15.012, paragraph (a), to protect consumers, state and local governments, health plan
18.5	companies, providers, pharmacies, and other health care system stakeholders from
18.6	unaffordable costs of certain prescription drugs.
18.7	Subd. 2. Membership. (a) The Prescription Drug Affordability Board consists of nine
18.8	members appointed as follows:
18.9	(1) seven voting members appointed by the governor;
18.10	(2) one nonvoting member appointed by the majority leader of the senate; and
18.11	(3) one nonvoting member appointed by the speaker of the house.
18.12	(b) All members appointed must have knowledge and demonstrated expertise in
18.13	pharmaceutical economics and finance or health care economics and finance. A member
18.14	must not be an employee of, a board member of, or a consultant to a manufacturer or trade
18.15	association for manufacturers, or a pharmacy benefit manager or trade association for
18.16	pharmacy benefit managers.
18.17	(c) Initial appointments must be made by January 1, 2024.
18.18	Subd. 3. Terms. (a) Board appointees shall serve four-year terms, except that initial
18.19	appointees shall serve staggered terms of two, three, or four years as determined by lot by
18.20	the secretary of state. A board member shall serve no more than two consecutive terms.
18.21	(b) A board member may resign at any time by giving written notice to the board.
18.22	Subd. 4. Chair; other officers. (a) The governor shall designate an acting chair from
18.23	the members appointed by the governor.
18.24	(b) The board shall elect a chair to replace the acting chair at the first meeting of the
18.25	board by a majority of the members. The chair shall serve for one year.
18.26	(c) The board shall elect a vice-chair and other officers from its membership as it deems
18.27	necessary.
18.28	Subd. 5. Staff; technical assistance. (a) The board shall hire an executive director and
18.29	other staff, who shall serve in the unclassified service. The executive director must have
18.30	knowledge and demonstrated expertise in pharmacoeconomics, pharmacology, health policy,
18.31	health services research, medicine, or a related field or discipline.

19.1

(b) The commissioner of health shall provide technical assistance to the board. The board

ADB

may also employ or contract for professional and technical assistance as the board deems 19.2 19.3 necessary to perform the board's duties. (c) The attorney general shall provide legal services to the board. 19.4 19.5 Subd. 6. Compensation. The board members shall not receive compensation but may receive reimbursement for expenses as authorized under section 15.059, subdivision 3. 19.6 19.7 Subd. 7. Meetings. (a) Meetings of the board are subject to chapter 13D. The board shall meet publicly at least every three months to review prescription drug product information 19.8 submitted to the board under section 62J.90. If there are no pending submissions, the chair 19.9 of the board may cancel or postpone the required meeting. The board may meet in closed 19.10 session when reviewing proprietary information, as determined under the standards developed 19.11 19.12 in accordance with section 62J.91, subdivision 3. (b) The board shall announce each public meeting at least three weeks prior to the 19.13 scheduled date of the meeting. Any materials for the meeting shall be made public at least 19.14 two weeks prior to the scheduled date of the meeting. 19.15 (c) At each public meeting, the board shall provide the opportunity for comments from 19.16 the public, including the opportunity for written comments to be submitted to the board 19.17 prior to a decision by the board. 19.18 19.19 Sec. 17. [62J.88] PRESCRIPTION DRUG AFFORDABILITY ADVISORY 19.20 COUNCIL. Subdivision 1. Establishment. The governor shall appoint a 18-member stakeholder 19.21 advisory council to provide advice to the board on drug cost issues and to represent 19.22 stakeholders' views. The governor shall appoint the members of the advisory council based 19.23 on the members' knowledge and demonstrated expertise in one or more of the following 19.24 areas: the pharmaceutical business; practice of medicine; patient perspectives; health care 19.25 cost trends and drivers; clinical and health services research; and the health care marketplace. 19.26 Subd. 2. Membership. The council's membership shall consist of the following: 19.27 19.28 (1) two members representing patients and health care consumers; 19.29 (2) two members representing health care providers; 19.30 (3) one member representing health plan companies; (4) two members representing employers, with one member representing large employers 19.31 and one member representing small employers; 19.32 Article 2 Sec. 17. 19

20.1	(5) one member representing government employee benefit plans;
20.2	(6) one member representing pharmaceutical manufacturers;
20.3	(7) one member who is a health services clinical researcher;
20.4	(8) one member who is a pharmacologist;
20.5	(9) one member representing the commissioner of health with expertise in health
20.6	economics;
20.7	(10) one member representing pharmaceutical wholesalers;
20.8	(11) one member representing pharmacy benefit managers;
20.9	(12) one member from the Rare Disease Advisory Council;
20.10	(13) one member representing generic drug manufacturers;
20.11	(14) one member representing pharmaceutical distributors; and
20.12	(15) one member who is an oncologist who is not employed by, under contract with, or
20.13	otherwise affiliated with a hospital.
20.14	Subd. 3. Terms. (a) The initial appointments to the advisory council must be made by
20.14 20.15	Subd. 3. Terms. (a) The initial appointments to the advisory council must be made by January 1, 2024. The initial appointed advisory council members shall serve staggered terms
20.15	January 1, 2024. The initial appointed advisory council members shall serve staggered terms
20.15 20.16	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial
20.15 20.16 20.17	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms.
20.1520.1620.1720.18	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section
 20.15 20.16 20.17 20.18 20.19 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059.
 20.15 20.16 20.17 20.18 20.19 20.20 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to
 20.15 20.16 20.17 20.18 20.19 20.20 20.21 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to section 15.059, except that those advisory council members designated in subdivision 2,
 20.15 20.16 20.17 20.18 20.19 20.20 20.21 20.22 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to section 15.059, except that those advisory council members designated in subdivision 2, clauses (10) to (15), must not be compensated.
 20.15 20.16 20.17 20.18 20.19 20.20 20.21 20.22 20.23 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to section 15.059, except that those advisory council members designated in subdivision 2, clauses (10) to (15), must not be compensated. Subd. 5. Meetings. Meetings of the advisory council are subject to chapter 13D. The
 20.15 20.16 20.17 20.18 20.19 20.20 20.21 20.22 20.23 20.24 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to section 15.059, except that those advisory council members designated in subdivision 2, clauses (10) to (15), must not be compensated. Subd. 5. Meetings. Meetings of the advisory council are subject to chapter 13D. The advisory council shall meet publicly at least every three months to advise the board on drug
 20.15 20.16 20.17 20.18 20.19 20.20 20.21 20.22 20.23 20.24 20.25 	January 1, 2024. The initial appointed advisory council members shall serve staggered terms of two, three, or four years, determined by lot by the secretary of state. Following the initial appointments, the advisory council members shall serve four-year terms. (b) Removal and vacancies of advisory council members shall be governed by section 15.059. Subd. 4. Compensation. Advisory council members may be compensated according to section 15.059, except that those advisory council members designated in subdivision 2, clauses (10) to (15), must not be compensated. Subd. 5. Meetings. Meetings of the advisory council are subject to chapter 13D. The advisory council shall meet publicly at least every three months to advise the board on drug cost issues related to the prescription drug product information submitted to the board under

21.1 Sec. 18. [62J.89] CONFLICTS OF INTEREST.

- 21.2 <u>Subdivision 1.</u> Definition. For purposes of this section, "conflict of interest" means a
- 21.3 <u>financial or personal association that has the potential to bias or have the appearance of</u>
- 21.4 <u>biasing a person's decisions in matters related to the board, the advisory council, or in the</u>
- 21.5 <u>conduct of the board's or council's activities. A conflict of interest includes any instance in</u>
- 21.6 which a person, a person's immediate family member, including a spouse, parent, child, or
- 21.7 <u>other legal dependent, or an in-law of any of the preceding individuals, has received or</u>
- 21.8 <u>could receive a direct or indirect financial benefit of any amount deriving from the result</u>
- 21.9 or findings of a decision or determination of the board. For purposes of this section, a
- 21.10 financial benefit includes honoraria, fees, stock, the value of the member's, immediate family
- 21.11 member's, or in-law's stock holdings, and any direct financial benefit deriving from the
- 21.12 finding of a review conducted under sections 62J.85 to 62J.95. Ownership of securities is
- 21.13 not a conflict of interest if the securities are: (1) part of a diversified mutual or exchange
- 21.14 traded fund; or (2) in a tax-deferred or tax-exempt retirement account that is administered
- 21.15 by an independent trustee.
- 21.16 Subd. 2. General. (a) Prior to the acceptance of an appointment or employment, or prior
- 21.17 to entering into a contractual agreement, a board or advisory council member, board staff
- 21.18 member, or third-party contractor must disclose to the appointing authority or the board
- 21.19 any conflicts of interest. The information disclosed must include the type, nature, and
- 21.20 magnitude of the interests involved.
- 21.21 (b) A board member, board staff member, or third-party contractor with a conflict of
- 21.22 interest with regard to any prescription drug product under review must recuse themselves
- 21.23 from any discussion, review, decision, or determination made by the board relating to the
- 21.24 prescription drug product.
- 21.25 (c) Any conflict of interest must be disclosed in advance of the first meeting after the 21.26 conflict is identified or within five days after the conflict is identified, whichever is earlier.
- 21.27 Subd. 3. **Prohibitions.** Board members, board staff, or third-party contractors are
- 21.28 prohibited from accepting gifts, bequeaths, or donations of services or property that raise
- 21.29 the specter of a conflict of interest or have the appearance of injecting bias into the activities
- 21.30 of the board.

22.1	Sec. 19. [62J.90] PRESCRIPTION DRUG PRICE INFORMATION; DECISION
22.2	TO CONDUCT COST REVIEW.
22.3	Subdivision 1. Drug price information from the commissioner of health and other
22.4	sources. (a) The commissioner of health shall provide to the board the information reported
22.5	to the commissioner by drug manufacturers under section 62J.84, subdivisions 3, 4, and 5.
22.6	The commissioner shall provide this information to the board within 30 days of the date the
22.7	information is received from drug manufacturers.
22.8	(b) The board may subscribe to one or more prescription drug pricing files, such as
22.9	Medispan or FirstDatabank, or as otherwise determined by the board.
22.10	Subd. 2. Identification of certain prescription drug products. (a) The board, in
22.11	consultation with the advisory council, shall identify selected prescription drug products
22.12	based on the following criteria:
22.13	(1) brand name drugs or biologics for which the WAC increases by \$3,000 during any
22.14	12-month period or course of treatment if less than 12 months, after adjusting for changes
22.15	in the consumer price index (CPI);
22.16	(2) brand name drugs or biologics with a WAC of \$60,000 or more per calendar year
22.17	or per course of treatment;
22.18	(3) biosimilar drugs that have a WAC that is not at least 20 percent lower than the
22.19	referenced brand name biologic at the time the biosimilar is introduced; and
22.20	(4) generic drugs for which:
22.21	(i) the price increase, adjusted for inflation using the Consumer Price Index, as defined
22.22	in section 62J.841, subdivision 2, exceeds:
22.23	(A) 15 percent of the wholesale acquisition cost over the immediately preceding calendar
22.24	year; or
22.25	(B) 40 percent of the wholesale acquisition cost over the immediately preceding three
22.26	calendar years; and
22.27	(ii) the price increase, adjusted for inflation utilizing the Consumer Price Index, exceeds
22.28	<u>\$30 for:</u>
22.29	(A) a 30-day supply of the drug; or
22.30	(B) a course of treatment lasting less than 30 days.

23.1	The board is not required to identify all prescription drug products that meet the criteria in
23.2	this paragraph.
23.3	(b) The board, in consultation with the advisory council and the commissioner of health,
23.4	may identify prescription drug products not described in paragraph (a) that may impose
23.5	costs that create significant affordability challenges for the state health care system or for
23.6	patients, including but not limited to drugs to address public health emergencies.
23.7	(c) The board shall make available to the public the names and related price information
23.8	of the prescription drug products identified under this subdivision, with the exception of
23.9	information determined by the board to be proprietary under the standards developed by
23.10	the board under section 62J.91, subdivision 3, and information provided by the commissioner
23.11	of health classified as not public data under section 13.02, subdivision 8a, or as trade secret
23.12	information under section 13.37, subdivision 1, paragraph (b), or as trade secret information
23.13	under the Defend Trade Secrets Act of 2016, United States Code, title 18, section 1836, as
23.14	amended.
23.15	Subd. 3. Determination to proceed with review. (a) The board may initiate a cost
23.16	review of a prescription drug product identified by the board under this section.
23.17	(b) The board shall consider requests by the public for the board to proceed with a cost
23.18	review of any prescription drug product identified under this section.
23.19	(c) If there is no consensus among the members of the board on whether to initiate a
23.20	cost review of a prescription drug product, any member of the board may request a vote to
23.21	determine whether to review the cost of the prescription drug product.
23.22	Sec. 20. [62J.91] PRESCRIPTION DRUG PRODUCT REVIEWS.
23.23	Subdivision 1. General. Once a decision by the board has been made to proceed with
23.24	a cost review of a prescription drug product, the board shall conduct the review and make
23.25	a determination as to whether appropriate utilization of the prescription drug under review,
23.26	based on utilization that is consistent with the United States Food and Drug Administration
23.27	(FDA) label or standard medical practice, has led or will lead to affordability challenges
23.28	for the state health care system or for patients.
23.29	Subd. 2. Review considerations. In reviewing the cost of a prescription drug product,
23.30	the board may consider the following factors:
23.31	(1) the price at which the prescription drug product has been and will be sold in the state;

	04/04/23	SENATEE	ADB	SS2744R
24.1	(2) manufacturer monetary price	e concessions, discount	s, or rebates, and dru	ig-specific
24.2	patient assistance;			
24.3	(3) the price of therapeutic altern	natives;		
24.4	(4) the cost to group purchasers b	based on patient access	consistent with the F	DA-labeled
24.5	indications and standard medical pr	actice;		
24.6	(5) measures of patient access, i	ncluding cost-sharing a	and other metrics;	
24.7	(6) the extent to which the attorned	ey general or a court has	s determined that a pr	ice increase
24.8	for a generic or off-patent prescription	on drug product was e	xcessive under section	ons 62J.842
24.9	and 62J.844;			
24.10	(7) any information a manufactu	arer chooses to provide	; and	
24.11	(8) any other factors as determine	ned by the board.		
24.12	Subd. 3. Public data; proprieta	ry information. (a) An	ny submission made	to the board
24.13	related to a drug cost review must b	e made available to the	e public with the exc	eption of
24.14	information determined by the boar	d to be proprietary and	information provide	ed by the
24.15	commissioner of health classified as	not public data under	section 13.02, subdiv	vision 8a, or
24.16	as trade secret information under se	ction 13.37, subdivisio	on 1, paragraph (b), o	r as trade
24.17	secret information under the Defend	Trade Secrets Act of	2016, United States	Code, title
24.18	18, section 1836, as amended.			
24.19	(b) The board shall establish the s	tandards for the informa	ation to be considered	proprietary
24.20	under paragraph (a) and section 62J	.90, subdivision 2, incl	luding standards for	heightened
24.21	consideration of proprietary information	ation for submissions f	or a cost review of a	drug that is
24.22	not yet approved by the FDA.			
24.23	(c) Prior to the board establishin	g the standards under p	paragraph (b), the pul	olic shall be
24.24	provided notice and the opportunity	to submit comments.		
24.25	(d) The establishment of standard	ls under this subdivisio	n is exempt from the	rulemaking
24.26	requirements under chapter 14, and	section 14.386 does no	ot apply.	
24.27	Sec. 21. [62J.92] DETERMINAT	FIONS; COMPLIAN	CE; REMEDIES.	
24.28	Subdivision 1. Upper payment	limit. (a) In the event t	the board finds that th	ne spending
24.29	on a prescription drug product revie			
24.30	challenge for the state health care sy	vstem or for patients, th	ne board shall establi	sh an upper
24.31	payment limit after considering:			

SENATEE

25.1	(1) extraordinary supply costs, if applicable;
25.2	(2) the range of prices at which the drug is sold in the United States according to one or
25.3	more pricing files accessed under section 62J.90, subdivision 1, and the range at which
25.4	pharmacies are reimbursed in Canada; and
25.5	(3) any other relevant pricing and administrative cost information for the drug.
25.6	(b) An upper payment limit applies to all purchases of, and payer reimbursements for,
25.7	a prescription drug that is dispensed or administered to individuals in the state in person,
25.8	by mail, or by other means, and for which an upper payment limit has been established.
25.9	Subd. 2. Implementation and administration of the upper payment limit. (a) An
25.10	upper payment limit may take effect no sooner than 120 days following the date of its public
25.11	release by the board.
25.12	(b) When setting an upper payment limit for a drug subject to the Medicare maximum
25.13	fair price under United States Code, title 42, section 1191(c), the board shall set the upper
25.14	payment limit at the Medicare maximum fair price.
25.15	(c) Pharmacy dispensing fees must not be counted toward or subject to any upper payment
25.16	limit. State-licensed independent pharmacies must not be reimbursed by health carriers and
25.17	pharmacy benefit managers at amounts that are less than the upper payment limit.
25.18	(d) Health plan companies and pharmacy benefit managers shall report annually to the
25.19	board, in the form and manner specified by the board, on how cost savings resulting from
25.20	the establishment of an upper payment limit have been used by the health plan company or
25.21	pharmacy benefit manager to benefit enrollees, including but not limited to reducing enrollee
25.22	cost-sharing.
25.23	Subd. 3. Noncompliance. (a) The board shall, and other persons may, notify the Office
25.24	of the Attorney General of a potential failure by an entity subject to an upper payment limit
25.25	to comply with that limit.
25.26	(b) If the Office of the Attorney General finds that an entity was noncompliant with the
25.27	upper payment limit requirements, the attorney general may pursue remedies consistent
25.28	with chapter 8 or appropriate criminal charges if there is evidence of intentional profiteering.
25.29	(c) An entity who obtains price concessions from a drug manufacturer that result in a
25.30	lower net cost to the stakeholder than the upper payment limit established by the board is
25.31	not considered noncompliant.

- 26.1 (d) The Office of the Attorney General may provide guidance to stakeholders concerning
 26.2 activities that could be considered noncompliant.
- 26.3 Subd. 4. Appeals. (a) Persons affected by a decision of the board may request an appeal
- 26.4 of the board's decision within 30 days of the date of the decision. The board shall hear the
- appeal and render a decision within 60 days of the hearing.
- 26.6 (b) All appeal decisions are subject to judicial review in accordance with chapter 14.

26.7 Sec. 22. [62J.93] REPORTS.

- 26.8 Beginning March 1, 2024, and each March 1 thereafter, the board shall submit a report
- 26.9 to the governor and legislature on general price trends for prescription drug products and
- 26.10 the number of prescription drug products that were subject to the board's cost review and
- 26.11 analysis, including the result of any analysis as well as the number and disposition of appeals
- 26.12 and judicial reviews.

26.13 Sec. 23. [62J.94] ERISA PLANS AND MEDICARE DRUG PLANS.

- 26.14 (a) Nothing in sections 62J.85 to 62J.95 shall be construed to require ERISA plans or
- 26.15 Medicare Part D plans to comply with decisions of the board. ERISA plans or Medicare
- 26.16 Part D plans are free to choose to exceed the upper payment limit established by the board
 26.17 under section 62J.92.
- 26.18 (b) Providers who dispense and administer drugs in the state must bill all payers no more
- 26.19 than the upper payment limit without regard to whether an ERISA plan or Medicare Part
- 26.20 D plan chooses to reimburse the provider in an amount greater than the upper payment limit
 26.21 established by the board.
- 26.22 (c) For purposes of this section, an ERISA plan or group health plan is an employee
- 26.23 welfare benefit plan established by or maintained by an employer or an employee
- 26.24 organization, or both, that provides employer sponsored health coverage to employees and
- 26.25 the employee's dependents and is subject to the Employee Retirement Income Security Act
 26.26 of 1974 (ERISA).
- 26.27 Sec. 24. [62J.95] SEVERABILITY.
- 26.28 If any provision of sections 62J.85 to 62J.94 or the application thereof to any person or
- 26.29 circumstance is held invalid for any reason in a court of competent jurisdiction, the invalidity
- 26.30 does not affect other provisions or any other application of sections 62J.85 to 62J.94 that
- 26.31 <u>can be given effect without the invalid provision or application.</u>

27.1

ADB

Subd. 4. Network adequacy. Each designated provider network must include a sufficient
number and type of providers, including providers that specialize in mental health and
substance use disorder services, to ensure that covered services are available to all enrollees
without unreasonable delay. In determining network adequacy, the commissioner of health
shall consider availability of services, including the following:

Sec. 25. Minnesota Statutes 2022, section 62K.10, subdivision 4, is amended to read:

27.7 (1) primary care physician services are available and accessible 24 hours per day, seven
27.8 days per week, within the network area;

(2) a sufficient number of primary care physicians have hospital admitting privileges at
one or more participating hospitals within the network area so that necessary admissions
are made on a timely basis consistent with generally accepted practice parameters;

27.12 (3) specialty physician service is available through the network or contract arrangement;

27.13 (4) mental health and substance use disorder treatment providers, including but not

27.14 <u>limited to psychiatric residential treatment facilities</u>, are available and accessible through
27.15 the network or contract arrangement;

(5) to the extent that primary care services are provided through primary care providers
other than physicians, and to the extent permitted under applicable scope of practice in state
law for a given provider, these services shall be available and accessible; and

(6) the network has available, either directly or through arrangements, appropriate and
sufficient personnel, physical resources, and equipment to meet the projected needs of
enrollees for covered health care services.

27.22 Sec. 26. Minnesota Statutes 2022, section 62Q.19, subdivision 1, is amended to read:

27.23 Subdivision 1. **Designation.** (a) The commissioner shall designate essential community 27.24 providers. The criteria for essential community provider designation shall be the following:

(1) a demonstrated ability to integrate applicable supportive and stabilizing services with
medical care for uninsured persons and high-risk and special needs populations, underserved,
and other special needs populations; and

- (2) a commitment to serve low-income and underserved populations by meeting thefollowing requirements:
- (i) has nonprofit status in accordance with chapter 317A;

(ii) has tax-exempt status in accordance with the Internal Revenue Service Code, section
501(c)(3);

(iii) charges for services on a sliding fee schedule based on current poverty incomeguidelines; and

28.5 (iv) does not restrict access or services because of a client's financial limitation;

(3) status as a local government unit as defined in section 62D.02, subdivision 11, a
hospital district created or reorganized under sections 447.31 to 447.37, an Indian tribal
government, an Indian health service unit, or a community health board as defined in chapter
145A;

(4) a former state hospital that specializes in the treatment of cerebral palsy, spina bifida,
epilepsy, closed head injuries, specialized orthopedic problems, and other disabling
conditions;

(5) a sole community hospital. For these rural hospitals, the essential community provider
designation applies to all health services provided, including both inpatient and outpatient
services. For purposes of this section, "sole community hospital" means a rural hospital
that:

(i) is eligible to be classified as a sole community hospital according to Code of Federal
Regulations, title 42, section 412.92, or is located in a community with a population of less
than 5,000 and located more than 25 miles from a like hospital currently providing acute
short-term services;

(ii) has experienced net operating income losses in two of the previous three most recentconsecutive hospital fiscal years for which audited financial information is available; and

28.23 (iii) consists of 40 or fewer licensed beds;

28.24 (6) a birth center licensed under section 144.615; or

(7) a hospital and affiliated specialty clinics that predominantly serve patients who are
under 21 years of age and meet the following criteria:

(i) provide intensive specialty pediatric services that are routinely provided in fewerthan five hospitals in the state; and

28.29 (ii) serve children from at least one-half of the counties in the state; or

- 28.30 (8) a psychiatric residential treatment facility, as defined in section 256B.0625,
- 28.31 subdivision 45a, paragraph (b), that is certified and licensed by the commissioner of health.

(b) Prior to designation, the commissioner shall publish the names of all applicants in 29.1 the State Register. The public shall have 30 days from the date of publication to submit 29.2 29.3 written comments to the commissioner on the application. No designation shall be made by the commissioner until the 30-day period has expired. 29.4 29.5 (c) The commissioner may designate an eligible provider as an essential community provider for all the services offered by that provider or for specific services designated by 29.6 the commissioner. 29.7 (d) For the purpose of this subdivision, supportive and stabilizing services include at a 29.8 minimum, transportation, child care, cultural, and linguistic services where appropriate. 29.9 Sec. 27. Minnesota Statutes 2022, section 62Q.46, subdivision 1, is amended to read: 29.10 29.11 Subdivision 1. Coverage for preventive items and services. (a) "Preventive items and services" has the meaning specified in the Affordable Care Act. Preventive items and services 29.12 29.13 includes: (1) evidence-based items or services that have in effect a rating of A or B in the current 29.14 recommendations of the United States Preventive Services Task Force with respect to the 29.15 individual involved; 29.16 (2) immunizations for routine use in children, adolescents, and adults that have in effect 29.17 a recommendation from the Advisory Committee on Immunization Practices of the Centers 29.18 for Disease Control and Prevention with respect to the individual involved. For purposes 29.19 29.20 of this clause, a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention is considered in effect after the 29.21 recommendation has been adopted by the Director of the Centers for Disease Control and 29.22 Prevention, and a recommendation is considered to be for routine use if the recommendation 29.23 is listed on the Immunization Schedules of the Centers for Disease Control and Prevention; 29.24 (3) with respect to infants, children, and adolescents, evidence-informed preventive care 29.25 and screenings provided for in comprehensive guidelines supported by the Health Resources 29.26 29.27 and Services Administration; (4) with respect to women, additional preventive care and screenings that are not listed 29.28 with a rating of A or B by the United States Preventive Services Task Force but that are 29.29 provided for in comprehensive guidelines supported by the Health Resources and Services 29.30 Administration; and 29.31 (5) all contraceptive methods established in guidelines published by the United States 29.32 Food and Drug Administration. 29.33

29

Article 2 Sec. 27.

30.1 (b) A health plan company must provide coverage for preventive items and services at
a participating provider without imposing cost-sharing requirements, including a deductible,
coinsurance, or co-payment. Nothing in this section prohibits a health plan company that
has a network of providers from excluding coverage or imposing cost-sharing requirements
for preventive items or services that are delivered by an out-of-network provider.

30.6 (c) A health plan company is not required to provide coverage for any items or services
30.7 specified in any recommendation or guideline described in paragraph (a) if the
30.8 recommendation or guideline is no longer included as a preventive item or service as defined
30.9 in paragraph (a). Annually, a health plan company must determine whether any additional
30.10 items or services must be covered without cost-sharing requirements or whether any items
30.11 or services are no longer required to be covered.

30.12 (d) Nothing in this section prevents a health plan company from using reasonable medical
30.13 management techniques to determine the frequency, method, treatment, or setting for a
30.14 preventive item or service to the extent not specified in the recommendation or guideline.

30.15 (e) This section does not apply to grandfathered plans.

30.16 (f) This section does not apply to plans offered by the Minnesota Comprehensive Health30.17 Association.

30.18 Sec. 28. Minnesota Statutes 2022, section 62Q.46, subdivision 3, is amended to read:

Subd. 3. Additional services not prohibited. Nothing in this section prohibits a health 30.19 plan company from providing coverage for preventive items and services in addition to 30.20 those specified in the Affordable Care Act under subdivision 1, paragraph (a), or from 30.21 denying coverage for preventive items and services that are not recommended as preventive 30.22 items and services specified under the Affordable Care Act subdivision 1, paragraph (a). A 30.23 health plan company may impose cost-sharing requirements for a treatment not described 30.24 30.25 in the Affordable Care Act under subdivision 1, paragraph (a), even if the treatment results from a preventive item or service described in the Affordable Care Act under subdivision 30.26 30.27 1, paragraph (a).

30.28 Sec. 29. [62Q.465] MENTAL HEALTH PARITY AND SUBSTANCE ABUSE 30.29 ACCOUNTABILITY OFFICE.

30.30 (a) The Mental Health Parity and Substance Abuse Accountability Office is established

- 30.31 within the Department of Commerce to create and execute effective strategies for
- 30.32 implementing the requirements under:

(1) section 62Q.47; 31.1 (2) the federal Mental Health Parity Act of 1996, Public Law 104-204; 31.2 (3) the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction 31.3 Equity Act of 2008, Public Law 110-343, division C, sections 511 and 512; 31.4 (4) the Affordable Care Act, as defined under section 62A.011, subdivision 1a; and 31.5 31.6 (5) amendments made to, and federal guidance or regulations issued or adopted under, the acts listed under clauses (2) to (4). 31.7 (b) The office may oversee compliance reviews, conduct and lead stakeholder 31.8 31.9 engagement, review consumer and provider complaints, and serve as a resource for ensuring health plan compliance with mental health and substance abuse requirements. 31.10 Sec. 30. Minnesota Statutes 2022, section 62Q.47, is amended to read: 31.11 31.12 62Q.47 ALCOHOLISM, MENTAL HEALTH, AND CHEMICAL DEPENDENCY **SERVICES.** 31.13 (a) All health plans, as defined in section 62Q.01, that provide coverage for alcoholism, 31.14 mental health, or chemical dependency services, must comply with the requirements of this 31.15 31.16 section. (b) Cost-sharing requirements and benefit or service limitations for outpatient mental 31.17 31.18 health and outpatient chemical dependency and alcoholism services, except for persons placed in chemical dependency services under Minnesota Rules, parts 9530.6600 to 31.19 9530.6655, must not place a greater financial burden on the insured or enrollee, or be more 31.20 restrictive than those requirements and limitations for outpatient medical services. 31.21 (c) Cost-sharing requirements and benefit or service limitations for inpatient hospital 31.22 mental health services, psychiatric residential treatment facility services, and inpatient 31.23 hospital and residential chemical dependency and alcoholism services, except for persons 31.24 placed in chemical dependency services under Minnesota Rules, parts 9530.6600 to 31.25 9530.6655, must not place a greater financial burden on the insured or enrollee, or be more 31.26 restrictive than those requirements and limitations for inpatient hospital medical services. 31.27 (d) A health plan company must not impose an NQTL with respect to mental health and 31.28 substance use disorders in any classification of benefits unless, under the terms of the health 31.29 plan as written and in operation, any processes, strategies, evidentiary standards, or other 31.30 factors used in applying the NQTL to mental health and substance use disorders in the 31.31 classification are comparable to, and are applied no more stringently than, the processes, 31.32

strategies, evidentiary standards, or other factors used in applying the NQTL with respect
to medical and surgical benefits in the same classification.

32.3 (e) All health plans must meet the requirements of the federal Mental Health Parity Act
32.4 of 1996, Public Law 104-204; Paul Wellstone and Pete Domenici Mental Health Parity and
32.5 Addiction Equity Act of 2008; the Affordable Care Act; and any amendments to, and federal
32.6 guidance or regulations issued under, those acts.

(f) The commissioner may require information from health plan companies to confirm
that mental health parity is being implemented by the health plan company. Information
required may include comparisons between mental health and substance use disorder
treatment and other medical conditions, including a comparison of prior authorization
requirements, drug formulary design, claim denials, rehabilitation services, and other
information the commissioner deems appropriate.

32.13 (g) Regardless of the health care provider's professional license, if the service provided
32.14 is consistent with the provider's scope of practice and the health plan company's credentialing
32.15 and contracting provisions, mental health therapy visits and medication maintenance visits
32.16 shall be considered primary care visits for the purpose of applying any enrollee cost-sharing
32.17 requirements imposed under the enrollee's health plan.

32.18 (h) All health plan companies offering health plans that provide coverage for alcoholism,
 32.19 mental health, or chemical dependency benefits shall provide reimbursement for the benefits
 32.20 delivered through the psychiatric Collaborative Care Model, which must include the following
 32.21 Current Procedural Terminology or Healthcare Common Procedure Coding System billing
 32.22 codes:

- 32.23 (1) 99492;
- 32.24 (2) 99493;
- 32.25 (3) 99494;
- 32.26 (4) G2214; and
- 32.27 <u>(5) G0512.</u>

32.28 This paragraph does not apply to: (i) managed care plans or county-based purchasing plans

32.29 when the plan provides coverage to public health care program enrollees under chapter

32.30 <u>256B or 256L; or (ii) health care coverage offered by the state employee group insurance</u>

32.31 program.

ADB

33.1	(i) The commissioner of commerce shall update the list of codes in paragraph (h) if any				
33.2	alterations or additions to the billing codes for the psychiatric Collaborative Care Model				
33.3	are made.				
33.4	(j) "Psychiatric Collaborative Care Model" means the evidence-based, integrated				
33.5	behavioral health service delivery method described at Federal Register, volume 81, page				
33.6	80230, which includes a formal collaborative arrangement among a primary care team				
33.7	consisting of a primary care provider, a care manager, and a psychiatric consultant, and				
33.8	includes but is not limited to the following elements:				
33.9	(1) care directed by the primary care team;				
33.10	(2) structured care management;				
33.11	(3) regular assessments of clinical status using validated tools; and				
33.12	(4) modification of treatment as appropriate.				
33.13	(h) (k) By June 1 of each year, beginning June 1, 2021, the commissioner of commerce,				
33.14	in consultation with the commissioner of health, shall submit a report on compliance and				
33.15	oversight to the chairs and ranking minority members of the legislative committees with				
33.16	jurisdiction over health and commerce. The report must:				
33.17	(1) describe the commissioner's process for reviewing health plan company compliance				
33.18	with United States Code, title 42, section 18031(j), any federal regulations or guidance				
33.19	relating to compliance and oversight, and compliance with this section and section 62Q.53;				
33.20	(2) identify any enforcement actions taken by either commissioner during the preceding				
33.21	12-month period regarding compliance with parity for mental health and substance use				
33.22	disorders benefits under state and federal law, summarizing the results of any market conduct				
33.23	examinations. The summary must include: (i) the number of formal enforcement actions				
33.24	taken; (ii) the benefit classifications examined in each enforcement action; and (iii) the				
33.25	subject matter of each enforcement action, including quantitative and nonquantitative				
33.26	treatment limitations;				
33.27	(3) detail any corrective action taken by either commissioner to ensure health plan				
33.28	company compliance with this section, section 62Q.53, and United States Code, title 42,				
33.29	section 18031(j); and				
33.30	(4) describe the information provided by either commissioner to the public about				
33.31	alcoholism, mental health, or chemical dependency parity protections under state and federal				

33.32 law.

34.1 The report must be written in nontechnical, readily understandable language and must be

34.2 made available to the public by, among other means as the commissioners find appropriate,

34.3 posting the report on department websites. Individually identifiable information must be

34.4 excluded from the report, consistent with state and federal privacy protections.

34.5 Sec. 31. [62Q.481] COST-SHARING FOR PRESCRIPTION DRUGS AND RELATED 34.6 MEDICAL SUPPLIES TO TREAT CHRONIC DISEASE.

34.7 Subdivision 1. Cost-sharing limits. (a) A health plan must limit the amount of any

34.8 <u>enrollee cost-sharing for prescription drugs prescribed to treat a chronic disease to no more</u>

34.9 than: (1) \$25 per one-month supply for each prescription drug, regardless of the amount or

34.10 type of medication required to fill the prescription; and (2) \$50 per month in total for all

34.11 related medical supplies. The cost-sharing limit for related medical supplies does not increase

34.12 with the number of chronic diseases for which an enrollee is treated. Coverage under this

- 34.13 <u>section shall not be subject to any</u> deductible.
- 34.14 (b) If application of this section before an enrollee has met the enrollee's plan deductible

34.15 results in: (1) health savings account ineligibility under United States Code, title 26, section

34.16 223; or (2) catastrophic health plan ineligibility under United States Code, title 42, section

34.17 <u>18022(e)</u>, this section applies to the specific prescription drug or related medical supply

```
34.18 only after the enrollee has met the enrollee's plan deductible.
```

34.19 Subd. 2. Definitions. (a) For purposes of this section, the following definitions apply.

- 34.20 (b) "Chronic disease" means diabetes, asthma, and allergies requiring the use of
- 34.21 <u>epinephrine auto-injectors.</u>
- 34.22 (c) "Cost-sharing" means co-payments and coinsurance.

34.23 (d) "Related medical supplies" means syringes, insulin pens, insulin pumps, test strips,
 34.24 glucometers, continuous glucose monitors, epinephrine auto-injectors, asthma inhalers, and
 34.25 other medical supply items necessary to effectively and appropriately treat a chronic disease

34.26 or administer a prescription drug prescribed to treat a chronic disease.

34.27 EFFECTIVE DATE. This section is effective January 1, 2024, and applies to health 34.28 plans offered, issued, or renewed on or after that date.

34.29 Sec. 32. Minnesota Statutes 2022, section 62Q.81, subdivision 4, is amended to read:

34.30 Subd. 4. Essential health benefits; definition. For purposes of this section, "essential

health benefits" has the meaning given under section 1302(b) of the Affordable Care Actand includes:

	04/04/23	SENATEE	ADB	SS2744R			
35.1	(1) ambulatory patient services;						
35.2	(2) emergency services;						
35.3	(3) hospitalization;						
35.4	(4) laboratory services;						
35.5	(5) maternity and newborn care;						
35.6	(6) mental health and substance use	disorder services, incl	uding behavioral h	ealth			
35.7	treatment;		0				
35.8	(7) pediatric services, including ora	l and vision care;					
35.9	(8) prescription drugs;						
35.10	(9) preventive and wellness service	s and chronic disease n	nanagement;				
35.11	(10) rehabilitative and habilitative s	ervices and devices; ar	ıd				
35.12	(11) additional essential health bene	fits included in the EHE	3-benchmark plan, a	as defined			
35.13	under the Affordable Care Act, and preventive items and services, as defined under section						
35.14	62Q.46, subdivision 1, paragraph (a).						
35.15	Sec. 33. Minnesota Statutes 2022, sec	tion 62Q.81, is amende	ed by adding a subd	livision to			
35.16	read:						
35.17	Subd. 7. Standard plans. (a) A hea	lth plan company that c	offers individual he	alth plans			
35.18	must ensure that no less than one indivi	dual health plan at each	n level of coverage	described			
35.19	in subdivision 1, paragraph (b), clause	(3), that the health plan	company offers in	each			
35.20	geographic rating area the health plan of	company serves, confor	ms to the standard	plan			
35.21	parameters determined by the commiss	ioner under paragraph	<u>(e).</u>				
35.22	(b) An individual health plan offere	d under this subdivisio	n must be:				
35.23	(1) clearly and appropriately labeled	as standard plans to aid	the purchaser in the	eselection			
35.24	process;						
35.25	(2) marketed as standard plans and	in the same manner as	other individual he	alth plans			
35.26	offered by the health plan company; an	<u>d</u>					
35.27	(3) offered for purchase to any indiv	vidual.					
35.28	(c) This subdivision does not apply	to catastrophic plans, g	grandfathered plans	s, small			
35.29	group health plans, large group health	plans, health savings ac	counts, qualified h	igh			

	04/04/23	SENATEE	ADB	SS2744R
36.1	deductible health benefit plans, limited	d health benefit pla	ns, or short-term lim	ited-duration
36.2	health insurance policies.			
36.3	(d) Health plan companies must me	eet the requirement	s in this subdivision s	separately for
36.4	plans offered through MNsure under c	chapter 62V and pl	ans offered outside o	f MNsure.
36.5	(e) The commissioner of commerc	e, in consultation	with the commissione	er of health,
36.6	must annually determine standard plan	parameters, includ	ling but not limited to	cost-sharing
36.7	structure and covered benefits, that co	mprise a standard	plan in Minnesota.	
36.8	EFFECTIVE DATE. This section	is effective Januar	y 1, 2025, and applies	to individual
36.9	health plans offered, issued, or renewe	ed on or after that o	late.	
36.10	Sec. 34. [62W.15] CLINICIAN-AD	DMINISTERED I	DRUGS.	
36.11	Subdivision 1. Definitions. (a) For	r purposes of this s	ection, the following	definitions
36.12	apply.			
36.13	(b) "Affiliated pharmacy" means a	pharmacy in whic	h a pharmacy benefit	t manager or
36.14	health carrier has an ownership interest	st either directly or	indirectly, or through	h an affiliate
36.15	or subsidiary.			
36.16	(c) "Clinician-administered drug"	means an outpatier	nt prescription drug o	ther than a
36.17	vaccine that:			
36.18	(1) cannot reasonably be self-admin	nistered by the pati	ent to whom the drug	is prescribed
36.19	or by an individual assisting the patier	nt with self-admini	stration; and	
36.20	(2) is typically administered:			
36.21	(i) by a health care provider author	rized to administer	the drug, including v	vhen acting
36.22	under a physician's delegation and sup	pervision; and		
36.23	(ii) in a physician's office, hospital	outpatient infusio	n center, or other clin	nical setting.
36.24	Subd. 2. Prohibition on requiring	g coverage as a ph	<mark>armacy benefit.</mark> A p	oharmacy
36.25	benefit manager or health carrier shall	not require that a	clinician-administere	d drug or the
36.26	administration of a clinician-administer	ered drug be cover	ed as a pharmacy ber	nefit.
36.27	Subd. 3. Enrollee choice. A pharm	nacy benefit manag	ger or health carrier:	
36.28	(1) shall permit an enrollee to obta	in a clinician-adm	inistered drug from a	health care
36.29	provider authorized to administer the	drug, or a pharmac	<u>y;</u>	

ADB

37.1	(2) shall not interfere with the enrollee's right to obtain a clinician-administered drug
37.2	from their provider or pharmacy of choice, and shall not offer financial or other incentives
37.3	to influence the enrollee's choice of a provider or pharmacy;
37.4	(3) shall not require clinician-administered drugs to be dispensed by a pharmacy selected
37.5	by the pharmacy benefit manager or health carrier; and
37.6	(4) shall not limit or exclude coverage for a clinician-administered drug when it is not
37.7	dispensed by a pharmacy selected by the pharmacy benefit manager or health carrier, if the
37.8	drug would otherwise be covered.
37.9	Subd. 4. Cost-sharing and reimbursement. A pharmacy benefit manager or health
37.10	carrier:
37.11	(1) may impose coverage or benefit limitations on an enrollee who obtains a
37.12	clinician-administered drug from a health care provider authorized to administer the drug
37.13	or a pharmacy, but only if the limitations would also be imposed if the drug was obtained
37.14	from an affiliated pharmacy or a pharmacy selected by the pharmacy benefit manager or
37.15	health carrier;
37.16	(2) may impose cost-sharing requirements on an enrollee who obtains a
37.17	clinician-administered drug from a health care provider authorized to administer the drug
37.18	or a pharmacy, but only if the requirements would also be imposed if the drug was obtained
37.19	from an affiliated pharmacy or a pharmacy selected by the pharmacy benefit manager or
37.20	health carrier; and
37.21	(3) shall not reimburse a health care provider or pharmacy for clinician-administered
37.22	drugs and the drugs administration at an amount that is lower than would be applied to an
37.23	affiliated pharmacy or pharmacy selected by the pharmacy benefit manager or health carrier.
37.24	Subd. 5. Other requirements. A pharmacy benefit manager or health carrier:
37.25	(1) shall not require or encourage the dispensing of a clinician-administered drug to an
37.26	enrollee in a manner that is inconsistent with the supply chain security controls and chain
37.27	of distribution set by the federal Drug Supply Chain Security Act, United States Code, title
37.28	21, section 360eee, et seq.;
37.29	(2) shall not require a specialty pharmacy to dispense a clinician-administered drug
37.30	directly to a patient with the intention that the patient transport the drug to a health care
37.31	provider for administration; and
37.32	(3) may offer, but shall not require:

	04/04/23	SENATEE	ADB	SS2744R
38.1	(i) the use of a home infusion pharma	cy to dispense or adm	inister clinician-a	dministered
38.2	drugs to enrollees; and	-		
38.3	(ii) the use of an infusion site externa	nt to the enrollee's pro	ovider office or cl	inic
38.4	Subd. 6. Exclusion. This section doe	s not apply to health	plans offered und	er chapter
38.5	<u>256B or 256L.</u>			
38.6	EFFECTIVE DATE. This section is	s effective January 1,	2024.	
38.7	Sec. 35. Minnesota Statutes 2022, sect	ion 151.071, subdivis	sion 1, is amended	l to read:
38.8	Subdivision 1. Forms of disciplinar	y action. When the b	oard finds that a l	icensee,
38.9	registrant, or applicant has engaged in co	onduct prohibited und	der subdivision 2,	it may do
38.10	one or more of the following:			
38.11	(1) deny the issuance of a license or	registration;		
38.12	(2) refuse to renew a license or regist	tration;		
38.13	(3) revoke the license or registration;			
38.14	(4) suspend the license or registration	1;		
38.15	(5) impose limitations, conditions, or	both on the license of	or registration, inc	luding but
38.16	not limited to: the limitation of practice	to designated settings	s; the limitation of	f the scope
38.17	of practice within designated settings; th	e imposition of retrai	ining or rehabilita	tion
38.18	requirements; the requirement of practice	under supervision; th	e requirement of p	articipation
38.19	in a diversion program such as that establi	shed pursuant to sect	ion 214.31 or the c	onditioning
38.20	of continued practice on demonstration of	of knowledge or skill	s by appropriate e	xamination
38.21	or other review of skill and competence;			
38.22	(6) impose a civil penalty not exceedi	ng \$10,000 for each s	separate violation,	except that
38.23	a civil penalty not exceeding \$25,000 ma	y be imposed for eacl	h separate violatio	n of section
38.24	62J.842, the amount of the civil penalty	to be fixed so as to de	eprive a licensee o	or registrant
38.25	of any economic advantage gained by reas	son of the violation, to	o discourage simila	ar violations
38.26	by the licensee or registrant or any other	licensee or registran	t, or to reimburse	the board
38.27	for the cost of the investigation and proc	eeding, including bu	t not limited to, fe	es paid for
38.28	services provided by the Office of Admir	nistrative Hearings, le	gal and investigat	ive services
38.29	provided by the Office of the Attorney G	eneral, court reporter	rs, witnesses, repr	oduction of
38.30	records, board members' per diem comp	ensation, board staff	time, and travel c	osts and
38.31	expenses incurred by board staff and boa	ard members; and		

- 39.1 Sec. 36. Minnesota Statutes 2022, section 151.071, subdivision 2, is amended to read:
- 39.2 Subd. 2. Grounds for disciplinary action. The following conduct is prohibited and is
 39.3 grounds for disciplinary action:

(1) failure to demonstrate the qualifications or satisfy the requirements for a license or
registration contained in this chapter or the rules of the board. The burden of proof is on
the applicant to demonstrate such qualifications or satisfaction of such requirements;

39.7 (2) obtaining a license by fraud or by misleading the board in any way during the application process or obtaining a license by cheating, or attempting to subvert the licensing 39.8 examination process. Conduct that subverts or attempts to subvert the licensing examination 39.9 process includes, but is not limited to: (i) conduct that violates the security of the examination 39.10 materials, such as removing examination materials from the examination room or having 39.11 unauthorized possession of any portion of a future, current, or previously administered 39.12 licensing examination; (ii) conduct that violates the standard of test administration, such as 39.13 communicating with another examinee during administration of the examination, copying 39.14 another examinee's answers, permitting another examinee to copy one's answers, or 39.15 possessing unauthorized materials; or (iii) impersonating an examinee or permitting an 39.16 impersonator to take the examination on one's own behalf; 39.17

(3) for a pharmacist, pharmacy technician, pharmacist intern, applicant for a pharmacist 39.18 or pharmacy license, or applicant for a pharmacy technician or pharmacist intern registration, 39.19 conviction of a felony reasonably related to the practice of pharmacy. Conviction as used 39.20 in this subdivision includes a conviction of an offense that if committed in this state would 39.21 be deemed a felony without regard to its designation elsewhere, or a criminal proceeding 39.22 where a finding or verdict of guilt is made or returned but the adjudication of guilt is either 39.23 withheld or not entered thereon. The board may delay the issuance of a new license or 39.24 registration if the applicant has been charged with a felony until the matter has been 39.25 39.26 adjudicated;

(4) for a facility, other than a pharmacy, licensed or registered by the board, if an owner
or applicant is convicted of a felony reasonably related to the operation of the facility. The
board may delay the issuance of a new license or registration if the owner or applicant has
been charged with a felony until the matter has been adjudicated;

39.31 (5) for a controlled substance researcher, conviction of a felony reasonably related to
39.32 controlled substances or to the practice of the researcher's profession. The board may delay
39.33 the issuance of a registration if the applicant has been charged with a felony until the matter
39.34 has been adjudicated;

40.1 (6) disciplinary action taken by another state or by one of this state's health licensing40.2 agencies:

(i) revocation, suspension, restriction, limitation, or other disciplinary action against a
license or registration in another state or jurisdiction, failure to report to the board that
charges or allegations regarding the person's license or registration have been brought in
another state or jurisdiction, or having been refused a license or registration by any other
state or jurisdiction. The board may delay the issuance of a new license or registration if an
investigation or disciplinary action is pending in another state or jurisdiction until the

40.10 (ii) revocation, suspension, restriction, limitation, or other disciplinary action against a license or registration issued by another of this state's health licensing agencies, failure to 40.11 report to the board that charges regarding the person's license or registration have been 40.12 brought by another of this state's health licensing agencies, or having been refused a license 40.13 or registration by another of this state's health licensing agencies. The board may delay the 40.14 issuance of a new license or registration if a disciplinary action is pending before another 40.15 of this state's health licensing agencies until the action has been dismissed or otherwise 40.16 resolved; 40.17

40.18 (7) for a pharmacist, pharmacy, pharmacy technician, or pharmacist intern, violation of 40.19 any order of the board, of any of the provisions of this chapter or any rules of the board or 40.20 violation of any federal, state, or local law or rule reasonably pertaining to the practice of 40.21 pharmacy;

40.22 (8) for a facility, other than a pharmacy, licensed by the board, violations of any order
40.23 of the board, of any of the provisions of this chapter or the rules of the board or violation
40.24 of any federal, state, or local law relating to the operation of the facility;

(9) engaging in any unethical conduct; conduct likely to deceive, defraud, or harm the
public, or demonstrating a willful or careless disregard for the health, welfare, or safety of
a patient; or pharmacy practice that is professionally incompetent, in that it may create
unnecessary danger to any patient's life, health, or safety, in any of which cases, proof of
actual injury need not be established;

40.30 (10) aiding or abetting an unlicensed person in the practice of pharmacy, except that it
40.31 is not a violation of this clause for a pharmacist to supervise a properly registered pharmacy
40.32 technician or pharmacist intern if that person is performing duties allowed by this chapter
40.33 or the rules of the board;

(11) for an individual licensed or registered by the board, adjudication as mentally ill
or developmentally disabled, or as a chemically dependent person, a person dangerous to
the public, a sexually dangerous person, or a person who has a sexual psychopathic
personality, by a court of competent jurisdiction, within or without this state. Such
adjudication shall automatically suspend a license for the duration thereof unless the board
orders otherwise;

(12) for a pharmacist or pharmacy intern, engaging in unprofessional conduct as specified
in the board's rules. In the case of a pharmacy technician, engaging in conduct specified in
board rules that would be unprofessional if it were engaged in by a pharmacist or pharmacist
intern or performing duties specifically reserved for pharmacists under this chapter or the
rules of the board;

41.12 (13) for a pharmacy, operation of the pharmacy without a pharmacist present and on
41.13 duty except as allowed by a variance approved by the board;

(14) for a pharmacist, the inability to practice pharmacy with reasonable skill and safety 41.14 to patients by reason of illness, use of alcohol, drugs, narcotics, chemicals, or any other type 41.15 of material or as a result of any mental or physical condition, including deterioration through 41.16 the aging process or loss of motor skills. In the case of registered pharmacy technicians, 41.17 pharmacist interns, or controlled substance researchers, the inability to carry out duties 41.18 allowed under this chapter or the rules of the board with reasonable skill and safety to 41.19 patients by reason of illness, use of alcohol, drugs, narcotics, chemicals, or any other type 41.20 of material or as a result of any mental or physical condition, including deterioration through 41.21 the aging process or loss of motor skills; 41.22

(15) for a pharmacist, pharmacy, pharmacist intern, pharmacy technician, medical gas
dispenser, or controlled substance researcher, revealing a privileged communication from
or relating to a patient except when otherwise required or permitted by law;

(16) for a pharmacist or pharmacy, improper management of patient records, including
failure to maintain adequate patient records, to comply with a patient's request made pursuant
to sections 144.291 to 144.298, or to furnish a patient record or report required by law;

41.29 (17) fee splitting, including without limitation:

41.30 (i) paying, offering to pay, receiving, or agreeing to receive, a commission, rebate,

41.31 kickback, or other form of remuneration, directly or indirectly, for the referral of patients;

41.32 (ii) referring a patient to any health care provider as defined in sections 144.291 to
41.33 144.298 in which the licensee or registrant has a financial or economic interest as defined

42.1 in section 144.6521, subdivision 3, unless the licensee or registrant has disclosed the
42.2 licensee's or registrant's financial or economic interest in accordance with section 144.6521;
42.3 and

(iii) any arrangement through which a pharmacy, in which the prescribing practitioner 42.4 does not have a significant ownership interest, fills a prescription drug order and the 42.5 prescribing practitioner is involved in any manner, directly or indirectly, in setting the price 42.6 for the filled prescription that is charged to the patient, the patient's insurer or pharmacy 42.7 benefit manager, or other person paying for the prescription or, in the case of veterinary 42.8 patients, the price for the filled prescription that is charged to the client or other person 42.9 paying for the prescription, except that a veterinarian and a pharmacy may enter into such 42.10 an arrangement provided that the client or other person paying for the prescription is notified, 42.11 in writing and with each prescription dispensed, about the arrangement, unless such 42.12 arrangement involves pharmacy services provided for livestock, poultry, and agricultural 42.13 production systems, in which case client notification would not be required; 42.14

42.15 (18) engaging in abusive or fraudulent billing practices, including violations of the
42.16 federal Medicare and Medicaid laws or state medical assistance laws or rules;

42.17 (19) engaging in conduct with a patient that is sexual or may reasonably be interpreted
42.18 by the patient as sexual, or in any verbal behavior that is seductive or sexually demeaning
42.19 to a patient;

42.20 (20) failure to make reports as required by section 151.072 or to cooperate with an
42.21 investigation of the board as required by section 151.074;

42.22 (21) knowingly providing false or misleading information that is directly related to the 42.23 care of a patient unless done for an accepted therapeutic purpose such as the dispensing and 42.24 administration of a placebo;

42.25 (22) aiding suicide or aiding attempted suicide in violation of section 609.215 as
42.26 established by any of the following:

42.27 (i) a copy of the record of criminal conviction or plea of guilty for a felony in violation
42.28 of section 609.215, subdivision 1 or 2;

42.29 (ii) a copy of the record of a judgment of contempt of court for violating an injunction
42.30 issued under section 609.215, subdivision 4;

42.31 (iii) a copy of the record of a judgment assessing damages under section 609.215,
42.32 subdivision 5; or

43.1 (iv) a finding by the board that the person violated section 609.215, subdivision 1 or 2.
43.2 The board must investigate any complaint of a violation of section 609.215, subdivision 1
43.3 or 2;

43.4 (23) for a pharmacist, practice of pharmacy under a lapsed or nonrenewed license. For
43.5 a pharmacist intern, pharmacy technician, or controlled substance researcher, performing
43.6 duties permitted to such individuals by this chapter or the rules of the board under a lapsed
43.7 or nonrenewed registration. For a facility required to be licensed under this chapter, operation
43.8 of the facility under a lapsed or nonrenewed license or registration; and

43.9 (24) for a pharmacist, pharmacist intern, or pharmacy technician, termination or discharge
43.10 from the health professionals services program for reasons other than the satisfactory

43.11 completion of the program.; and

43.12 (25) for a manufacturer, a violation of section 62J.842 or 62J.845.

43.13 Sec. 37. Minnesota Statutes 2022, section 256B.0631, subdivision 1, is amended to read:

43.14 Subdivision 1. Cost-sharing. (a) Except as provided in subdivision 2, the medical
43.15 assistance benefit plan shall include the following cost-sharing for all recipients, effective
43.16 for services provided on or after September 1, 2011:

(1) \$3 per nonpreventive visit, except as provided in paragraph (b). For purposes of this
subdivision, a visit means an episode of service which is required because of a recipient's
symptoms, diagnosis, or established illness, and which is delivered in an ambulatory setting
by a physician or physician assistant, chiropractor, podiatrist, nurse midwife, advanced
practice nurse, audiologist, optician, or optometrist;

43.22 (2) \$3.50 for nonemergency visits to a hospital-based emergency room, except that this
43.23 co-payment shall be increased to \$20 upon federal approval;

(3) \$3 per brand-name drug prescription, \$1 per generic drug prescription, and \$1 per
prescription for a brand-name multisource drug listed in preferred status on the preferred
drug list, subject to a \$12 per month maximum for prescription drug co-payments. No
co-payments shall apply to antipsychotic drugs when used for the treatment of mental illness;

(4) a family deductible equal to \$2.75 per month per family and adjusted annually by
the percentage increase in the medical care component of the CPI-U for the period of
September to September of the preceding calendar year, rounded to the next higher five-cent
increment; and

(5) total monthly cost-sharing must not exceed five percent of family income. For
purposes of this paragraph, family income is the total earned and unearned income of the
individual and the individual's spouse, if the spouse is enrolled in medical assistance and
also subject to the five percent limit on cost-sharing. This paragraph does not apply to
premiums charged to individuals described under section 256B.057, subdivision 9-; and

44.6 (6) cost-sharing for prescription drugs and related medical supplies to treat chronic
44.7 disease must comply with the requirements of section 62Q.481.

(b) Recipients of medical assistance are responsible for all co-payments and deductibles
in this subdivision.

(c) Notwithstanding paragraph (b), the commissioner, through the contracting process
under sections 256B.69 and 256B.692, may allow managed care plans and county-based
purchasing plans to waive the family deductible under paragraph (a), clause (4). The value
of the family deductible shall not be included in the capitation payment to managed care
plans and county-based purchasing plans. Managed care plans and county-based purchasing
plans shall certify annually to the commissioner the dollar value of the family deductible.

(d) Notwithstanding paragraph (b), the commissioner may waive the collection of the
family deductible described under paragraph (a), clause (4), from individuals and allow
long-term care and waivered service providers to assume responsibility for payment.

(e) Notwithstanding paragraph (b), the commissioner, through the contracting process
under section 256B.0756 shall allow the pilot program in Hennepin County to waive
co-payments. The value of the co-payments shall not be included in the capitation payment
amount to the integrated health care delivery networks under the pilot program.

44.23 **EFFECTIVE DATE.** This section is effective January 1, 2024.

44.24 Sec. 38. Minnesota Statutes 2022, section 256L.03, subdivision 5, is amended to read:

Subd. 5. Cost-sharing. (a) Co-payments, coinsurance, and deductibles do not apply to
children under the age of 21 and to American Indians as defined in Code of Federal
Regulations, title 42, section 600.5.

(b) The commissioner shall adjust co-payments, coinsurance, and deductibles for covered
services in a manner sufficient to maintain the actuarial value of the benefit to 94 percent.
The cost-sharing changes described in this paragraph do not apply to eligible recipients or
services exempt from cost-sharing under state law. The cost-sharing changes described in
this paragraph shall not be implemented prior to January 1, 2016.

ADB

45.1	(c) The cost-sharing changes authorized under paragraph (b) must satisfy the requirements
45.2	for cost-sharing under the Basic Health Program as set forth in Code of Federal Regulations,
45.3	title 42, sections 600.510 and 600.520.
45.4	(d) Cost-sharing for prescription drugs and related medical supplies to treat chronic
45.5	disease must comply with the requirements of section 62Q.481.
45.6	EFFECTIVE DATE. This section is effective January 1, 2024.
45.7	Sec. 39. EVALUATION OF EXISTING STATUTORY HEALTH BENEFIT
45.8	MANDATES.
45.9	(a) The commissioner of commerce must evaluate existing Minnesota statutory provisions
45.10	that would constitute a state-required benefit included in Minnesota's EHB-benchmark plan,
45.11	as defined in Code of Federal Regulations, title 45, section 156.20, if the statutory provision
45.12	was offered as a legislative proposal on the date of enactment of this act.
45.13	(b) The commissioner must conduct the evaluation using the process established under
45.14	Minnesota Statutes, section 62J.26, subdivision 2.
45.15	(c) The commissioner may prioritize and determine the order in which statutory provisions
45.16	are evaluated under this section, provided that at least one statutory provision is evaluated
45.17	each year.
45.18	(d) This section expires January 1, 2034.
45.19	EFFECTIVE DATE. This section is effective the day following final enactment.
45.20	ARTICLE 3
45.21	FINANCIAL INSTITUTIONS
45.22	Section 1. Minnesota Statutes 2022, section 46.131, subdivision 11, is amended to read:
45.23	Subd. 11. Financial institutions account; appropriation. (a) The financial institutions
45.24	account is created as a separate account in the special revenue fund. Earnings, including
45.25	interest, dividends, and any other earnings arising from account assets, must be credited to
45.26	the account.
45.27	(b) The account consists of funds received from assessments under subdivision 7,
45.28	examination fees under subdivision 8, and funds received pursuant to subdivision 10 and
45.29	the following provisions: sections 46.04; 46.041; 46.048, subdivision 1; 47.101; 47.54,

45.30 subdivision 1; 47.60, subdivision 3; 47.62, subdivision 4; 48.61, subdivision 7, paragraph

45.31 (b); 49.36, subdivision 1; 52.203; 53B.09; 53B.11, subdivision 1; 53B.38; 53B.41; 53B.43;

	04/04/23	SENATEE	ADB	SS2744R
46.1	53C.02; 56.02; 58.10; 58A.045, subdiv	ision 2; 59A.03; 216	6C.437, subdivision 1	12; 332A.04;
46.2	and 332B.04.			
46.3	(c) Funds in the account are annual	lly appropriated to t	the commissioner of	commerce
46.4	for activities under this section.			
46.5	Sec. 2. [53B.28] DEFINITIONS.			
46.6	Subdivision 1. Terms. For the purp	ooses of this chapter	; the terms defined in	this section
46.7	have the meanings given them.			
46.8	Subd. 2. Acting in concert. "Acting	g in concert" means p	persons knowingly ac	ting together
46.9	with a common goal of jointly acquiring	ng control of a licer	usee, whether or not	pursuant to
46.10	an express agreement.			
46.11	Subd. 3. Authorized delegate. "A	uthorized delegate"	means a person a lic	censee
46.12	designates to engage in money transm	ission on behalf of	the licensee.	
46.13	Subd. 4. Average daily money tra	nsmission liability	v. "Average daily mo	ney
46.14	transmission liability" means the amou	ant of the licensee's	outstanding money	transmission
46.15	obligations in Minnesota at the end of	each day in a given	period of time, add	ed together,
46.16	and divided by the total number of day	vs in the given perio	od of time. For purpo	oses of
46.17	calculating average daily money transport	mission liability un	der this chapter for a	ny licensee
46.18	required to do so, the given period of t	ime shall be the qu	arters ending March	31, June 30,
46.19	September 30, and December 31.			
46.20	Subd. 5. Bank Secrecy Act. "Bank	s Secrecy Act" mea	ns the Bank Secrecy	Act under
46.21	United States Code, title 31, section 53	11, et seq., and the E	Bank Secrecy Act's in	nplementing
46.22	regulations, as amended and recodified	d from time to time	<u>-</u>	
46.23	Subd. 6. Closed loop stored value	. "Closed loop store	ed value" means store	ed value that
46.24	is redeemable by the issuer only for a	good or service pro	vided by the issuer,	the issuer's
46.25	affiliate, the issuer's franchisees, or an	affiliate of the issu	er's franchisees, exce	ept to the
46.26	extent required by applicable law to be	e redeemable in cas	h for the good or ser	vice's cash
46.27	value.			
46.28	Subd. 7. Control. "Control" means	<u>s:</u>		
46.29	(1) the power to vote, directly or in	directly, at least 25	percent of the outsta	nding voting
46.30	shares or voting interests of a licensee	or person in contro	l of a licensee;	

ADB

- 47.1 (2) the power to elect or appoint a majority of key individuals or executive officers, managers, directors, trustees, or other persons exercising managerial authority of a person 47.2 47.3 in control of a licensee; or (3) the power to exercise, directly or indirectly, a controlling influence over the 47.4 47.5 management or policies of a licensee or person in control of a licensee. Subd. 8. Eligible rating. "Eligible rating" means a credit rating of any of the three highest 47.6 rating categories provided by an eligible rating service, whereby each category may include 47.7 rating category modifiers such as "plus" or "minus" or the equivalent for any other eligible 47.8 rating service. Long-term credit ratings are deemed eligible if the rating is equal to A- or 47.9 47.10 higher or the equivalent from any other eligible rating service. Short-term credit ratings are deemed eligible if the rating is equal to or higher than A-2 or SP-2 by S&P, or the equivalent 47.11 from any other eligible rating service. In the event that ratings differ among eligible rating 47.12 services, the highest rating shall apply when determining whether a security bears an eligible 47.13 rating. 47.14 47.15 Subd. 9. Eligible rating service. "Eligible rating service" means any Nationally Recognized Statistical Rating Organization (NRSRO), as defined by the United States 47.16 Securities and Exchange Commission and any other organization designated by the 47.17 commissioner by rule or order. 47.18 47.19 Subd. 10. Federally insured depository financial institution. "Federally insured depository financial institution" means a bank, credit union, savings and loan association, 47.20 trust company, savings association, savings bank, industrial bank, or industrial loan company 47.21 organized under the laws of the United States or any state of the United States, when the 47.22 bank, credit union, savings and loan association, trust company, savings association, savings 47.23 bank, industrial bank, or industrial loan company has federally insured deposits. 47.24 Subd. 11. In Minnesota. "In Minnesota" means at a physical location within the state 47.25 of Minnesota for a transaction requested in person. For a transaction requested electronically 47.26 or by telephone, the provider of money transmission may determine if the person requesting 47.27 47.28 the transaction is in Minnesota by relying on other information provided by the person regarding the location of the individual's residential address or a business entity's principal 47.29 place of business or other physical address location, and any records associated with the 47.30 47.31 person that the provider of money transmission may have that indicate the location, including but not limited to an address associated with an account. 47.32
- 47.33 Subd. 12. Individual. "Individual" means a natural person.

48.1	Subd. 13. Key individual. "Key individual" means any individual ultimately responsible
48.2	for establishing or directing policies and procedures of the licensee, including but not limited
48.3	to as an executive officer, manager, director, or trustee.
48.4	Subd. 14. Licensee. "Licensee" means a person licensed under this chapter.
48.5	Subd. 15. Material litigation. "Material litigation" means litigation that, according to
48.6	United States generally accepted accounting principles, is significant to a person's financial
48.7	health and would be required to be disclosed in the person's annual audited financial
48.8	statements, report to shareholders, or similar records.
48.9	Subd. 16. Money. "Money" means a medium of exchange that is authorized or adopted
48.10	by the United States or a foreign government. Money includes a monetary unit of account
48.11	established by an intergovernmental organization or by agreement between two or more
48.12	governments.
48.13	Subd. 17. Monetary value. "Monetary value" means a medium of exchange, whether
48.14	or not redeemable in money.
48.15	Subd. 18. Money transmission. (a) "Money transmission" means:
48.16	(1) selling or issuing payment instruments to a person located in this state;
48.17	(2) selling or issuing stored value to a person located in this state; or
48.18	(3) receiving money for transmission from a person located in this state.
48.19	(b) Money includes payroll processing services. Money does not include the provision
48.20	solely of online or telecommunications services or network access.
48.21	Subd. 19. Money services business accredited state or MSB accredited state. "Money
48.22	services businesses accredited state" or "MSB accredited state" means a state agency that
48.23	is accredited by the Conference of State Bank Supervisors and Money Transmitter Regulators
48.24	Association for money transmission licensing and supervision.
48.25	Subd. 20. Multistate licensing process. "Multistate licensing process" means any
48.26	agreement entered into by and among state regulators relating to coordinated processing of
48.27	applications for money transmission licenses, applications for the acquisition of control of
48.28	a licensee, control determinations, or notice and information requirements for a change of
48.29	key individuals.
48.30	Subd. 21. NMLS. "NMLS" means the Nationwide Multistate Licensing System and
48.31	Registry developed by the Conference of State Bank Supervisors and the American
48.32	Association of Residential Mortgage Regulators and owned and operated by the State

49.1	Regulatory Registry, LLC, or any successor or affiliated entity, for the licensing and
49.2	registration of persons in financial services industries.
49.3	Subd. 22. Outstanding money transmission obligations. (a) "Outstanding money
49.4	transmission obligations" must be established and extinguished in accordance with applicable
49.5	state law and means:
49.6	(1) any payment instrument or stored value issued or sold by the licensee to a person
49.7	located in the United States or reported as sold by an authorized delegate of the licensee to
49.8	a person that is located in the United States that has not yet been paid or refunded by or for
49.8	the licensee, or escheated in accordance with applicable abandoned property laws; or
49.9	the needsee, or eschedeed in accordance with applicable abandoned property laws, or
49.10	(2) any money received for transmission by the licensee or an authorized delegate in the
49.11	United States from a person located in the United States that has not been received by the
49.12	payee or refunded to the sender, or escheated in accordance with applicable abandoned
49.13	property laws.
49.14	(b) For purposes of this subdivision, "in the United States" includes, to the extent
49.15	applicable, a person in any state, territory, or possession of the United States; the District
49.16	of Columbia; the Commonwealth of Puerto Rico; or a U.S. military installation that is
49.17	located in a foreign country.
49.18	Subd. 23. Passive investor. "Passive investor" means a person that:
49.19	(1) does not have the power to elect a majority of key individuals or executive officers,
49.20	managers, directors, trustees, or other persons exercising managerial authority of a person
49.21	in control of a licensee;
49.22	(2) is not employed by and does not have any managerial duties of the licensee or person
49.23	in control of a licensee;
49.24	(3) does not have the power to exercise, directly or indirectly, a controlling influence
49.25	over the management or policies of a licensee or person in control of a licensee; and
49.26	(4) attests to clauses (1), (2), and (3), in a form and in a medium prescribed by the
49.27	commissioner, or commits to the passivity characteristics under clauses (1), (2), and (3) in
49.28	a written document.
49.29	Subd. 24. Payment instrument. (a) "Payment instrument" means a written or electronic
49.30	check, draft, money order, traveler's check, or other written or electronic instrument for the
10.01	

49.31 transmission or payment of money or monetary value, whether or not negotiable.

ADB

50.1	(b) Payment instrument does not include stored value or any instrument that is: (1)
50.2	redeemable by the issuer only for goods or services provided by the issuer, the issuer's
50.3	affiliate, the issuer's franchisees, or an affiliate of the issuer's franchisees, except to the
50.4	extent required by applicable law to be redeemable in cash for its cash value; or (2) not sold
50.5	to the public but issued and distributed as part of a loyalty, rewards, or promotional program.
50.6	Subd. 25. Payroll processing services. "Payroll processing services" means receiving
50.7	money for transmission pursuant to a contract with a person to deliver wages or salaries,
50.8	make payment of payroll taxes to state and federal agencies, make payments relating to
50.9	employee benefit plans, or make distributions of other authorized deductions from wages
50.10	or salaries. The term payroll processing services does not include an employer performing
50.11	payroll processing services on the employer's own behalf or on behalf of the employer's
50.12	affiliate, or a professional employment organization subject to regulation under other
50.13	applicable state law.
50.14	Subd. 26. Person. "Person" means any individual, general partnership, limited partnership,
50.15	limited liability company, corporation, trust, association, joint stock corporation, or other
50.16	corporate entity identified by the commissioner.
50.17	Subd. 27. Receiving money for transmission or money received for
	Subd. 27. Receiving money for transmission or money received for transmission. "Receiving money for transmission" or "money received for transmission"
50.18	transmission. "Receiving money for transmission" or "money received for transmission"
50.18 50.19	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or
50.18 50.19 50.20	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means.
50.1850.1950.2050.21	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim
50.1950.2050.2150.22	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and
50.18 50.19 50.20 50.21 50.22 50.23	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for
50.18 50.19 50.20 50.21 50.22 50.23 50.24	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined
50.18 50.19 50.20 50.21 50.22 50.23 50.24 50.25	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined under Code of Federal Regulations, title 31, part 1010.100, as amended or recodified from
50.18 50.19 50.20 50.21 50.22 50.23 50.24 50.25 50.26	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined under Code of Federal Regulations, title 31, part 1010.100, as amended or recodified from time to time.
50.18 50.19 50.20 50.21 50.22 50.23 50.24 50.25 50.26 50.26	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined under Code of Federal Regulations, title 31, part 1010.100, as amended or recodified from time to time. (b) Notwithstanding this subdivision, stored value does not include: (1) a payment
50.18 50.19 50.20 50.21 50.22 50.23 50.24 50.25 50.26 50.27 50.28	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined under Code of Federal Regulations, title 31, part 1010.100, as amended or recodified from time to time. (b) Notwithstanding this subdivision, stored value does not include: (1) a payment instrument or closed loop stored value; or (2) stored value not sold to the public but issued
50.18 50.19 50.20 50.21 50.22 50.23 50.24 50.25 50.26 50.27 50.28 50.29	transmission. "Receiving money for transmission" or "money received for transmission" means receiving money or monetary value in the United States for transmission within or outside the United States by electronic or other means. Subd. 28. Stored value. (a) "Stored value" means monetary value representing a claim against the issuer evidenced by an electronic or digital record, and that is intended and accepted for use as a means of redemption for money or monetary value, or payment for goods or services. Stored value includes but is not limited to prepaid access, as defined under Code of Federal Regulations, title 31, part 1010.100, as amended or recodified from time to time. (b) Notwithstanding this subdivision, stored value does not include: (1) a payment instrument or closed loop stored value; or (2) stored value not sold to the public but issued and distributed as part of a loyalty, rewards, or promotional program.

	04/04/23	SENATEE	ADB	SS2744R	
51.1	Sec. 3. [53B.29] EXEMPTIONS.				
51.2	This chapter does not apply to:				
51.3	(1) an operator of a payment system (1)	m, to the extent the	operator of a paym	ent system	
51.4	provides processing, clearing, or settle	ement services betw	veen or among perso	ons exempted	
51.5	by this section or licensees in connect	ion with wire transfe	ers, credit card trans	sactions, debit	
51.6	card transactions, stored-value transac	ctions, automated cl	earing house transfe	ers, or similar	
51.7	funds transfers;				
51.8	(2) a person appointed as an agent	of a payee to collec	et and process a pay	ment from a	
51.9	payor to the payee for goods or servic	es, other than mone	y transmission itsel	f, provided to	
51.10	the payor by the payee, provided that:	<u>.</u>			
51.11	(i) there exists a written agreemen	t between the payee	and the agent direc	ting the agent	
51.12	to collect and process payments from	payors on the payed	e's behalf;		
51.13	(ii) the payee holds the agent out to	the public as accepti	ng payments for goo	ods or services	
51.14	on the payee's behalf; and				
51.15	(iii) payment for the goods and services is treated as received by the payee upon receipt				
51.16	by the agent so that the payor's obligation	tion is extinguished	and there is no risk	t of loss to the	
51.17	payor if the agent fails to remit the funds to the payee;				
51.18	(3) a person that acts as an intermediary by processing payments between an entity that			an entity that	
51.19	has directly incurred an outstanding n	noney transmission	obligation to a send	ler, and the	
51.20	sender's designated recipient, provide	d that the entity:			
51.21	(i) is properly licensed or exempt	from licensing requi	irements under this	chapter;	
51.22	(ii) provides a receipt, electronic r	ecord, or other writt	ten confirmation to	the sender	
51.23	identifying the entity as the provider of	of money transmissi	on in the transactio	n; and	
51.24	(iii) bears sole responsibility to sat	tisfy the outstanding	g money transmissio	on obligation	
51.25	to the sender, including the obligation	to make the sender	whole in connection	on with any	
51.26	failure to transmit the funds to the ser	nder's designated rec	zipient;		
51.27	(4) the United States; a departmen	t, agency, or instrun	nentality of the Uni	ted States; or	
51.28	an agent of the United States;				
51.29	(5) money transmission by the Uni	ited States Postal Se	rvice or by an agent	of the United	
51.30	States Postal Service;				
51.31	(6) a state; county; city; any other	governmental agen	cy, governmental su	ubdivision, or	
51.32	instrumentality of a state; or the state'	s agent;			

ADB

52.1	(7) a federally insured depository financial institution; bank holding company; office of
52.2	an international banking corporation; foreign bank that establishes a federal branch pursuant
52.3	to the International Bank Act, United States Code, title 12, section 3102, as amended or
52.4	recodified from time to time; corporation organized pursuant to the Bank Service Corporation
52.5	Act, United States Code, title 12, sections 1861 to 1867, as amended or recodified from
52.6	time to time; or corporation organized under the Edge Act, United States Code, title 12,
52.7	sections 611 to 633, as amended or recodified from time to time;
52.8	(8) electronic funds transfer of governmental benefits for a federal, state, county, or
52.9	governmental agency by a contractor on behalf of the United States or a department, agency,
52.10	or instrumentality thereof, or on behalf of a state or governmental subdivision, agency, or
52.11	instrumentality thereof;
52.12	(9) a board of trade designated as a contract market under the federal Commodity
52.13	Exchange Act, United States Code, title 7, sections 1 to 25, as amended or recodified from
52.14	time to time; or a person that in the ordinary course of business provides clearance and
52.15	settlement services for a board of trade to the extent of its operation as or for a board;
52.16	(10) a registered futures commission merchant under the federal commodities laws, to
52.17	the extent of the registered futures commission merchant's operation as a merchant;
52.18	(11) a person registered as a securities broker-dealer under federal or state securities
52.19	laws, to the extent of the person's operation as a securities broker-dealer;
52.20	(12) an individual employed by a licensee, authorized delegate, or any person exempted
52.21	from the licensing requirements under this chapter when acting within the scope of
52.22	employment and under the supervision of the licensee, authorized delegate, or exempted
52.23	person as an employee and not as an independent contractor;
52.24	(13) a person expressly appointed as a third-party service provider to or agent of an
52.25	entity exempt under clause (7), solely to the extent that:
52.26	(i) the service provider or agent is engaging in money transmission on behalf of and
52.27	pursuant to a written agreement with the exempt entity that sets forth the specific functions
52.28	that the service provider or agent is to perform; and
52.29	(ii) the exempt entity assumes all risk of loss and all legal responsibility for satisfying
52.30	the outstanding money transmission obligations owed to purchasers and holders of the
52.31	outstanding money transmission obligations upon receipt of the purchaser's or holder's
52.32	money or monetary value by the service provider or agent; or

	04/04/23	SENATEE	ADB	SS2744R
53.1	(14) a person exempt by regulation	n or order if the co	mmissioner finds that	t (i) the
53.2	exemption is in the public interest, an	d (ii) the regulation	of the person is not	necessary for
53.3	the purposes of this chapter.			
53.4	Sec. 4. [53B.30] AUTHORITY TO) REQUIRE DEM	IONSTRATION OF	<u>?</u>
53.5	EXEMPTION.			
53.6	The commissioner may require any	person that claims	to be exempt from lic	ensing under
53.7	section 53B.29 to provide to the com	missioner informat	ion and documentation	on that
53.8	demonstrates the person qualifies for	any claimed exemp	otion.	
53.9	Sec. 5. [53B.31] IMPLEMENTAT	ION.		
53.10	Subdivision 1. General authority	In order to carry o	out the purposes of thi	s chapter, the
53.11	commissioner may, subject to section	53B.32, paragraph	us (a) and (b):	
53.12	(1) enter into agreements or relation	onships with other g	overnment officials of	or federal and
53.13	state regulatory agencies and regulate	ory associations in o	order to (i) improve e	fficiencies
53.14	and reduce regulatory burden by stand	dardizing methods	or procedures, and (i	i) share
53.15	resources, records, or related informa	tion obtained under	r this chapter;	
53.16	(2) use, hire, contract, or employ a	analytical systems,	methods, or software	to examine
53.17	or investigate any person subject to the	nis chapter;		
53.18	(3) accept from other state or fede	ral government age	encies or officials any	/ licensing,
53.19	examination, or investigation reports n	nade by the other st	ate or federal governn	nent agencies
53.20	or officials; and			
53.21	(4) accept audit reports made by a	n independent cert	ified public accounta	nt or other
53.22	qualified third-party auditor for an ap	plicant or licensee	and incorporate the a	udit report in
53.23	any report of examination or investig	ation.		
53.24	Subd. 2. Administrative authorit	y. The commission	ier is granted broad a	dministrative
53.25	authority to: (1) administer, interpret,	and enforce this ch	napter; (2) adopt regu	lations to
53.26	implement this chapter; and (3) recov	er the costs incurre	ed to administer and e	enforce this
53.27	chapter by imposing and collecting pr	coportionate and eq	uitable fees and cost	s associated
53.28	with applications, examinations, inve	stigations, and othe	er actions required to	achieve the
53.29	purpose of this chapter.			

ADB

54.1	Sec. 6. [53B.32] CONFIDENTIALITY.
54.2	(a) All information or reports obtained by the commissioner contained in or related to
54.3	an examination that is prepared by, on behalf of, or for the use of the commissioner are
54.4	confidential and are not subject to disclosure under section 46.07.
54.5	(b) The commissioner may disclose information not otherwise subject to disclosure
54.6	under paragraph (a) to representatives of state or federal agencies pursuant to section 53B.31,
54.7	subdivision 1.
54.8	(c) This section does not prohibit the commissioner from disclosing to the public a list
54.9	of all licensees or the aggregated financial or transactional data concerning those licensees.
54.10	Sec. 7. [53B.33] SUPERVISION.
54.11	(a) The commissioner may conduct an examination or investigation of a licensee or
54.12	authorized delegate or otherwise take independent action authorized by this chapter, or by
54.13	a rule adopted or order issued under this chapter, as reasonably necessary or appropriate to
54.14	administer and enforce this chapter, rules implementing this chapter, and other applicable
54.15	law, including the Bank Secrecy Act and the USA PATRIOT Act, Public Law 107-56. The
54.16	commissioner may:
54.17	(1) conduct an examination either on site or off site as the commissioner may reasonably
54.18	require;
54.19	(2) conduct an examination in conjunction with an examination conducted by
54.20	representatives of other state agencies or agencies of another state or of the federal
54.21	government;
54.22	(3) accept the examination report of another state agency or an agency of another state
54.23	or of the federal government, or a report prepared by an independent accounting firm, which
54.24	on being accepted is considered for all purposes as an official report of the commissioner;
54.25	and
54.26	(4) summon and examine under oath a key individual or employee of a licensee or
54.27	authorized delegate and require the person to produce records regarding any matter related
54.28	to the condition and business of the licensee or authorized delegate.
54.29	(b) A licensee or authorized delegate must provide, and the commissioner has full and
54.30	complete access to, all records the commissioner may reasonably require to conduct a
54.31	complete examination. The records must be provided at the location and in the format
54.32	specified by the commissioner. The commissioner may use multistate record production

	04/04/23	SENATEE	ADB	SS2744R	
55.1	standards and examination procedures when the standards reasonably achieve the				
55.2	requirements of this paragraph.				
55.3	(c) Unless otherwise directed by the	e commissioner, a licen	usee must pay all co	osts	
55.4	reasonably incurred in connection with		.		
55.5	authorized delegates.				
55.6	Sec. 8. [53B.34] NETWORKED SU	PERVISION.			
55.7	(a) To efficiently and effectively add	minister and enforce th	is chapter and to n	ninimize	
55.8	regulatory burden, the commissioner is	authorized to participa	ate in multistate su	pervisory	
55.9	processes established between states and	d coordinated through t	the Conference of S	State Bank	
55.10	Supervisors, the Money Transmitter Reg	gulators Association, an	d the affiliates and s	successors	
55.11	of the Conference of State Bank Superv	visors and the Money 7	Fransmitter Regula	tors	
55.12	Association for all licensees that hold li	censes in this state and	other states. As a p	participant	
55.13	in multistate supervision, the commissi	oner may:			
55.14	(1) cooperate, coordinate, and share information with other state and federal regulators				
55.15	in accordance with section 53B.32;				
55.16	(2) enter into written cooperation, coordination, or information-sharing contracts or				
55.17	agreements with organizations the men	bership of which is m	ade up of state or f	ederal	
55.18	governmental agencies; and				
55.19	(3) cooperate, coordinate, and share	information with orga	nizations the mem	bership of	
55.20	which is made up of state or federal gov	ernmental agencies, pr	ovided that the org	anizations	
55.21	agree in writing to maintain the confide	entiality and security of	f the shared inform	ation in	
55.22	accordance with section 53B.32.				
55.23	(b) The commissioner is prohibited t	from waiving, and noth	ing in this section c	onstitutes	
55.24	a waiver of, the commissioner's authori	ty to conduct an exam	ination or investiga	ation or	
55.25	otherwise take independent action auth	orized by this chapter,	or a rule adopted of	or order	
55.26	issued under this chapter, to enforce co	mpliance with applicat	ole state or federal	law.	
55.27	(c) A joint examination or investigation	ion, or acceptance of an	examination or inv	vestigation	
55.28	report, does not waive an examination	fee provided for in this	chapter.		
55.29	Sec. 9. [53B.35] RELATIONSHIP	TO FEDERAL LAW.			
55.30	(a) In the event state money transmi	ission jurisdiction is co	onditioned on a fed	eral law,	
55.31	any inconsistencies between a provision	of this chapter and the	federal law governi	ing money	
55.32	transmission is governed by the application	ble federal law to the	extent of the incon	sistency.	

	04/04/23	SENATEE	ADB	SS2744R
56.1	(b) In the event of any inconsistence	ies between this chap	pter and a federal law	v that governs
56.2	pursuant to paragraph (a), the commis	ssioner may provide	interpretive guidan	ce that:
56.3	(1) identifies the inconsistency; and	<u>ıd</u>		
56.4	(2) identifies the appropriate mean	ns of compliance wit	th federal law.	
56.5	Sec. 10. [53B.36] LICENSE REQ	U IRED.		
56.6	(a) A person is prohibited from en	gaging in the busine	ess of money transm	ission, or
56.7	advertising, soliciting, or representing	that the person prov	vides money transm	ission, unless
56.8	the person is licensed under this chap	ter.		
56.9	(b) Paragraph (a) does not apply to	<u>o:</u>		
56.10	(1) a person that is an authorized d	elegate of a person l	licensed under this c	hapter acting
56.11	within the scope of authority conferre	d by a written contr	act with the licensee	e; or
56.12	(2) a person that is exempt under s	section 53B.29 and	does not engage in r	noney
56.13	transmission outside the scope of the	exemption.		
56.14	(c) A license issued under section	53B.40 is not transf	ferable or assignable	<u>.</u>
56.15	Sec. 11. [53B.37] CONSISTENT S	STATE LICENSIN	<u>G.</u>	
56.16	(a) To establish consistent licensir	ig between Minneso	ta and other states,	the
56.17	commissioner is authorized to:			
56.18	(1) implement all licensing provision	ons of this chapter i	n a manner that is co	onsistent with
56.19	(i) other states that have adopted substa	ntially similar licens	ing requirements, or	(ii) multistate
56.20	licensing processes; and			
56.21	(2) participate in nationwide protoc	cols for licensing coc	peration and coordinate	nation among
56.22	state regulators, provided that the pro	tocols are consistent	t with this chapter.	
56.23	(b) In order to fulfill the purposes	of this chapter, the	commissioner is aut	horized to
56.24	establish relationships or contracts wi	th NMLS or other e	ntities designated by	y NMLS to
56.25	enable the commissioner to:			
56.26	(1) collect and maintain records;			
56.27	(2) coordinate multistate licensing	processes and supe	rvision processes;	
56.28	(3) process fees; and			

 57.1 (4) facilitate communication between the commissioner and licensees or other personal subject to this chapter. 57.2 (c) The commissioner is authorized to use NMLS for all aspects of licensing in accord with this chapter, including but not limited to license applications, applications for 	<u>dance</u> credit
57.3 (c) The commissioner is authorized to use NMLS for all aspects of licensing in accor	credit
	credit
	credit
57.5 acquisitions of control, surety bonds, reporting, criminal history background checks,	
57.6 checks, fee processing, and examinations.	
57.7 (d) The commissioner is authorized to use NMLS forms, processes, and function	; <u>1n</u>
57.8 accordance with this chapter. If NMLS does not provide functionality, forms, or proc	esses
57.9 for a requirement under this chapter, the commissioner is authorized to implement th	e
57.10 requirements in a manner that facilitates uniformity with respect to licensing, superv	sion,
57.11 reporting, and regulation of licensees which are licensed in multiple jurisdictions.	
57.12 (e) For the purpose of participating in the NMLS registry, the commissioner is authority	orized
57.13 to, by rule or order: (1) waive or modify, in whole or in part, any or all of the requirem	ients;
57.14 and (2) establish new requirements as reasonably necessary to participate in the NM	<u>LS</u>
57.15 registry.	
57.16 Sec. 12. [53B.38] APPLICATION FOR LICENSE.	
57.17 (a) An applicant for a license must apply in a form and in a medium as prescribed	l by
57.18 the commissioner. The application must state or contain, as applicable:	
57.19 (1) the legal name and residential and business addresses of the applicant and any	r _
57.20 <u>fictitious or trade name used by the applicant in conducting business;</u>	
57.21 (2) a list of any criminal convictions of the applicant and any material litigation in v	vhich
57.22 the applicant has been involved in the ten-year period next preceding the submission	of the
57.23 <u>application;</u>	
57.24 (3) a description of any money transmission previously provided by the applicant	and
57.25 the money transmission that the applicant seeks to provide in this state;	
(4) a list of the applicant's proposed authorized delegates and the locations in this	state
57.27 where the applicant and the applicant's authorized delegates propose to engage in mo	ney
57.28 <u>transmission;</u>	
(5) a list of other states in which the applicant is licensed to engage in money transm	ssion
57.30 and any license revocations, suspensions, or other disciplinary action taken against t	<u>ne</u>
57.31 <u>applicant in another state;</u>	

58.1	(6) information concerning any bankruptcy or receivership proceedings affecting the
58.2	licensee or a person in control of a licensee;
58.3	(7) a sample form of contract for authorized delegates, if applicable;
58.4	(8) a sample form of payment instrument or stored value, as applicable;
58.5	(9) the name and address of any federally insured depository financial institution through
58.6	which the applicant plans to conduct money transmission; and
58.7	(10) any other information the commissioner or NMLS reasonably requires with respect
58.8	to the applicant.
58.9	(b) If an applicant is a corporation, limited liability company, partnership, or other legal
58.10	entity, the applicant must also provide:
58.11	(1) the date of the applicant's incorporation or formation and state or country of
58.12	incorporation or formation;
58.13	(2) if applicable, a certificate of good standing from the state or country in which the
58.14	applicant is incorporated or formed;
58.15	(3) a brief description of the structure or organization of the applicant, including any
58.16	parents or subsidiaries of the applicant, and whether any parents or subsidiaries are publicly
58.17	traded;
58.18	(4) the legal name, any fictitious or trade name, all business and residential addresses,
58.19	and the employment, as applicable, in the ten-year period next preceding the submission of
58.20	the application of each key individual and person in control of the applicant;
58.21	(5) a list of any criminal convictions and material litigation in which a person in control
58.22	of the applicant that is not an individual has been involved in the ten-year period preceding
58.23	the submission of the application;
58.24	(6) a copy of audited financial statements of the applicant for the most recent fiscal year
58.25	and for the two-year period next preceding the submission of the application or, if the
58.26	commissioner deems acceptable, certified unaudited financial statements for the most recent
58.27	fiscal year or other period acceptable to the commissioner;
58.28	(7) a certified copy of unaudited financial statements of the applicant for the most recent
58.29	fiscal quarter;
58.30	(8) if the applicant is a publicly traded corporation, a copy of the most recent report filed
58.31	with the United States Securities and Exchange Commission under section 13 of the federal

	04/04/23	SENATEE	ADB	SS2744R
59.1	Securities Exchange Act of 1934, United	States Code, titl	e 15, section 78m, as	amended or
59.2	recodified from time to time;			
59.3	(9) if the applicant is a wholly owned	l subsidiary of:		
59.4	(i) a corporation publicly traded in th	e United States,	a copy of audited fina	ancial
59.5	statements for the parent corporation for	the most recent	fiscal year or a copy of	of the parent
59.6	corporation's most recent report filed une	der section 13 of	the Securities Excha	nge Act of
59.7	1934, United States Code, title 15, section	n 78m, as amende	ed or recodified from	time to time;
59.8	or			
59.9	(ii) a corporation publicly traded outs	side the United S	tates, a copy of simil	ar
59.10	documentation filed with the regulator o	f the parent corpo	oration's domicile ou	tside the
59.11	United States;			
59.12	(10) the name and address of the app	licant's registered	d agent in this state; a	ind
59.13	(11) any other information the comm	issioner reasonal	bly requires with resp	pect to the
59.14	applicant.			
59.15	(c) A nonrefundable application fee of	of \$4,000 must ac	ccompany an applica	tion for a
59.16	license under this section.			
59.17	(d) The commissioner may: (1) waive	e one or more rec	quirements of paragra	aphs (a) and
59.18	(b); or (2) permit an applicant to submit of	ther information i	in lieu of the required	information.
59.19	Sec. 13. [53B.39] INFORMATION R	EQUIREMEN	FS; CERTAIN INDI	VIDUALS.
59.20	Subdivision 1. Individuals with or s	eeking control.	Any individual in co	ntrol of a
59.21	licensee or applicant, any individual that	seeks to acquire	control of a licensee	, and each
59.22	key individual must furnish to the comm	issioner through	NMLS:	
59.23	(1) the individual's fingerprints for su	bmission to the	Federal Bureau of In	vestigation
59.24	and the commissioner for a national crim	ninal history back	kground check, unles	s the person
59.25	currently resides outside of the United S	tates and has resi	ided outside of the U	nited States
59.26	for the last ten years; and			
59.27	(2) personal history and business exp	erience in a form	n and in a medium pr	escribed by
59.28	the commissioner, to obtain:			
59.29	(i) an independent credit report from	a consumer repo	orting agency;	
59.30	(ii) information related to any crimin	al convictions or	pending charges; and	<u>d</u>

60.1	(iii) information related to any regulatory or administrative action and any civil litigation
60.2	involving claims of fraud, misrepresentation, conversion, mismanagement of funds, breach
60.3	of fiduciary duty, or breach of contract.
60.4	Subd. 2. Individuals having resided outside the United States. (a) If an individual
60.5	has resided outside of the United States at any time in the last ten years, the individual must
60.6	also provide an investigative background report prepared by an independent search firm
60.7	that meets the requirements of this subdivision.
60.8	(b) At a minimum, the search firm must:
60.9	(1) demonstrate that the search firm has sufficient knowledge, resources, and employs
60.10	accepted and reasonable methodologies to conduct the research of the background report;
60.11	and
60.12	(2) not be affiliated with or have an interest with the individual the search firm is
60.13	researching.
60.14	(c) At a minimum, the investigative background report must be written in English and
60.15	must contain:
60.16	(1) if available in the individual's current jurisdiction of residency, a comprehensive
60.17	credit report, or any equivalent information obtained or generated by the independent search
60.18	firm to accomplish a credit report, including a search of the court data in the countries,
60.19	provinces, states, cities, towns, and contiguous areas where the individual resided and
60.20	worked;
60.21	(2) criminal records information for the past ten years, including but not limited to
60.22	felonies, misdemeanors, or similar convictions for violations of law in the countries,
60.23	provinces, states, cities, towns, and contiguous areas where the individual resided and
60.24	worked;
60.25	(3) employment history;
60.26	(4) media history, including an electronic search of national and local publications, wire
60.27	services, and business applications; and
60.28	(5) financial services-related regulatory history, including but not limited to money
60.29	transmission, securities, banking, consumer finance, insurance, and mortgage-related

60.30 industries.

SENATEE

61.1	Sec. 14. [53B.40] LICENSE ISSUANCE.
61.2	(a) When an application for an original license under this chapter includes all of the
61.3	items and addresses all of the matters that are required, the application is complete and the
61.4	commissioner must promptly notify the applicant in a record of the date on which the
61.5	application is determined to be complete.
61.6	(b) The commissioner's determination that an application is complete and accepted for
61.7	processing means only that the application, on the application's face, appears to include all
61.8	of the items, including the criminal background check response from the Federal Bureau
61.9	of Investigation, and address all of the matters that are required. The commissioner's
61.10	determination that an application is complete is not an assessment of the substance of the
61.11	application or of the sufficiency of the information provided.
61.12	(c) When an application is filed and considered complete under this section, the
61.13	commissioner must investigate the applicant's financial condition and responsibility, financial
61.14	and business experience, character, and general fitness. The commissioner may conduct an
61.15	investigation of the applicant, the reasonable cost of which the applicant must pay. The
61.16	commissioner must issue a license to an applicant under this section if the commissioner
61.17	finds:
61.18	(1) the applicant has complied with sections 53B.38 and 53B.39; and
61.19	(2) the financial condition and responsibility; financial and business experience,
61.20	competence, character, and general fitness of the applicant; and the competence, experience,
61.21	character, and general fitness of the key individuals and persons in control of the applicant
61.22	indicate that it is in the interest of the public to permit the applicant to engage in money
61.23	transmission.
61.24	(d) If an applicant avails itself of or is otherwise subject to a multistate licensing process:
61.25	(1) the commissioner is authorized to accept the investigation results of a lead
61.26	investigative state for the purposes of paragraph (c); or
61.27	(2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate
61.28	the applicant pursuant to paragraph (c) and the time frames established by agreement through
61.29	the multistate licensing process, provided that the time frame complies with the application
61.30	review period provided under paragraph (e).
61.31	(e) The commissioner must approve or deny the application within 120 days after the
61.32	date the application is deemed complete. If the application is not approved or denied within

	04/04/23	SENATEE	ADB	SS2744R
62.1	120 days after the completion date	, the application is appr	oved and the licens	se takes effect
62.2	on the first business day after the 1	20-day period expires.		
62.3	(f) The commissioner must issu	ue a formal written noti	ce of the denial of	a license
62.4	application within 30 days of the d	ate the decision to deny	y the application is	made. The
62.5	commissioner must set forth in the	notice of denial the spe	cific reasons for the	e denial of the
62.6	application. An applicant whose ap	pplication is denied by	the commissioner u	under this
62.7	paragraph may appeal within 30 da	ys of the date the writte	n notice of the deni	al is received.
62.8	The commissioner must set a heari	ng date that is not later	than 60 days after	service of the
62.9	response, unless a later date is set v	with the consent of the	denied applicant.	
62.10	(g) The initial license term beg	ins on the day the appli	cation is approved.	The license
62.11	expires on December 31 of the year	in which the license ter	m began, unless the	initial license
62.12	date is between November 1 and D	December 31, in which o	case the initial licer	nse term runs
62.13	through December 31 of the follow	ving year. If a license is	approved between	November 1
62.14	and December 31, the applicant is su	ubject to the renewal fee	under section 53B.	.31, paragraph
62.15	<u>(a).</u>			
62.16	Sec. 15. [53B.41] LICENSE RE	CNEWAL.		
62.17	(a) A license under this chapter	must be renewed annu	ally. An annual rer	newal fee of
62.18	\$2,500 must be paid no more than	60 days before the lice	nse expires. The re-	newal term is
62.19	a period of one year and begins on	January 1 each year af	ter the initial licens	se term. The
62.20	renewal term expires on December	x 31 of the year the rene	ewal term begins.	
62.21	(b) A licensee must submit a re	newal report with the r	enewal fee, in a for	rm and in a
62.22	medium prescribed by the commis	sioner. The renewal rep	port must state or co	ontain a
62.23	description of each material change	in information submitte	ed by the licensee in	the licensee's
62.24	original license application that ha	s not been previously re	eported to the com	nissioner.
62.25	(c) The commissioner may gran	nt an extension of the re	enewal date for goo	od cause.
62.26	(d) The commissioner is author	rized to use the NMLS	to process license r	enewals,
62.27	provided that the NMLS functiona	lity is consistent with the	nis section.	
62.28	Sec. 16. [53B.42] MAINTENA N	NCE OF LICENSE.		
62.29	(a) If a licensee does not contin	ue to meet the qualification	ations or satisfy the	requirements
62.30	that apply to an applicant for a new	v money transmission l	icense, the commis	sioner may
62.31	suspend or revoke the licensee's licenseee's licensee's licensee's licensee's licensee's licensee's	cense in accordance wit	h the procedures ea	stablished by
62.32	this chapter or other applicable star	te law for license suspe	nsion or revocation	<u>ı.</u>

ADB

63.1	(b) An applicant for a money transmission license must demonstrate that the applicant
63.2	meets or will meet, and a money transmission licensee must at all times meet, the
63.3	requirements in sections 53B.59 to 53B.61.
63.4	Sec. 17. [53B.43] ACQUISITION OF CONTROL.
63.5	(a) Any person, or group of persons acting in concert, seeking to acquire control of a
63.6	licensee must obtain the commissioner's written approval before acquiring control. An
63.7	individual is not deemed to acquire control of a licensee and is not subject to these acquisition
63.8	of control provisions when that individual becomes a key individual in the ordinary course
63.9	of business.
63.10	(b) For the purpose of this section, a person is presumed to exercise a controlling influence
63.11	when the person holds the power to vote, directly or indirectly, at least ten percent of the
63.12	outstanding voting shares or voting interests of a licensee or person in control of a licensee.
63.13	A person presumed to exercise a controlling influence as defined by this subdivision can
63.14	rebut the presumption of control if the person is a passive investor.
63.15	(c) For purposes of determining the percentage of a person controlled by any other
63.16	person, the person's interest must be aggregated with the interest of any other immediate
63.17	family member, including the person's spouse, parents, children, siblings, mothers- and
63.18	fathers-in-law, sons- and daughters-in-law, brothers- and sisters-in-law, and any other person
63.19	who shares the person's home.
63.20	(d) A person, or group of persons acting in concert, seeking to acquire control of a
63.21	licensee must, in cooperation with the licensee:
63.22	(1) submit an application in a form and in a medium prescribed by the commissioner;
63.23	and
63.24	(2) submit a nonrefundable fee of \$4,000 with the request for approval.
63.25	(e) Upon request, the commissioner may permit a licensee or the person, or group of
63.26	persons acting in concert, to submit some or all information required by the commissioner
63.27	pursuant to paragraph (d), clause (1), without using NMLS.
63.28	(f) The application required by paragraph (d), clause (1), must include information
63.29	required by section 53B.39 for any new key individuals that have not previously completed
63.30	the requirements of section 53B.39 for a licensee.
63.31	(g) When an application for acquisition of control under this section appears to include
63.32	all of the items and address all of the matters that are required, the application is considered

04/04/23 SENATEE ADB SS2744R complete and the commissioner must promptly notify the applicant in a record of the date 64.1 on which the application was determined to be complete. 64.2 64.3 (h) The commissioner must approve or deny the application within 60 days after the completion date. If the application is not approved or denied within 60 days after the 64.4 64.5 completion date, the application is approved and the person, or group of persons acting in concert, are not prohibited from acquiring control. The commissioner may extend the 64.6 application period for good cause. 64.7 (i) The commissioner's determination that an application is complete and is accepted for 64.8 processing means only that the application, on the application's face, appears to include all 64.9 64.10 of the items and address all of the matters that are required. The commissioner's determination that an application is complete is not an assessment of the application's substance or of the 64.11 sufficiency of the information provided. 64.12 (j) When an application is filed and considered complete under paragraph (g), the 64.13 commissioner must investigate the financial condition and responsibility; the financial and 64.14 business experience; character; and the general fitness of the person, or group of persons 64.15 acting in concert, seeking to acquire control. The commissioner must approve an acquisition 64.16 of control under this section if the commissioner finds: 64.17 (1) the requirements of paragraphs (d) and (f) have been met, as applicable; and 64.18 (2) the financial condition and responsibility, financial and business experience, 64.19 competence, character, and general fitness of the person, or group of persons acting in 64.20 concert, seeking to acquire control; and the competence, experience, character, and general 64.21 fitness of the key individuals and persons that control the licensee after the acquisition of 64.22 control indicate that it is in the interest of the public to permit the person, or group of persons 64.23 acting in concert, to control the licensee. 64.24 (k) If an applicant avails itself of or is otherwise subject to a multistate licensing process: 64.25 (1) the commissioner is authorized to accept the investigation results of a lead 64.26 investigative state for the purposes of paragraph (j); or 64.27 (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate 64.28 the applicant under paragraph (j) and consistent with the time frames established by 64.29 agreement through the multistate licensing process. 64.30 (1) The commissioner must issue a formal written notice of the denial of an application 64.31 to acquire control. The commissioner must set forth in the notice of denial the specific 64.32 reasons the application was denied. An applicant whose application is denied by the 64.33

	04/04/23	SENATEE	ADB	SS2744R
65.1	commissioner under this paragraph ma	y appeal the denia	al within 30 days of th	ne date the
65.2	written notice of the denial is received.	Chapter 14 applie	es to appeals under thi	is paragraph.
65.3	(m) Paragraphs (a) and (d) do not a	pply to:		
65.4	(1) a person that acts as a proxy for (1)	the sole purpose	of voting at a designa	ted meeting
65.5	of the shareholders or holders of voting	g shares or voting	interests of a licensee	e or a person
65.6	in control of a licensee;			
65.7	(2) a person that acquires control of	a licensee by dev	vise or descent;	
65.8	(3) a person that acquires control of	f a licensee as a pe	ersonal representative	, custodian,
65.9	guardian, conservator, or trustee, or as	an officer appoint	ed by a court of com	petent
65.10	jurisdiction or by operation of law;			
65.11	(4) a person that is exempt under se	ection 53B.29, cla	use (7);	
65.12	(5) a person that the commissioner	determines is not	subject to paragraph ((a), based on
65.13	the public interest;			
65.14	(6) a public offering of securities of	a licensee or a pe	erson in control of a li	icensee; or
65.15	(7) an internal reorganization of a p	erson controlling	the licensee, where the	ne ultimate
65.16	person controlling the licensee remains	the same.		
65.17	(n) A person identified in paragraph	n (m), clause (2), ((3), (4), or (6), that is	cooperating
65.18	with the licensee must notify the comm	nissioner within 1	5 days of the date the	acquisition
65.19	of control occurs.			
65.20	(o) Paragraphs (a) and (d) do not ap	ply to a person the	at has complied with	and received
65.21	approval to engage in money transmiss	ion under this cha	apter, or that was iden	tified as a
65.22	person in control in a prior application	filed with and app	proved by the commis	ssioner or by
65.23	another state pursuant to a multistate li	censing process, p	provided that:	
65.24	(1) the person has not had a license	revoked or suspe	nded or controlled a l	icensee that
65.25	has had a license revoked or suspended	l while the person	was in control of the	licensee in
65.26	the previous five years;			
65.27	(2) if the person is a licensee, the pe	erson is well mana	aged and has received	l at least a
65.28	satisfactory rating for compliance at the	e person's most re	cent examination by	an
65.29	MSB-accredited state if a rating was gi	ven;		
65.30	(3) the licensee to be acquired is pro-	ojected to meet the	e requirements of sec	tions 53B.59
65.31	to 53B.61 after the acquisition of contr	ol is completed, a	nd if the person acqu	iring control

ADB

66.1	is a licensee, the acquiring licensee is also projected to meet the requirements of sections
66.2	53B.59 to 53B.61 after the acquisition of control is completed;
66.2	(4) the licensee to be acquired does not implement any material changes to the acquired
66.3	licensee's business plan as a result of the acquisition of control, and if the person acquiring
66.4	control is a licensee, the acquiring licensee does not implement any material changes to the
66.5	acquiring licensee's business plan as a result of the acquisition of control; and
66.6	acquiring neensee's business plan as a result of the acquisition of control, and
66.7	(5) the person provides notice of the acquisition in cooperation with the licensee and
66.8	attests to clauses (1), (2), (3), and (4) in a form and in a medium prescribed by the
66.9	commissioner.
66.10	(p) If the notice under paragraph (o), clause (5), is not disapproved within 30 days after
66.11	the date on which the notice was determined to be complete, the notice is deemed approved.
66.12	(q) Before filing an application for approval to acquire control of a licensee, a person
66.13	may request in writing a determination from the commissioner as to whether the person
66.14	would be considered a person in control of a licensee upon consummation of a proposed
66.15	transaction. If the commissioner determines that the person would not be a person in control
66.16	of a licensee, the proposed person and transaction is not subject to paragraphs (a) and (d).
66.17	(r) If a multistate licensing process includes a determination pursuant to paragraph (q)
66.18	and an applicant avails itself or is otherwise subject to the multistate licensing process:
66.19	(1) the commissioner is authorized to accept the control determination of a lead
66.20	
	investigative state with sufficient staffing, expertise, and minimum standards for the purposes
66.21	investigative state with sufficient staffing, expertise, and minimum standards for the purposes of paragraph (q); or
66.21 66.22	
	of paragraph (q); or
66.22	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate
66.22 66.23 66.24	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process.
66.2266.2366.2466.25	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process. Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND
 66.22 66.23 66.24 66.25 66.26 	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process. Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND INFORMATION REQUIREMENTS.
66.2266.2366.2466.25	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process. Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND
 66.22 66.23 66.24 66.25 66.26 	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process. Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND INFORMATION REQUIREMENTS.
 66.22 66.23 66.24 66.25 66.26 66.27 	of paragraph (q); or (2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate the applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process. Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND INFORMATION REQUIREMENTS. (a) A licensee that adds or replaces any key individual must:
 66.22 66.23 66.24 66.25 66.26 66.27 66.28 	of paragraph (q); or(2) if Minnesota is a lead investigative state, the commissioner is authorized to investigatethe applicant under paragraph (q) and consistent with the time frames established by agreement through the multistate licensing process.Sec. 18. [53B.44] CHANGE OF KEY INDIVIDUALS; NOTICE AND INFORMATION REQUIREMENTS.(a) A licensee that adds or replaces any key individual must: (1) provide notice, in a manner prescribed by the commissioner, within 15 days after

ADB

67.1	(b) Within 90 days of the date on which the notice provided under section 53B.44,
67.2	paragraph (a), was determined to be complete, the commissioner may issue a notice of
67.3	disapproval of a key individual if the commissioner finds that the competence, business
67.4	experience, character, or integrity of the individual is not in the best interests of the public
67.5	or the customers of the licensee.
67.6	(c) A notice of disapproval must contain a statement of the basis for disapproval and
67.7	must be sent to the licensee and the disapproved individual. A licensee may appeal a notice
67.8	of disapproval pursuant to chapter 14 within 30 days of the date the notice of disapproval
67.9	is received.
67.10	(d) If the notice provided under paragraph (a) is not disapproved within 90 days after
67.11	the date on which the notice was determined to be complete, the key individual is deemed
67.12	approved.
67.13	(e) If a multistate licensing process includes a key individual notice review and
67.14	disapproval process under this section and the licensee avails itself of or is otherwise subject
67.15	to the multistate licensing process:
67.16	(1) the commissioner is authorized to accept the determination of another state if the
67.17	investigating state has sufficient staffing, expertise, and minimum standards for the purposes
67.18	of this section; or
67.19	(2) if Minnesota is a lead investigative state, the commissioner is authorized to investigate
67.20	the applicant under paragraph (b) and the time frames established by agreement through
67.21	the multistate licensing process.
67.22	Sec. 19. [53B.45] REPORT OF CONDITION.
67.23	(a) Each licensee must submit a report of condition within 45 days of the end of the
67.24	calendar quarter, or within any extended time the commissioner prescribes.
67.25	(b) The report of condition must include:
67.26	(1) financial information at the licensee level;
67.27	(2) nationwide and state-specific money transmission transaction information in every
67.28	jurisdiction in the United States where the licensee is licensed to engage in money
67.29	transmission;
67.30	(3) a permissible investments report;
67.31	(4) transaction destination country reporting for money received for transmission, if

67.32 applicable; and

Article 3 Sec. 19.

	04/04/23	SENATEE	ADB	SS2744R
68.1	(5) any other information the co	mmissioner reasonabl	y requires with respe	et to the
68.2	licensee.			
68.3	(c) The commissioner is authori	zed to use NMLS to su	ubmit the report requ	ired under
68.4	paragraph (a).			
68.5	(d) The information required by	paragraph (b), clause	(4), must only be inc	cluded in a
68.6	report of condition submitted within			
				<u> </u>
68.7	Sec. 20. [53B.46] AUDITED FIN	NANCIAL STATEM	ENTS.	
68.8	(a) Each licensee must, within 9	0 days after the end of	f each fiscal year, or	within any
68.9	extended time the commissioner pr	escribes, file with the	commissioner:	
68.10	(1) an audited financial statement	t of the licensee for the	fiscal year prepared in	n accordance
68.11	with United States generally accept	ed accounting principl	les; and	
68.12	(2) any other information the co	ommissioner may reaso	onably require.	
68.13	(b) The audited financial stateme	ents must be prepared b	y an independent cer	tified public
68.14	accountant or independent public a	ccountant who is satisf	factory to the commi	ssioner.
68.15	(c) The audited financial statem	ents must include or be	e accompanied by a c	certificate of
68.16	opinion prepared by the independent	nt certified public acco	ountant or independen	nt public
68.17	accountant that is satisfactory in for	rm and content to the c	ommissioner. If the o	certificate or
68.18	opinion is qualified, the commissio	ner may order the licer	nsee to take any action	on the
68.19	commissioner finds necessary to en	able the independent of	or certified public acc	countant or
68.20	independent public accountant to re	emove the qualification	<u>ı.</u>	
68.21	Sec. 21. [53B.47] AUTHORIZE	D DELEGATE REP	ORTING.	
68.22	(a) Each licensee must submit a	report of authorized de	elegates within 45 day	ys of the end
68.23	of the calendar quarter. The commi	ssioner is authorized to	o use NMLS to subm	it the report
68.24	required by this paragraph, provided	that the functionality is	s consistent with the r	equirements
68.25	of this section.			
68.26	(b) The authorized delegate repor	t must include, at a min	imum, each authorize	ed delegate's:
68.27	(1) company legal name;			
68.28	(2) taxpayer employer identification	ation number;		
68.29	(3) principal provider identifier;	<u>.</u>		
68.30	(4) physical address;			

SENATEE

69.1	(5) mailing address;
69.2	(6) any business conducted in other states;
69.3	(7) any fictitious or trade name;
69.4	(8) contact person name, telephone number, and email;
69.5	(9) start date as the licensee's authorized delegate;
69.6	(10) end date acting as the licensee's authorized delegate, if applicable;
69.7	(11) court orders under section 53B.53; and
69.8	(12) any other information the commissioner reasonably requires with respect to the
69.9	authorized delegate.
07.7	
69.10	Sec. 22. [53B.48] REPORTS OF CERTAIN EVENTS.
69.11	(a) A licensee must file a report with the commissioner within ten business days after
69.12	the licensee has reason to know any of the following events has occurred:
69.13	(1) a petition by or against the licensee under the United States Bankruptcy Code, United
69.14	States Code, title 11, sections 101 to 110, as amended or recodified from time to time, for
69.15	bankruptcy or reorganization has been filed;
69.16	(2) a petition by or against the licensee for receivership, the commencement of any other
69.17	judicial or administrative proceeding for the licensee's dissolution or reorganization, or the
69.18	making of a general assignment for the benefit of the licensee's creditors has been filed; or
69.19	(3) a proceeding to revoke or suspend the licensee's license in a state or country in which
69.20	the licensee engages in business or is licensed has been commenced.
69.21	(b) A licensee must file a report with the commissioner within ten business days after
69.22	the licensee has reason to know any of the following events has occurred:
69.23	(1) the licensee or a key individual or person in control of the licensee is charged with
69.24	or convicted of a felony related to money transmission activities; or
69.25	(2) an authorized delegate is charged with or convicted of a felony related to money
69.26	transmission activities.
69.27	Sec. 23. [53B.49] BANK SECRECY ACT REPORTS.
69.28	A licensee and an authorized delegate must file all reports required by federal currency
(0.00	non artiga magand learning and quantations activity non artiga a series of a set fauth in the

69.29 reporting, record keeping, and suspicious activity reporting requirements as set forth in the

	04/04/23 SENATEE ADB SS2744R
70.1	Bank Secrecy Act and other federal and state laws pertaining to money laundering. A licensee
70.2	and authorized delegate that timely files with the appropriate federal agency a complete and
70.3	accurate report required under this section is deemed to comply with the requirements of
70.4	this section.
70.5	Sec. 24. [53B.50] RECORDS.
70.6	(a) A licensee must maintain the following records, for purposes of determining the
70.7	licensee's compliance with this chapter, for at least three years:
70.8	(1) a record of each outstanding money transmission obligation sold;
70.9	(2) a general ledger posted at least monthly containing all asset, liability, capital, income,
70.10	and expense accounts;
70.11	(3) bank statements and bank reconciliation records;
70.12	(4) records of outstanding money transmission obligations;
70.13	(5) records of each outstanding money transmission obligation paid within the three-year
70.14	period;
70.15	(6) a list of the last known names and addresses of all of the licensee's authorized
70.16	delegates; and
70.17	(7) any other records the commissioner reasonably requires by administrative rule.
70.18	(b) The items specified in paragraph (a) may be maintained in any form of record.
70.19	(c) The records specified in paragraph (a) may be maintained outside of Minnesota if
70.20	the records are made accessible to the commissioner upon seven business-days' notice that
70.21	is sent in a record.
70.22	(d) All records maintained by the licensee as required under paragraphs (a) to (c) are
70.23	open to inspection by the commissioner under section 53B.33, paragraph (a).
70.24	Sec. 25. [53B.51] RELATIONSHIP BETWEEN LICENSEE AND AUTHORIZED
70.25	DELEGATE.
70.26	(a) For purposes of this section, "remit" means to make direct payments of money to (1)
70.27	a licensee, or (2) a licensee's representative authorized to receive money or to deposit money
70.28	in a bank in an account specified by the licensee.
70.29	(b) Before a licensee is authorized to conduct business through an authorized delegate
70.30	or allows a person to act as the licensee's authorized delegate, the licensee must:

ADB

71.1	(1) adopt, and update as necessary, written policies and procedures reasonably designed
71.2	to ensure that the licensee's authorized delegates comply with applicable state and federal
71.3	<u>law;</u>
71.4	(2) enter into a written contract that complies with paragraph (d); and
71.5	(3) conduct a reasonable risk-based background investigation sufficient for the licensee
71.6	to determine whether the authorized delegate has complied and will likely comply with
71.7	applicable state and federal law.
71.8	(c) An authorized delegate must operate in full compliance with this chapter.
71.9	(d) The written contract required by paragraph (b) must be signed by the licensee and
71.10	the authorized delegate. The written contract must, at a minimum:
71.11	(1) appoint the person signing the contract as the licensee's authorized delegate with the
71.12	authority to conduct money transmission on behalf of the licensee;
71.13	(2) set forth the nature and scope of the relationship between the licensee and the
71.14	authorized delegate and the respective rights and responsibilities of the parties;
71.15	(3) require the authorized delegate to agree to fully comply with all applicable state and
71.16	federal laws, rules, and regulations pertaining to money transmission, including this chapter
71.17	and regulations implementing this chapter, relevant provisions of the Bank Secrecy Act and
71.18	the USA PATRIOT Act, Public Law 107-56;
71.19	(4) require the authorized delegate to remit and handle money and monetary value in
71.20	accordance with the terms of the contract between the licensee and the authorized delegate;
71.21	(5) impose a trust on money and monetary value net of fees received for money
71.22	transmission for the benefit of the licensee;
71.23	(6) require the authorized delegate to prepare and maintain records as required by this
71.24	chapter or administrative rules implementing this chapter, or as reasonably requested by
71.25	the commissioner;
71.26	(7) acknowledge that the authorized delegate consents to examination or investigation
71.27	by the commissioner;
71.28	(8) state that the licensee is subject to regulation by the commissioner and that as part
71.29	of that regulation the commissioner may (1) suspend or revoke an authorized delegate
71.30	designation, or (2) require the licensee to terminate an authorized delegate designation; and
71.31	(9) acknowledge receipt of the written policies and procedures required under paragraph
71.32	(b), clause (1).

72.1	(e) If the licensee's license is suspended, revoked, surrendered, or expired, within five
72.2	business days the licensee must provide documentation to the commissioner that the licensee
72.3	has notified all applicable authorized delegates of the licensee whose names are in a record
72.4	filed with the commissioner of the suspension, revocation, surrender, or expiration of a
72.5	license. Upon suspension, revocation, surrender, or expiration of a license, applicable
72.6	authorized delegates must immediately cease to provide money transmission as an authorized
72.7	delegate of the licensee.

- (f) An authorized delegate of a licensee holds in trust for the benefit of the licensee all
 money net of fees received from money transmission. If an authorized delegate commingles
 any funds received from money transmission with other funds or property owned or
 controlled by the authorized delegate, all commingled funds and other property are considered
- 72.11 controlled by the authorized delegate, all commingled funds and other property are considered
- 72.12 <u>held in trust in favor of the licensee in an amount equal to the amount of money net of fees</u>
- 72.13 received from money transmission.
- 72.14 (g) An authorized delegate is prohibited from using a subdelegate to conduct money
 72.15 transmission on behalf of a licensee.

72.16 Sec. 26. [53B.52] UNAUTHORIZED ACTIVITIES.

72.17A person is prohibited from engaging in the business of money transmission on behalf72.18of a person not licensed under this chapter or not exempt under sections 53B.29 and 53B.30.72.19A person that engages in the business of money transmission on behalf of a person that is72.20not licensed under this chapter or not exempt under sections 53B.29 and 53B.30 provides72.21money transmission to the same extent as if the person were a licensee, and is jointly and72.22severally liable with the unlicensed or nonexempt person.

72.23 Sec. 27. [53B.53] PROHIBITED AUTHORIZED DELEGATES.

72.24 (a) The district court in an action brought by a licensee has jurisdiction to grant

72.25 appropriate equitable or legal relief, including without limitation prohibiting the authorized

- 72.26 delegate from directly or indirectly acting as an authorized delegate for any licensee in
- 72.27 Minnesota and the payment of restitution, damages, or other monetary relief, if the district
- 72.28 <u>court finds that an authorized delegate failed to remit money in accordance with the written</u>
- contract required by section 53B.51, paragraph (b), or as otherwise directed by the licensee
- 72.30 or required by law.
- (b) If the district court issues an order prohibiting a person from acting as an authorized
 delegate for any licensee under paragraph (a), the licensee that brought the action must

04/04/23 SENATEE ADB SS2744R report the order to the commissioner within 30 days of the date of the order and must report 73.1 the order through NMLS within 90 days of the date of the order. 73.2 Sec. 28. [53B.54] TIMELY TRANSMISSION. 73.3 (a) Every licensee must forward all money received for transmission in accordance with 73.4 the terms of the agreement between the licensee and the sender, unless the licensee has a 73.5 reasonable belief or a reasonable basis to believe that the sender may be a victim of fraud 73.6 or that a crime or violation of law, rule, or regulation has occurred, is occurring, or may 73.7 73.8 occur. (b) If a licensee fails to forward money received for transmission as provided under this 73.9 section, the licensee must respond to inquiries by the sender with the reason for the failure, 73.10 73.11 unless providing a response would violate a state or federal law, rule, or regulation. Sec. 29. [53B.55] REFUNDS. 73.12 (a) This section does not apply to: 73.13 (1) money received for transmission that is subject to the federal remittance rule under 73.14 Code of Federal Regulations, title 12, part 1005, subpart B, as amended or recodified from 73.15 time to time; or 73.16 73.17 (2) money received for transmission pursuant to a written agreement between the licensee and payee to process payments for goods or services provided by the payee. 73.18 (b) A licensee must refund to the sender within ten days of the date the licensee receives 73.19 the sender's written request for a refund of any and all money received for transmission, 73.20 unless: 73.21 (1) the money has been forwarded within ten days of the date on which the money was 73.22 received for transmission; 73.23 (2) instructions have been given committing an equivalent amount of money to the 73.24 person designated by the sender within ten days of the date on which the money was received 73.25 for transmission; 73.26 (3) the agreement between the licensee and the sender instructs the licensee to forward 73.27 the money at a time that is beyond ten days of the date on which the money was received 73.28 for transmission. If money has not been forwarded in accordance with the terms of the 73.29 agreement between the licensee and the sender, the licensee must issue a refund in accordance 73.30 with the other provisions of this section; or 73.31

- 74.1 (4) the refund is requested for a transaction that the licensee has not completed based
- 74.2 on a reasonable belief or a reasonable basis to believe that a crime or violation of law, rule,
- 74.3 or regulation has occurred, is occurring, or may occur.
- 74.4 (c) A refund request does not enable the licensee to identify:
- 74.5 (1) the sender's name and address or telephone number; or
- 74.6 (2) the particular transaction to be refunded in the event the sender has multiple
- 74.7 <u>transactions outstanding.</u>
- 74.8 Sec. 30. [53B.56] RECEIPTS.

Subdivision 1. Definition. For purposes of this section, "receipt" means a paper receipt, electronic record, or other written confirmation.

- 74.11 Subd. 2. Exemption. This section does not apply to:
- 74.12 (1) money received for transmission that is subject to the federal remittance rule under
- 74.13 Code of Federal Regulations, title 12, part 1005, subpart B, as amended or recodified from
- 74.14 time to time;
- 74.15 (2) money received for transmission that is not primarily for personal, family, or
- 74.16 household purposes;
- 74.17 (3) money received for transmission pursuant to a written agreement between the licensee
- and payee to process payments for goods or services provided by the payee; or
- 74.19 (4) payroll processing services.
- 74.20 Subd. 3. Transaction types; receipts form. For a transaction conducted in person, the
- receipt may be provided electronically if the sender requests or agrees to receive an electronic
- 74.22 receipt. For a transaction conducted electronically or by telephone, a receipt may be provided
- 74.23 electronically. All electronic receipts must be provided in a retainable form.
- 74.24 Subd. 4. Receipts required. (a) Every licensee or the licensee's authorized delegate
- 74.25 <u>must provide the sender a receipt for money received for transmission.</u>
- 74.26 (b) The receipt must contain, as applicable:
- 74.27 (1) the name of the sender;
- 74.28 (2) the name of the designated recipient;
- 74.29 (3) the date of the transaction;
- 74.30 (4) the unique transaction or identification number;

SENATEE

ADB

75.1	(5) the name of the licensee, NMLS Unique ID, the licensee's business address, and the
75.2	licensee's customer service telephone number;
75.3	(6) the transaction amount, expressed in United States dollars;
75.4	(7) any fee the licensee charges the sender for the transaction; and
75.5	(8) any taxes the licensee collects from the sender for the transaction.
75.6	(c) The receipt required by this section must be provided in (1) English, and (2) the
75.7	language principally used by the licensee or authorized delegate to advertise, solicit, or
75.8	negotiate, either orally or in writing, for a transaction conducted in person, electronically,
75.9	or by telephone, if the language principally used is a language other than English.
75.10	Sec. 31. [53B.57] NOTICE.
75.11	Every licensee or authorized delegate must include on a receipt or disclose on the
75.12	licensee's website or mobile application the name and telephone number of the department
75.13	and a statement that the licensee's customers can contact the department with questions or
75.14	complaints about the licensee's money transmission services.
75.15	Sec. 32. [53B.58] PAYROLL PROCESSING SERVICES; DISCLOSURES.
75.16	(a) A licensee that provides payroll processing services must:
75.17	(1) issue reports to clients detailing client payroll obligations in advance of the payroll
75.18	funds being deducted from an account; and
75.19	(2) make available worker pay stubs or an equivalent statement to workers.
75.20	(b) Paragraph (a) does not apply to a licensee providing payroll processing services if
75.21	the licensee's client designates the intended recipients to the licensee and is responsible for
75.22	providing the disclosures required by paragraph (a), clause (2).
75.23	Sec. 33. [53B.59] NET WORTH.
75.24	(a) A licensee under this chapter must maintain at all times a tangible net worth that is
75.25	the greater of: (1) \$100,000; or (2) three percent of total assets for the first \$100,000,000;
75.26	two percent of additional assets between \$100,000,000 to \$1,000,000,000; and one-half
75.27	percent of additional assets over \$1,000,000,000.
75.28	(b) Tangible net worth must be demonstrated in the initial application by the applicant's
75.29	most recent audited or unaudited financial statements under section 53B.38, paragraph (b),
75.30	<u>clause (6).</u>

Article 3 Sec. 33.

ADB

76.1	(c) Notwithstanding paragraphs (a) and (b), the commissioner has the authority, for good
76.2	cause shown, to exempt any applicant or licensee in-part or in whole from the requirements
76.3	of this section.
76.4	Sec. 34. [53B.60] SURETY BOND.
76.5	(a) An applicant for a money transmission license must provide, and a licensee must at
76.6	all times maintain (1) security consisting of a surety bond in a form satisfactory to the
76.7	commissioner, or (2) with the commissioner's approval, a deposit instead of a bond in
76.8	accordance with this section.
76.9	(b) The amount of the required security under this section is:
76.10	(1) the greater of (i) \$100,000, or (ii) an amount equal to one hundred percent of the
76.11	licensee's average daily money transmission liability in Minnesota, calculated for the most
76.12	recently completed three-month period, up to a maximum of \$500,000; or
76.13	(2) in the event that the licensee's tangible net worth exceeds ten percent of total assets,
76.14	the licensee must maintain a surety bond of \$100,000.
76.15	(c) A licensee that maintains a bond in the maximum amount provided for in paragraph
76.16	(b), clause (1) or (2), as applicable, is not required to calculate the licensee's average daily
76.17	money transmission liability in Minnesota for purposes of this section.
/0.1/	
76.18	(d) A licensee may exceed the maximum required bond amount pursuant to section
76.19	53B.62, paragraph (a), clause (5).
76.20	(e) The security device remains effective until cancellation, which may occur only after
76.21	30 days' written notice to the commissioner. Cancellation does not affect the rights of any
76.22	claimant for any liability incurred or accrued during the period for which the bond was in
76.23	force.
76.24	(f) The security device must remain in place for no longer than five years after the
76.25	licensee ceases money transmission operations in Minnesota. Notwithstanding this paragraph,
76.26	the commissioner may permit the security device to be reduced or eliminated before that
76.27	time to the extent that the amount of the licensee's payment instruments outstanding in
76.28	Minnesota are reduced. The commissioner may also permit a licensee to substitute a letter
76.29	of credit or other form of security device acceptable to the commissioner for the security
76.30	device in place at the time the licensee ceases money transmission operations in Minnesota.

77.1	Sec. 35. [53B.61] MAINTENANCE OF PERMISSIBLE INVESTMENTS.
77.2	(a) A licensee must maintain at all times permissible investments that have a market
77.3	value computed in accordance with United States generally accepted accounting principles
77.4	of not less than the aggregate amount of all of the licensee's outstanding money transmission
77.5	obligations.
77.6	(b) Except for permissible investments enumerated in section 53B.62, paragraph (a),
77.7	the commissioner may by administrative rule or order, with respect to any licensee, limit
77.8	the extent to which a specific investment maintained by a licensee within a class of
77.9	permissible investments may be considered a permissible investment, if the specific
77.10	investment represents undue risk to customers not reflected in the market value of
77.11	investments.
77.12	(c) Permissible investments, even if commingled with other assets of the licensee, are
77.13	held in trust for the benefit of the purchasers and holders of the licensee's outstanding money
77.14	transmission obligations in the event of insolvency; the filing of a petition by or against the
77.15	licensee under the United States Bankruptcy Code, United States Code, title 11, sections
77.16	101 to 110, as amended or recodified from time to time, for bankruptcy or reorganization;
77.17	the filing of a petition by or against the licensee for receivership; the commencement of any
77.18	other judicial or administrative proceeding for the licensee's dissolution or reorganization;
77.19	or in the event of an action by a creditor against the licensee who is not a beneficiary of this
77.20	statutory trust. No permissible investments impressed with a trust pursuant to this paragraph
77.21	are subject to attachment, levy of execution, or sequestration by order of any court, except
77.22	for a beneficiary of the statutory trust.
77.23	(d) Upon the establishment of a statutory trust in accordance with paragraph (c), or when
77.24	any funds are drawn on a letter of credit pursuant to section 53B.62, paragraph (a), clause
77.25	(4), the commissioner must notify the applicable regulator of each state in which the licensee
77.26	is licensed to engage in money transmission, if any, of the establishment of the trust or the
77.27	funds drawn on the letter of credit, as applicable. Notice is deemed satisfied if performed
77.28	pursuant to a multistate agreement or through NMLS. Funds drawn on a letter of credit, and
77.29	any other permissible investments held in trust for the benefit of the purchasers and holders
77.30	of the licensee's outstanding money transmission obligations, are deemed held in trust for
77.31	the benefit of the purchasers and holders of the licensee's outstanding money transmission
77.32	obligations on a pro rata and equitable basis in accordance with statutes pursuant to which
77.33	permissible investments are required to be held in Minnesota and other states, as defined
77.34	by a substantially similar statute in the other state. Any statutory trust established under this

	04/04/23	SENATEE	ADB	SS2744R
78.1	section terminates upon extinguishment	of all of the lice	nsee's outstanding mor	ney
78.2	transmission obligations.			
78.3	(e) The commissioner may by rule or	r by order allow	other types of investme	ents that the
78.4	commissioner determines are of sufficie			
78.5	investment. The commissioner is authoriz	<u> </u>		
78.6	to determine that other types of investm			
78.7	permissible investment.			
78.8	Sec. 36. [53B.62] PERMISSIBLE IN	VESTMENTS.	<u>.</u>	
78.9	Subdivision 1. Certain investments	permissible. Th	ne following investmen	its are
78.10	permissible under section 53B.61:			
78.11	(1) cash, including demand deposits	, savings deposit	s, and funds in account	s held for
78.12	the benefit of the licensee's customers in	a federally insur	ed depository financial	institution;
78.13	and cash equivalents, including ACH ite	ems in transit to	the licensee and ACH i	tems or
78.14	international wires in transit to a payee,	cash in transit vi	a armored car, cash in s	smart safes,
78.15	cash in licensee-owned locations, debit	card or credit car	d funded transmission	receivables
78.16	owed by any bank, or money market mu	tual funds rated	AAA or the equivalent	t from any
78.17	eligible rating service;			
78.18	(2) certificates of deposit or senior de	ebt obligations of	f an insured depository	institution,
78.19	as defined in section 3 of the Federal De	eposit Insurance	Act, United States Cod	le, title 12,
78.20	section 1813, as amended or recodified	from time to tim	e, or as defined under t	the federal
78.21	Credit Union Act, United States Code, ti	tle 12, section 17	81, as amended or reco	dified from
78.22	time to time;			
78.23	(3) an obligation of the United States	or a commission,	agency, or instrumenta	lity thereof;
78.24	an obligation that is guaranteed fully as	to principal and i	interest by the United S	states; or an
78.25	obligation of a state or a governmental s	subdivision, ager	ncy, or instrumentality	thereof;
78.26	(4) the full drawable amount of an ir	revocable standb	by letter of credit, for w	hich the
78.27	stated beneficiary is the commissioner,	that stipulates that	at the beneficiary need	only draw
78.28	a sight draft under the letter of credit an	d present the sig	ht draft to obtain funds	up to the
78.29	letter of credit amount within seven days	of presentation o	f the items required by	subdivision
78.30	2, paragraph (c); and			
78.31	(5) one hundred percent of the surety	bond or deposit	provided for under sect	tion 53B.60
78.32	that exceeds the average daily money tr	ansmission liabil	ity in Minnesota.	

04/04/23 SENATEE ADB SS2744R Subd. 2. Letter of credit; requirements. (a) A letter of credit under subdivision 1, 79.1 79.2 clause (4), must: (1) be issued by a federally insured depository financial institution, a foreign bank that 79.3 is authorized under federal law to maintain a federal agency or federal branch office in a 79.4 state or states, or a foreign bank that is authorized under state law to maintain a branch in 79.5 a state that: (i) bears an eligible rating or whose parent company bears an eligible rating; 79.6 and (ii) is regulated, supervised, and examined by United States federal or state authorities 79.7 having regulatory authority over banks, credit unions, and trust companies; 79.8 (2) be irrevocable, unconditional, and indicate that it is not subject to any condition or 79.9 79.10 qualifications outside of the letter of credit; (3) not contain reference to any other agreements, documents, or entities, or otherwise 79.11 79.12 provide for any security interest in the licensee; and (4) contain an issue date and expiration date, and expressly provide for automatic 79.13 extension without a written amendment, for an additional period of one year from the present 79.14 or each future expiration date, unless the issuer of the letter of credit notifies the 79.15 commissioner in writing by certified or registered mail or courier mail or other receipted 79.16 means, at least 60 days before any expiration date, that the irrevocable letter of credit will 79.17 79.18 not be extended. (b) In the event of any notice of expiration or nonextension of a letter of credit issued 79.19 under paragraph (a), clause (4), the licensee must demonstrate to the satisfaction of the 79.20 commissioner, 15 days before the letter or credit's expiration, that the licensee maintains 79.21 and will maintain permissible investments in accordance with section 53B.61, paragraph 79.22 (a), upon the expiration of the letter of credit. If the licensee is not able to do so, the 79.23 commissioner may draw on the letter of credit in an amount up to the amount necessary to 79.24 meet the licensee's requirements to maintain permissible investments in accordance with 79.25 section 53B.61, paragraph (a). Any draw under this paragraph must be offset against the 79.26 licensee's outstanding money transmission obligations. The drawn funds must be held in 79.27 79.28 trust by the commissioner or the commissioner's designated agent, to the extent authorized by law, as agent for the benefit of the purchasers and holders of the licensee's outstanding 79.29 money transmission obligations. 79.30 (c) The letter of credit must provide that the issuer of the letter of credit must honor, at 79.31 sight, a presentation made by the beneficiary to the issuer of the following documents on 79.32 or before the expiration date of the letter of credit: 79.33

79.34 (1) the original letter of credit, including any amendments; and

80.1	(2) a written statement from the beneficiary stating that any of the following events have
80.2	occurred:
80.3	(i) the filing of a petition by or against the licensee under the United States Bankruptcy
80.4	Code, United States Code, title 11, sections 101 to 110, as amended or recodified from time
80.5	to time, for bankruptcy or reorganization;
00 (
80.6	(ii) the filing of a petition by or against the licensee for receivership, or the
80.7	commencement of any other judicial or administrative proceeding for the licensee's
80.8	dissolution or reorganization;
80.9	(iii) the seizure of assets of a licensee by a commissioner of any other state pursuant to
80.10	an emergency order issued in accordance with applicable law, on the basis of an action,
80.11	violation, or condition that has caused or is likely to cause the insolvency of the licensee;
80.12	<u>or</u>
80.13	(iv) the beneficiary has received notice of expiration or nonextension of a letter of credit
80.14	and the licensee failed to demonstrate to the satisfaction of the beneficiary that the licensee
80.15	will maintain permissible investments in accordance with section 53B.61, paragraph (a),
80.16	upon the expiration or nonextension of the letter of credit.
80.17	(d) The commissioner may designate an agent to serve on the commissioner's behalf as
80.18	beneficiary to a letter of credit, provided the agent and letter of credit meet requirements
80.19	the commissioner establishes. The commissioner's agent may serve as agent for multiple
80.20	licensing authorities for a single irrevocable letter of credit if the proceeds of the drawable
80.21	amount for the purposes of subdivision 1, clause (4), and this subdivision are assigned to
80.22	the commissioner.
80.23	(e) The commissioner is authorized to participate in multistate processes designed to
80.24	facilitate the issuance and administration of letters of credit, including but not limited to
80.25	services provided by the NMLS and State Regulatory Registry, LLC.
80.26	Subd. 3. Other permissible investments. Unless the commissioner by administrative
80.27	rule or order otherwise permits an investment to exceed the limit set forth in this subdivision,
80.27	the following investments are permissible under section 53B.61 to the extent specified:
00.20	are renowing investments are permissione under section 550.01 to the extent specified.
80.29	(1) receivables that are payable to a licensee from its authorized delegates in the ordinary
80.30	course of business that are less than seven days old, up to 50 percent of the aggregate value
80.31	of the licensee's total permissible investments;

	04/04/23	SENATEE	ADB	SS2744R
81.1	(2) of the receivables permissible	under clause (1), re	ceivables that are pay	vable to a
81.2	licensee from a single authorized dele			
81.3	ten percent of the aggregate value of	the licensee's total p	oermissible investme	nts;
81.4	(3) the following investments are p	permissible up to 20 p	bercent per category a	nd combined
81.5	up to 50 percent of the aggregate val	ue of the licensee's t	otal permissible inve	estments:
81.6	(i) a short-term investment of up	to six months bearin	g an eligible rating;	
81.7	(ii) commercial paper bearing an	eligible rating;		
81.8	(iii) a bill, note, bond, or debentu	re bearing an eligibl	e rating;	
81.9	(iv) United States tri-party repurc	hase agreements col	lateralized at 100 per	cent or more
81.10	with United States government or ag	ency securities, mur	nicipal bonds, or othe	er securities
81.11	bearing an eligible rating;			
81.12	(v) money market mutual funds ra	ated less than "AAA	" and equal to or high	ner than "A-"
81.13	by S&P, or the equivalent from any c	other eligible rating s	service; and	
81.14	(vi) a mutual fund or other invest	ment fund composed	d solely and exclusiv	ely of one or
81.15	more permissible investments listed	in subdivision 1, cla	uses (1) to (3); and	
81.16	(4) cash, including demand depos	sits, savings deposits	s, and funds in account	nts held for
81.17	the benefit of the licensee's customer	rs, at foreign deposito	ory institutions are pe	ermissible up
81.18	to ten percent of the aggregate value	of the licensee's tota	ıl permissible investr	ments, if the
81.19	licensee has received a satisfactory ra	ating in the licensee's	s most recent examin	ation and the
81.20	foreign depository institution:			
81.21	(i) has an eligible rating;			
81.22	(ii) is registered under the Foreign	n Account Tax Com	pliance Act, Public L	.aw 111-147;
81.23	(iii) is not located in any country	subject to sanctions	from the Office of F	oreign Asset
81.24	Control; and			
81.25	(iv) is not located in a high-risk o	or noncooperative jui	risdiction, as designa	ted by the
81.26	Financial Action Task Force.			
81.27	Sec. 37. [53B.63] SUSPENSION;	REVOCATION.		
81.28	(a) The commissioner may suspen	nd or revoke a licens	e or order a licensee	to revoke the
81.29	designation of an authorized delegate	e if:		
81.30	(1) the licensee violates this chapt	er, or an administrati	ve rule adopted or an	order issued
81.31	under this chapter;			

Article 3 Sec. 37.

04/04/23 SENATEE ADB SS2744R (2) the licensee does not cooperate with an examination or investigation conducted by 82.1 82.2 the commissioner; (3) the licensee engages in fraud, intentional misrepresentation, or gross negligence; 82.3 (4) an authorized delegate is convicted of a violation of a state or federal statute 82.4 82.5 prohibiting money laundering, or violates an administrative rule adopted or an order issued under this chapter, as a result of the licensee's willful misconduct or willful blindness; 82.6 82.7 (5) the competence, experience, character, or general fitness of the licensee, authorized delegate, person in control of a licensee, key individual, or responsible person of the 82.8 authorized delegate indicates that it is not in the public interest to permit the person to 82.9 provide money transmission; 82.10 (6) the licensee engages in an unsafe or unsound practice; 82.11 82.12 (7) the licensee is insolvent, suspends payment of the licensee's obligations, or makes a general assignment for the benefit of the licensee's creditors; or 82.13 82.14 (8) the licensee does not remove an authorized delegate after the commissioner issues and serves upon the licensee a final order that includes a finding that the authorized delegate 82.15 has violated this chapter. 82.16 (b) When determining whether a licensee is engaging in an unsafe or unsound practice, 82.17 the commissioner may consider the size and condition of the licensee's money transmission, 82.18 the magnitude of the loss, the gravity of the violation of this chapter, and the previous 82.19 conduct of the person involved. 82.20 Sec. 38. [53B.64] AUTHORIZED DELEGATES; SUSPENSION AND 82.21 **REVOCATION.** 82.22 (a) The commissioner may issue an order suspending or revoking the designation of an 82.23 82.24 authorized delegate if the commissioner finds: (1) the authorized delegate violated this chapter, or an administrative rule adopted or an 82.25 82.26 order issued under this chapter; (2) the authorized delegate did not cooperate with an examination or investigation 82.27 82.28 conducted by the commissioner; (3) the authorized delegate engaged in fraud, intentional misrepresentation, or gross 82.29 negligence; 82.30

	04/04/23	SENATEE	ADB	SS2744R
83.1	(4) the authorized delegate is co	nvicted of a violation	of a state or federa	l anti-money
83.2	laundering statute;			<u> </u>
83.3	(5) the competence, experience,	character, or general	fitness of the autho	rized delegate
83.4	or a person in control of the authoriz			
83.5	to permit the authorized delegate to	provide money trans	mission; or	
83.6	(6) the authorized delegate is en	gaging in an unsafe o	r unsound practice.	
83.7	(b) When determining whether ar	authorized delegate is	s engaging in an uns	afe or unsound
83.8	practice, the commissioner may con	sider the size and con	dition of the author	zed delegate's
83.9	provision of money transmission, th	ne magnitude of the lo	oss, the gravity of th	ne violation of
83.10	this chapter, or an administrative ru	le adopted or order is	sued under this cha	pter, and the
83.11	previous conduct of the authorized	delegate.		
83.12	(c) An authorized delegate may	apply for relief from	a suspension or rev	ocation of
83.13	designation as an authorized delega	te in the same manner	r as a licensee.	
83.14 83.15	Sec. 39. [53B.65] ENFORCEME Section 45.027 applies to this ch			
83.16	Sec. 40. [53B.66] CRIMINAL P.	ENALTIES.		
83.17	(a) A person who intentionally r	nakes a false statemer	nt, misrepresentatio	n, or false
83.18	certification in a record filed or requ	uired to be maintained	l under this chapter	or that
83.19	intentionally makes a false entry or	omits a material entry	y in a record filed o	r required to
83.20	be maintained under this chapter is	guilty of a felony.		
83.21	(b) A person who knowingly eng	gages in an activity for	which a license is 1	equired under
83.22	this chapter without being licensed	under this chapter, an	d who receives mor	re than \$1,000
83.23	in compensation within a 30-day pe	priod from the activity	, is guilty of a felor	<u>ıy.</u>
83.24	(c) A person who knowingly eng	gages in an activity for	which a license is 1	equired under
83.25	this chapter without being licensed	under this chapter, an	d who receives mo	re than \$500
83.26	but less than \$1,000 in compensation	on within a 30-day per	riod from the activit	ty, is guilty of
83.27	a gross misdemeanor.			
83.28	(d) A person who knowingly eng	gages in an activity for	which a license is 1	equired under
83.29	this chapter without being licensed	under this chapter, and	l who receives no m	ore than \$500
83.30	in compensation within a 30-day pe	eriod from the activity	r, is guilty of a misd	emeanor.

Sec. 41. [53B.67] SEVERABILITY. 84.1 If any provision of this chapter or the chapter's application to any person or circumstance 84.2 84.3 is held invalid, the invalidity does not affect other provisions or applications of this chapter that can be given effect without the invalid provision or application. 84.4 Sec. 42. [53B.68] TRANSITION PERIOD. 84.5 (a) A person licensed in Minnesota to engage in the business of money transmission is 84.6 not subject to the provisions of this chapter to the extent that this chapter's provisions conflict 84.7 with current law or establish new requirements not imposed under current law until the 84.8 licensee renews the licensee's current license or for five months after the effective date of 84.9 this chapter, whichever is later. 84.10 84.11 (b) Notwithstanding paragraph (a), a licensee is only required to amend the licensee's authorized delegate contracts for contracts entered into or amended after the effective date 84.12 84.13 or the completion of any transition period contemplated under paragraph (a). Nothing in this section limits an authorized delegate's obligations to operate in full compliance with 84.14 84.15 this chapter, as required under section 53B.51, paragraph (c). Sec. 43. [53B.69] DEFINITIONS. 84.16 Subdivision 1. Terms. For purposes of sections 53B.70 to 53B.74, the following terms 84.17 have the meaning given them. 84.18 Subd. 2. Control of virtual currency. "Control of virtual currency," when used in 84.19 reference to a transaction or relationship involving virtual currency, means the power to 84.20

84.21 execute unilaterally or prevent indefinitely a virtual currency transaction.

84.22Subd. 3. Exchange. "Exchange," used as a verb, means to assume control of virtual84.23currency from or on behalf of a person, at least momentarily, to sell, trade, or convert:

84.24 (1) virtual currency for money, bank credit, or one or more forms of virtual currency;
84.25 or

84.26 (2) money or bank credit for one or more forms of virtual currency.

84.27 <u>Subd. 4. Transfer.</u> "Transfer" means to assume control of virtual currency from or on
84.28 behalf of a person and to:

- 84.29 (1) credit the virtual currency to the account of another person;
- 84.30 (2) move the virtual currency from one account of a person to another account of the
- 84.31 same person; or

85.1	(3) relinquish control of virtual currency to another person.
85.2	Subd. 5. United States dollar equivalent of virtual currency. "United States dollar
85.3	equivalent of virtual currency" means the equivalent value of a particular virtual currency
85.4	in United States dollars shown on a virtual-currency exchange based in the United States
85.5	for a particular date or period specified in this chapter.
85.6	Subd. 6. Virtual currency. (a) "Virtual currency" means a digital representation of value
85.7	that:
85.8	(1) is used as a medium of exchange, unit of account, or store of value; and
85.9	(2) is not money, whether or not denominated in money.
85.10	(b) Virtual currency does not include:
85.11	(1) a transaction in which a merchant grants, as part of an affinity or rewards program,
85.12	value that cannot be taken from or exchanged with the merchant for money, bank credit, or
85.13	virtual currency; or
85.14	(2) a digital representation of value issued by or on behalf of a publisher and used solely
85.15	within an online game, game platform, or family of games sold by the same publisher or
85.16	offered on the same game platform.
85.17	Subd. 7. Virtual-currency administration. "Virtual-currency administration" means
85.18	issuing virtual currency with the authority to redeem the currency for money, bank credit,
85.19	or other virtual currency.
85.20	Subd. 8. Virtual-currency business activity. "Virtual-currency business activity" means:
85.21	(1) exchanging, transferring, or storing virtual currency or engaging in virtual-currency
85.22	administration, whether directly or through an agreement with a virtual-currency
85.23	control-services vendor;
85.24	(2) holding electronic precious metals or electronic certificates representing interests in
85.25	precious metals on behalf of another person or issuing shares or electronic certificates
85.26	representing interests in precious metals; or
85.27	(3) exchanging one or more digital representations of value used within one or more
85.28	online games, game platforms, or family of games for:
85.29	(i) virtual currency offered by or on behalf of the same publisher from which the original
85.30	digital representation of value was received; or

86.1	(ii) money or bank credit outside the online game, game platform, or family of games
86.2	offered by or on behalf of the same publisher from which the original digital representation
86.3	of value was received.
86.4	Subd. 9. Virtual-currency control-services vendor. "Virtual-currency control-services
86.5	vendor" means a person that has control of virtual currency solely under an agreement with
86.6	a person that, on behalf of another person, assumes control of virtual currency.
86.7	Sec. 44. [53B.70] SCOPE.
86.8	(a) Sections 53B.71 to 53B.74 do not apply to the exchange, transfer, or storage of virtual
86.9	currency or to virtual-currency administration to the extent the Electronic Fund Transfer
86.10	Act of 1978, United States Code, title 15, sections 1693 to 1693r, as amended or recodified
86.11	from time to time; the Securities Exchange Act of 1934, United States Code, title 15, sections
86.12	78a to 7800, as amended or recodified from time to time; the Commodities Exchange Act
86.13	of 1936, United States Code, title 7, sections 1 to 27f, as amended or recodified from time
86.14	to time; or chapter 80A govern the activity.
86.15	(b) Sections 53B.71 to 53B.74 do not apply to activity by:
86.16	(1) a person that:
86.17	(i) contributes only connectivity software or computing power to a decentralized virtual
86.18	currency, or to a protocol governing transfer of the digital representation of value;
86.19	(ii) provides only data storage or security services for a business engaged in
86.20	virtual-currency business activity and does not otherwise engage in virtual-currency business
86.21	activity on behalf of another person; or
86.22	(iii) provides only to a person otherwise exempt from this chapter virtual currency as
86.23	one or more enterprise solutions used solely among each other and has no agreement or
86.24	relationship with a person that is an end-user of virtual currency;
86.25	(2) a person using virtual currency, including creating, investing, buying or selling, or
86.26	obtaining virtual currency as payment for the purchase or sale of goods or services, solely:
86.27	(i) on the person's own behalf;
86.28	(ii) for personal, family, or household purposes; or
86.29	(iii) for academic purposes;

ADB

87.1	(3) a person whose virtual-currency business activity with or on behalf of persons is
87.2	reasonably expected to be valued, in the aggregate, on an annual basis at \$5,000 or less,
87.3	measured by the United States dollar equivalent of virtual currency;
87.4	(4) an attorney to the extent of providing escrow services to a person;
87.5	(5) a title insurance company to the extent of providing escrow services to a person; or
87.6	(6) a securities intermediary, as defined under section $336.8-102(14)$, or a commodity
87.7	intermediary, as defined under section 336.9-102(17), that:
87.8	(i) does not engage in the ordinary course of business in virtual-currency business activity
87.9	with or on behalf of a person in addition to maintaining securities accounts or commodities
87.10	accounts and is regulated as a securities intermediary or commodity intermediary under
87.11	federal law, law of Minnesota other than this chapter, or law of another state; and
87.12	(ii) affords a person protections comparable to those set forth under section 53B.37.
87.13	(c) Sections 53B.71 to 53B.74 do not apply to a secured creditor, as defined under
87.14	sections 336.9-101 to 336.9-809 or to a creditor with a judicial lien or lien arising by
87.15	operation of law on collateral that is virtual currency, if the virtual-currency business activity
87.16	of the creditor is limited to enforcement of the security interest in compliance with sections
87.17	336.9-101 to 336.9-809 or lien in compliance with the law applicable to the lien.
87.18	(d) Sections 53B.71 to 53B.74 do not apply to a virtual-currency control-services vendor.
87.19	(e) Sections 53B.71 to 53B.74 do not apply to a person that:
87.20	(1) does not receive compensation from a person to:
87.21	(i) provide virtual-currency products or services; or
87.22	(ii) conduct virtual-currency business activity; or
87.23	(2) is engaged in testing products or services with the person's own money.
87.24	(f) The commissioner may determine that a person or class of persons, given facts
87.25	particular to the person or class, should be exempt from this chapter, whether the person or
87.26	class is covered by requirements imposed under federal law on a money-service business.
87.27	Sec. 45. [53B.71] VIRTUAL CURRENCY BUSINESS ACTIVITY; CONDITIONS
87.28	PRECEDENT.
87.29	(a) A person may not engage in virtual-currency business activity, or hold itself out as
87.30	being able to engage in virtual-currency business activity, with or on behalf of another

87.31 person unless the person is:

	04/04/23	SENATEE	ADB	SS2744R
88.1	(1) licensed in Minnesota by the co	mmissioner under sec	tion 53B.40; or	
88.2	(2) exempt from licensing under se	ction 53B.29.		
88.3 88.4	(b) A person that is licensed to engin the business of money transmission			
88.5	Sec. 46. [53B.72] REQUIRED DIS	CLOSURES.		
88.6	(a) A licensee that engages in virtua	l currency business act	ivity must provid	le to a person
88.7	who uses the licensee's products or ser	vices the disclosures re	equired by parage	raph (b) and
88.8	any additional disclosure the commission	oner by administrative	e rule determines	reasonably
88.9	necessary to protect persons. The com	nissioner must determ	ine by administra	ative rule the
88.10	time and form required for disclosure.	A disclosure required	by this section m	ust be made
88.11	separately from any other information pr	rovided by the licensee	and in a clear and	conspicuous
88.12	manner in a record the person may kee	p. A licensee may pro	pose for the com	missioner's
88.13	approval alternate disclosures as more a	ppropriate for the licen	see's virtual-curre	ency business
88.14	activity with or on behalf of persons.			
88.15	(b) Before establishing a relationsh	ip with a person, a lice	ensee must disclo	ose, to the
88.16	extent applicable to the virtual-currence	y business activity the	licensee underta	kes with the
88.17	person:			
88.18	(1) a schedule of fees and charges t	he licensee may assess	s, the manner by	which fees
88.19	and charges are calculated if the fees an	nd charges are not set	n advance and di	isclosed, and
88.20	the timing of the fees and charges;			
88.21	(2) whether the product or service	provided by the license	e is covered by:	
88.22	(i) a form of insurance or is otherwis	se guaranteed against lo	oss by an agency of	of the United
88.23	States:			
88.24	(A) up to the full United States doll	ar equivalent of virtual	currency purcha	sed from the
88.25	licensee or for control of virtual curren	cy by the licensee as o	f the date of the p	placement or
88.26	purchase, including the maximum amo	unt provided by insura	nce under the Fed	leral Deposit
88.27	Insurance Corporation or otherwise av	ailable from the Secur	ities Investor Pro	tection
88.28	Corporation; or			
88.29	(B) if not provided at the full United	States dollar equivalen	t of virtual current	cy purchased
88.30	from the licensee or for control of virtu	al currency by the lice	ensee, the maxim	um amount
88.31	of coverage for each person expressed	in the United States de	ollar equivalent o	of the virtual
88.32	currency; or			

89.1	(ii) private insurance against theft or loss, including cyber theft or theft by other means;
89.2	(3) the irrevocability of a transfer or exchange and any exception to irrevocability;
89.3	(4) a description of:
89.4	(i) liability for an unauthorized, mistaken, or accidental transfer or exchange;
89.5	(ii) the person's responsibility to provide notice to the licensee of the transfer or exchange;
89.6	(iii) the basis for any recovery by the person from the licensee;
89.7	(iv) general error-resolution rights applicable to the transfer or exchange; and
89.8	(v) the method for the person to update the person's contact information with the licensee;
89.9	(5) that the date or time when the transfer or exchange is made and the person's account
89.10	is debited may differ from the date or time when the person initiates the instruction to make
89.11	the transfer or exchange;
89.12	(6) whether the person has a right to stop a preauthorized payment or revoke authorization
89.13	for a transfer, and the procedure to initiate a stop-payment order or revoke authorization
89.14	for a subsequent transfer;
89.15	(7) the person's right to receive a receipt, trade ticket, or other evidence of the transfer
89.16	or exchange;
89.17	(8) the person's right to at least 30 days' prior notice of a change in the licensee's fee
89.18	schedule, other terms and conditions of operating the licensee's virtual-currency business
89.19	activity with the person, and the policies applicable to the person's account; and
89.20	(9) that virtual currency is not money.
89.21	(c) Except as otherwise provided in paragraph (d), at the conclusion of a virtual-currency
89.22	transaction with or on behalf of a person, a licensee must provide the person a confirmation
89.23	in a record. The record must contain:
89.24	(1) the name and contact information of the licensee, including information the person
89.25	may need to ask a question or file a complaint;
89.26	(2) the type, value, date, precise time, and amount of the transaction; and
89.27	(3) the fee charged for the transaction, including any charge for conversion of virtual
89.28	currency to money, bank credit, or other virtual currency.
89.29	(d) If a licensee discloses that it provides a daily confirmation in the initial disclosure
89.30	under paragraph (c), the licensee may elect to provide a single, daily confirmation for all

	04/04/23	SENATEE	ADB	SS2744R
90.1	transactions with or on behalf of a per	rson on that day ins	stead of a per-transac	ction
90.2	confirmation.	2		
90.3	Sec. 47. [53B.73] PROPERTY INT	FERESTS AND E	NTITLEMENTS T	O VIRTUAL
90.4	CURRENCY.			
90.5	(a) A licensee that has control of vi	irtual currency for o	one or more persons r	<u>nust maintain</u>
90.6	control of virtual currency in each type	e of virtual currency	y sufficient to satisfy	the aggregate
90.7	entitlements of the persons to the type	e of virtual currenc	<u>y.</u>	
90.8	(b) If a licensee violates paragraph	(a), the property in	terests of the persons	s in the virtual
90.9	currency are pro rata property interest	ts in the type of vir	tual currency to whic	the persons
90.10	are entitled, without regard to the time	e the persons becar	ne entitled to the vir	tual currency
90.11	or the licensee obtained control of the	e virtual currency.		
90.12	(c) The virtual currency referred to	o in this section is:		
90.13	(1) held for the persons entitled to	the virtual currence	<u>×y;</u>	
90.14	(2) not property of the licensee;			
90.15	(3) not subject to the claims of cre	editors of the licens	ee; and	
90.16	(4) a permissible investment unde	r this chapter.		
90.17	Sec. 48. [53B.74] VIRTUAL CURF	RENCY BUSINES	S ACTIVITIES; AI	DDITIONAL
90.18	REQUIREMENTS.			
90.19	(a) A licensee engaged in virtual cu	rrency business act	ivities may include vi	rtual currency
90.20	in the licensee's calculation of tangibl	e net worth, by me	asuring the average	value of the
90.21	virtual currency in United States dolla	ar equivalent over t	he prior six months,	excluding
90.22	control of virtual currency for a perso	on entitled to the pr	otections under secti	on 53B.73.
90.23	(b) A licensee must maintain, for a	Ill virtual-currency	business activity wit	h or on behalf
90.24	of a person five years after the date of	f the activity, a reco	ord of:	
90.25	(1) each of the licensee's transactio	ns with or on behal	f of the person, or for	the licensee's
90.26	account in Minnesota, including:			
90.27	(i) the identity of the person;			
90.28	(ii) the form of the transaction;			
90.29	(iii) the amount, date, and payment	nt instructions given	n by the person; and	

91.1	(iv) the account number, name, and United States Postal Service address of the person,
91.2	and, to the extent feasible, other parties to the transaction;
91.3	(2) the aggregate number of transactions and aggregate value of transactions by the
91.4	licensee with or on behalf of the person and for the licensee's account in this state, expressed
91.5	in the United States dollar equivalent of the virtual currency for the previous 12 calendar
91.6	months;
91.7	(3) each transaction in which the licensee exchanges one form of virtual currency for
91.8	money or another form of virtual currency with or on behalf of the person;
91.9	(4) a general ledger posted at least monthly that lists all of the licensee's assets, liabilities,
91.10	capital, income, and expenses;
91.11	(5) each business-call report the licensee is required to create or provide to the department
91.12	or NMLS;
91.13	(6) bank statements and bank reconciliation records for the licensee and the name,
91.14	account number, and United States Postal Service address of each bank the licensee uses
91.15	to conduct virtual-currency business activity with or on behalf of the person;
91.16	(7) a report of any dispute with the person; and
91.17	(8) a report of any virtual-currency business activity transaction with or on behalf of a
91.18	person which the licensee was unable to complete.
91.19	(c) A licensee must maintain records required by paragraph (b) in a form that enables
91.20	the commissioner to determine whether the licensee is in compliance with this chapter, any
91.21	court order, and law of Minnesota other than this chapter.
91.22	Sec. 49. [58B.011] STUDENT LOAN ADVOCATE.
91.23	Subdivision 1. Designation of a student loan advocate. The commissioner of commerce
91.24	must designate a student loan advocate within the Department of Commerce to provide
91.25	timely assistance to borrowers and to effectuate this chapter.
91.26	Subd. 2. Duties. The student loan advocate has the following duties:
91.27	(1) receive, review, and attempt to resolve complaints from borrowers, including but
91.28	not limited to attempts to resolve borrower complaints in collaboration with institutions of
91.29	higher education, student loan servicers, and any other participants in student loan lending;
91.30	(2) compile and analyze data on borrower complaints received under clause (1);

92.1	(3) help borrowers understand the rights and responsibilities under the terms of student
92.2	loans;
92.3	(4) provide information to the public, state agencies, legislators, and relevant stakeholders
92.4	regarding the problems and concerns of borrowers;
92.5	(5) make recommendations to resolve the problems of borrowers;
92.6	(6) analyze and monitor the development and implementation of federal, state, and local
92.7	laws, regulations, and policies relating to borrowers, and recommend any changes deemed
92.8	necessary;
92.9	(7) review the complete student loan history for any borrower who has provided written
92.10	consent to conduct the review;
92.11	(8) increase public awareness that the advocate is available to assist in resolving the
92.12	student loan servicing concerns of potential and actual borrowers, institutions of higher
92.13	education, student loan servicers, and any other participant in student loan lending; and
92.14	(9) take other actions as necessary to fulfill the duties of the advocate, as provided under
92.15	this section.
92.16	Subd. 3. Student loan education course. The advocate must establish and maintain a
92.17	borrower education course. The course must include educational presentations and materials
92.18	regarding important topics in student loans, including but not limited to:
92.19	(1) the meaning of important terminology used in student lending;
92.20	(2) documentation requirements;
92.21	(3) monthly payment obligations;
92.22	(4) income-based repayment options;
92.23	(5) the availability of state and federal loan forgiveness programs; and
92.24	(6) disclosure requirements.
92.25	Subd. 4. Reporting. By January 15 of each odd-numbered year, the advocate must report
92.26	to the legislative committees with jurisdiction over commerce and higher education. The
92.27	report must describe the advocate's implementation of this section, the outcomes achieved
92.28	by the advocate during the previous two years, and recommendations to improve the
92.29	regulation of student loan servicers.

SENATEE

93.1	Sec. 50. <u>REPEALER.</u>
93.2	Minnesota Statutes 2022, sections 53B.01; 53B.02; 53B.03; 53B.04; 53B.05; 53B.06;
93.3	53B.07; 53B.08; 53B.09; 53B.10; 53B.11; 53B.12; 53B.13; 53B.14; 53B.15; 53B.16;
93.4	53B.17; 53B.18; 53B.19; 53B.20; 53B.21; 53B.22; 53B.23; 53B.24; 53B.25; 53B.26; and
93.5	53B.27, subdivisions 1, 2, 5, 6, and 7, are repealed.
93.6	ARTICLE 4
93.7	WEIGHTS AND MEASURES
93.8	Section 1. Minnesota Statutes 2022, section 239.791, subdivision 8, is amended to read:
93.9	Subd. 8. Disclosure: reporting. (a) A refinery or terminal, shall provide, at the time
93.10	gasoline is sold or transferred from the refinery or terminal, a bill of lading or shipping
93.11	manifest to the person who receives the gasoline. For oxygenated gasoline, the bill of lading
93.12	or shipping manifest must include the identity and the volume percentage or gallons of
93.13	oxygenate included in the gasoline, and it must state: "This fuel contains an oxygenate. Do
93.14	not blend this fuel with ethanol or with any other oxygenate." For nonoxygenated gasoline
93.15	sold or transferred after September 30, 1997, the bill or manifest must state: "This fuel is
93.16	not oxygenated. It must not be sold at retail in Minnesota." This subdivision does not apply
93.17	to sales or transfers of gasoline between refineries, between terminals, or between a refinery
93.18	and a terminal.
93.19	(b) A delivery ticket required under section 239.092 for biofuel blended with gasoline
93.20	must state the volume percentage of biofuel blended into gasoline delivered through a meter
93.21	into a storage tank used for dispensing by persons not exempt under subdivisions 10 to 14
93.22	<u>and 16</u> .
93.23	(c) On or before the 23rd day of each month, a person responsible for the product must
93.24	report to the department, in the form prescribed by the commissioner, the gross number of
93.25	gallons of intermediate blends sold at retail by the person during the preceding calendar
93.26	month. The report must identify the number of gallons by blend type. For purposes of this
93.27	subdivision, "intermediate blends" means blends of gasoline and biofuel in which the biofuel
93.28	content, exclusive of denaturants and other permitted components, is greater than ten percent
93.29	and no more than 50 percent by volume. This paragraph only applies to a person who is
93.30	responsible for selling intermediate blends at retail at more than ten locations. A person
93.31	responsible for the product at fewer than ten locations is not precluded from reporting the
93.32	gross number of intermediate blends if a report is available.

94.1	(d) All reports provided pursuant to paragraph (c) are nonpublic data as defined in section
94.2	13.02, subdivision 9.
94.3	EFFECTIVE DATE. This section is effective July 1, 2023."
94.4	Delete the title and insert:
94.5	A bill for an act
94.6	relating to commerce; establishing a biennial budget for Department of Commerce;
94.7	modifying various provisions governing insurance; regulating virtual currency
94.8	activities; providing for reports relating to retail sales of intermediate blends of
94.9	gasoline and biofuel; prohibiting excessive price increases by pharmaceutical
94.10	manufacturers; establishing a Prescription Drug Affordability Board; establishing
94.11	a student loan advocate position; regulating money transmitters; making technical
94.12	changes; establishing penalties; authorizing administrative rulemaking; requiring
94.13	reports; appropriating money; amending Minnesota Statutes 2022, sections 46.131,
94.14	subdivision 11; 60A.14, subdivision 1; 62A.152, subdivision 3; 62D.02, by adding
94.15	a subdivision; 62D.095, subdivisions 2, 3, 4, 5; 62K.10, subdivision 4; 62Q.19,
94.16	subdivision 1; 62Q.46, subdivisions 1, 3; 62Q.47; 62Q.81, subdivision 4, by adding
94.17	a subdivision; 151.071, subdivisions 1, 2; 239.791, subdivision 8; 256B.0631,
94.18	subdivision 1; 256L.03, subdivision 5; Laws 2022, chapter 93, article 1, section
94.19	2, subdivision 5; proposing coding for new law in Minnesota Statutes, chapters
94.20	53B; 58B; 62J; 62Q; 62W; repealing Minnesota Statutes 2022, sections 53B.01;
94.21	53B.02; 53B.03; 53B.04; 53B.05; 53B.06; 53B.07; 53B.08; 53B.09; 53B.10;
94.22	53B.11; 53B.12; 53B.13; 53B.14; 53B.15; 53B.16; 53B.17; 53B.18; 53B.19;
94.23	53B.20; 53B.21; 53B.22; 53B.23; 53B.24; 53B.25; 53B.26; 53B.27, subdivisions
94.24	1, 2, 5, 6, 7.

And when so amended the bill do pass and be re-referred to the Committee on Finance. 94.25

Amendments adopted. Report adopted. 94.26

(Committee Chair)

94.29 94.30

94.27 94.28

> March 30, 2023..... (Date of Committee recommendation)